PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 23484918-6 2013 CONCLUSIONS: An elevated maternal serum CRP concentration in the context of IAI is an indicator that the development of amnionitis, an intense fetal and AF inflammatory response are likely in patients with PTL. parthenolide 206-209 C-reactive protein Homo sapiens 40-43 22688575-0 2013 Parthenolide induces caspase-independent and AIF-mediated cell death in human osteosarcoma and melanoma cells. parthenolide 0-12 apoptosis inducing factor mitochondria associated 1 Homo sapiens 45-48 23691032-10 2013 The most active adiponectin receptor 2 agonists are parthenolide, taxifoliol, deoxyschizandrin, and syringin. parthenolide 52-64 adiponectin receptor 2 Homo sapiens 16-38 22688575-3 2013 In particular treatment with parthenolide rapidly stimulated (1-2 h) reactive oxygen species (ROS) generation by inducing activation of extracellular signal-regulated kinase 1/2 (ERK 1/2) and NADPH oxidase. parthenolide 29-41 mitogen-activated protein kinase 1 Homo sapiens 136-177 22688575-3 2013 In particular treatment with parthenolide rapidly stimulated (1-2 h) reactive oxygen species (ROS) generation by inducing activation of extracellular signal-regulated kinase 1/2 (ERK 1/2) and NADPH oxidase. parthenolide 29-41 mitogen-activated protein kinase 3 Homo sapiens 179-186 22688575-10 2013 We suggest that AIF exerts a crucial role in parthenolide action. parthenolide 45-57 apoptosis inducing factor mitochondria associated 1 Homo sapiens 16-19 22688575-11 2013 In accordance, down-regulation of AIF markedly inhibited parthenolide effect on the production of cells with apoptotic or necrotic signs. parthenolide 57-69 apoptosis inducing factor mitochondria associated 1 Homo sapiens 34-37 22688575-12 2013 Taken together our results demonstrate that parthenolide causes in the two cell lines a caspase-independent cell death, which is mediated by AIF. parthenolide 44-56 apoptosis inducing factor mitochondria associated 1 Homo sapiens 141-144 23192276-0 2013 Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres. parthenolide 0-12 ATP binding cassette subfamily B member 5 Homo sapiens 38-43 23086737-1 2013 The aims of this study were to assess the effects and potential mechanisms of parthenolide on the expression of vascular endothelial growth factor (VEGF), interleukin 8 (IL-8) and matrix metalloproteinase 9 (MMP-9) in human breast cancer cell line MDA-MB-231. parthenolide 78-90 vascular endothelial growth factor A Homo sapiens 112-146 23086737-1 2013 The aims of this study were to assess the effects and potential mechanisms of parthenolide on the expression of vascular endothelial growth factor (VEGF), interleukin 8 (IL-8) and matrix metalloproteinase 9 (MMP-9) in human breast cancer cell line MDA-MB-231. parthenolide 78-90 vascular endothelial growth factor A Homo sapiens 148-152 23086737-1 2013 The aims of this study were to assess the effects and potential mechanisms of parthenolide on the expression of vascular endothelial growth factor (VEGF), interleukin 8 (IL-8) and matrix metalloproteinase 9 (MMP-9) in human breast cancer cell line MDA-MB-231. parthenolide 78-90 C-X-C motif chemokine ligand 8 Homo sapiens 155-168 23086737-1 2013 The aims of this study were to assess the effects and potential mechanisms of parthenolide on the expression of vascular endothelial growth factor (VEGF), interleukin 8 (IL-8) and matrix metalloproteinase 9 (MMP-9) in human breast cancer cell line MDA-MB-231. parthenolide 78-90 C-X-C motif chemokine ligand 8 Homo sapiens 170-174 23086737-1 2013 The aims of this study were to assess the effects and potential mechanisms of parthenolide on the expression of vascular endothelial growth factor (VEGF), interleukin 8 (IL-8) and matrix metalloproteinase 9 (MMP-9) in human breast cancer cell line MDA-MB-231. parthenolide 78-90 matrix metallopeptidase 9 Homo sapiens 180-206 23086737-1 2013 The aims of this study were to assess the effects and potential mechanisms of parthenolide on the expression of vascular endothelial growth factor (VEGF), interleukin 8 (IL-8) and matrix metalloproteinase 9 (MMP-9) in human breast cancer cell line MDA-MB-231. parthenolide 78-90 matrix metallopeptidase 9 Homo sapiens 208-213 23086737-5 2013 The real-time PCR and Western blot data showed that the expressions of VEGF, IL-8 and MMP-9 were significantly inhibited by parthenolide at both transcription level and protein level in MDA-MB-231 cells. parthenolide 124-136 vascular endothelial growth factor A Homo sapiens 71-75 23086737-5 2013 The real-time PCR and Western blot data showed that the expressions of VEGF, IL-8 and MMP-9 were significantly inhibited by parthenolide at both transcription level and protein level in MDA-MB-231 cells. parthenolide 124-136 C-X-C motif chemokine ligand 8 Homo sapiens 77-81 23086737-5 2013 The real-time PCR and Western blot data showed that the expressions of VEGF, IL-8 and MMP-9 were significantly inhibited by parthenolide at both transcription level and protein level in MDA-MB-231 cells. parthenolide 124-136 matrix metallopeptidase 9 Homo sapiens 86-91 23086737-8 2013 Hence, the expression of VEGF, IL-8 and MMP-9 may be suppressed by parthenolide through the inhibition of NF-kappaB DNA-binding activity in MDA-MB-231 cells. parthenolide 67-79 vascular endothelial growth factor A Homo sapiens 25-29 23086737-8 2013 Hence, the expression of VEGF, IL-8 and MMP-9 may be suppressed by parthenolide through the inhibition of NF-kappaB DNA-binding activity in MDA-MB-231 cells. parthenolide 67-79 C-X-C motif chemokine ligand 8 Homo sapiens 31-35 23086737-8 2013 Hence, the expression of VEGF, IL-8 and MMP-9 may be suppressed by parthenolide through the inhibition of NF-kappaB DNA-binding activity in MDA-MB-231 cells. parthenolide 67-79 matrix metallopeptidase 9 Homo sapiens 40-45 23192276-11 2013 The potential clinical significance of our findings is based on the ability of parthenolide to affect both bulk and melanoma stem-like cells with clonogenic capacity and high expression of the ABCB5 transporter. parthenolide 79-91 ATP binding cassette subfamily B member 5 Homo sapiens 193-198 23066037-7 2013 Parthenolide has an anti-inflammatory activity and suppressed NF-kappaB activity by inhibition of IkappaBalpha phosphorylation after TNF-alpha stimulation and strongly inhibited TNF-alpha-induced VCAM-1 expression on MSCs. parthenolide 0-12 vascular cell adhesion molecule 1 Mus musculus 196-202 23935248-0 2013 Parthenolide is neuroprotective in rat experimental stroke model: downregulating NF-kappaB, phospho-p38MAPK, and caspase-1 and ameliorating BBB permeability. parthenolide 0-12 caspase 1 Rattus norvegicus 113-122 23066037-7 2013 Parthenolide has an anti-inflammatory activity and suppressed NF-kappaB activity by inhibition of IkappaBalpha phosphorylation after TNF-alpha stimulation and strongly inhibited TNF-alpha-induced VCAM-1 expression on MSCs. parthenolide 0-12 tumor necrosis factor Mus musculus 133-142 23066037-7 2013 Parthenolide has an anti-inflammatory activity and suppressed NF-kappaB activity by inhibition of IkappaBalpha phosphorylation after TNF-alpha stimulation and strongly inhibited TNF-alpha-induced VCAM-1 expression on MSCs. parthenolide 0-12 tumor necrosis factor Mus musculus 178-187 24080940-2 2013 Susceptibility to eryptosis is enhanced in aged erythrocytes and stimulated by NFkappaB-inhibitors Bay 11-7082 and parthenolide. parthenolide 115-127 nuclear factor kappa B subunit 1 Homo sapiens 79-87 24080940-10 2013 CONCLUSION: NFkappaB protein abundance is lowest and spontaneous eryptosis as well as susceptibility to Bay 11-7082 and parthenolide highest in aged erythrocytes. parthenolide 120-132 nuclear factor kappa B subunit 1 Homo sapiens 12-20 23383347-6 2013 The involvement of Akt and NF-kappaB signaling pathways in the EGF-induced IL-1beta gene expression was confirmed by knockdown of RelA and Akt in cells or treating cells with Akt and NF-kappaB inhibitors, LY294002 and parthenolide, respectively. parthenolide 218-230 AKT serine/threonine kinase 1 Homo sapiens 19-22 23383347-6 2013 The involvement of Akt and NF-kappaB signaling pathways in the EGF-induced IL-1beta gene expression was confirmed by knockdown of RelA and Akt in cells or treating cells with Akt and NF-kappaB inhibitors, LY294002 and parthenolide, respectively. parthenolide 218-230 epidermal growth factor Homo sapiens 63-66 23383347-6 2013 The involvement of Akt and NF-kappaB signaling pathways in the EGF-induced IL-1beta gene expression was confirmed by knockdown of RelA and Akt in cells or treating cells with Akt and NF-kappaB inhibitors, LY294002 and parthenolide, respectively. parthenolide 218-230 interleukin 1 beta Homo sapiens 75-83 23383347-8 2013 Using immunofluorescence staining assay, the EGF-stimulated nuclear translocation of NF-kappaB (p65) was inhibited by pre-treating cells with LY294002 and parthenolide. parthenolide 155-167 epidermal growth factor Homo sapiens 45-48 23383347-8 2013 Using immunofluorescence staining assay, the EGF-stimulated nuclear translocation of NF-kappaB (p65) was inhibited by pre-treating cells with LY294002 and parthenolide. parthenolide 155-167 nuclear factor kappa B subunit 1 Homo sapiens 85-94 23383347-8 2013 Using immunofluorescence staining assay, the EGF-stimulated nuclear translocation of NF-kappaB (p65) was inhibited by pre-treating cells with LY294002 and parthenolide. parthenolide 155-167 RELA proto-oncogene, NF-kB subunit Homo sapiens 96-99 22683888-8 2012 Consistent with a role for NF-kappaB in the changes caused by TNF-alpha, treatment with the NF-kappaB inhibitor parthenolide restored PPAR DNA-binding activity, the expression of PPARbeta/delta-target genes and the expression of SIRT1 and PPARbeta/delta. parthenolide 112-124 nuclear factor kappa B subunit 1 Homo sapiens 27-36 22939972-1 2012 Previously we reported that the sesquiterpene lactone parthenolide induces oxidative stress in cardiac myocytes, which blocks Janus kinase (JAK) activation by the interleukin 6 (IL-6)-type cytokines. parthenolide 54-66 interleukin 6 Homo sapiens 163-176 22939972-1 2012 Previously we reported that the sesquiterpene lactone parthenolide induces oxidative stress in cardiac myocytes, which blocks Janus kinase (JAK) activation by the interleukin 6 (IL-6)-type cytokines. parthenolide 54-66 interleukin 6 Homo sapiens 178-182 23037503-0 2012 Inhibition of tumor promotion by parthenolide: epigenetic modulation of p21. parthenolide 33-45 H3 histone pseudogene 16 Homo sapiens 72-75 23039130-0 2012 Involvement of Akt/NF-kappaB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. parthenolide 61-73 AKT serine/threonine kinase 1 Homo sapiens 15-18 23039130-0 2012 Involvement of Akt/NF-kappaB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. parthenolide 61-73 nuclear factor kappa B subunit 1 Homo sapiens 19-28 23037503-2 2012 We investigated whether the NF-kB inhibitor, parthenolide, currently in cancer clinical trials, attenuates tumor promotion by modulating the epigenetically regulated NF-kB target genes, p21 and cyclin D1. parthenolide 45-57 H3 histone pseudogene 16 Homo sapiens 186-189 23037503-2 2012 We investigated whether the NF-kB inhibitor, parthenolide, currently in cancer clinical trials, attenuates tumor promotion by modulating the epigenetically regulated NF-kB target genes, p21 and cyclin D1. parthenolide 45-57 cyclin D1 Homo sapiens 194-203 23037503-5 2012 Furthermore, parthenolide decreased tumor promoter-induced NF-kB activity, increased p21, and decreased cyclin D1 expression. parthenolide 13-25 H3 histone pseudogene 16 Homo sapiens 85-88 23037503-5 2012 Furthermore, parthenolide decreased tumor promoter-induced NF-kB activity, increased p21, and decreased cyclin D1 expression. parthenolide 13-25 cyclin D1 Homo sapiens 104-113 23037503-6 2012 In parthenolide-treated cells, p21 transcription correlated with relaxed chromatin and p65/NF-kB binding at the p21 promoter. parthenolide 3-15 H3 histone pseudogene 16 Homo sapiens 31-34 23037503-6 2012 In parthenolide-treated cells, p21 transcription correlated with relaxed chromatin and p65/NF-kB binding at the p21 promoter. parthenolide 3-15 RELA proto-oncogene, NF-kB subunit Homo sapiens 87-90 23037503-6 2012 In parthenolide-treated cells, p21 transcription correlated with relaxed chromatin and p65/NF-kB binding at the p21 promoter. parthenolide 3-15 H3 histone pseudogene 16 Homo sapiens 112-115 23037503-9 2012 Because p21 expression by parthenolide was sustained, we used p21-siRNA and p21 -/- cancer cells and showed that the loss of p21 is cytoprotective against parthenolide. parthenolide 26-38 H3 histone pseudogene 16 Homo sapiens 8-11 23037503-11 2012 Tissue microarray of mouse tumors showed that parthenolide decreased scores of the cell proliferation marker Ki67 and p65/NF-kB, whereas it increased p21 expression. parthenolide 46-58 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 118-121 23037503-11 2012 Tissue microarray of mouse tumors showed that parthenolide decreased scores of the cell proliferation marker Ki67 and p65/NF-kB, whereas it increased p21 expression. parthenolide 46-58 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 150-153 23037503-12 2012 These results show that low doses of parthenolide inhibit tumor promotion and epigenetically modulate p21 expression, highlighting the potential role of this drug as a chemopreventive agent and in epigenetic cancer therapy. parthenolide 37-49 H3 histone pseudogene 16 Homo sapiens 102-105 23039130-4 2012 Our study aimed to evaluate the antitumour effects of parthenolide, a NF-kappaB inhibitor, in two human glioblastoma cell lines (U87MG and U373) and in glioblastoma xenografts. parthenolide 54-66 nuclear factor kappa B subunit 1 Homo sapiens 70-79 23039130-11 2012 Furthermore, parthenolide reduced Akt phosphorylation and activated mitochondrial signalling, suggesting that the antitumour function of parthenolide may be mediated not only by the inhibition of NF-kappaB but also by the inhibition of Akt signalling and the activation of apoptotic proteins. parthenolide 13-25 AKT serine/threonine kinase 1 Homo sapiens 34-37 23039130-11 2012 Furthermore, parthenolide reduced Akt phosphorylation and activated mitochondrial signalling, suggesting that the antitumour function of parthenolide may be mediated not only by the inhibition of NF-kappaB but also by the inhibition of Akt signalling and the activation of apoptotic proteins. parthenolide 13-25 nuclear factor kappa B subunit 1 Homo sapiens 196-205 23039130-11 2012 Furthermore, parthenolide reduced Akt phosphorylation and activated mitochondrial signalling, suggesting that the antitumour function of parthenolide may be mediated not only by the inhibition of NF-kappaB but also by the inhibition of Akt signalling and the activation of apoptotic proteins. parthenolide 13-25 AKT serine/threonine kinase 1 Homo sapiens 236-239 23039130-11 2012 Furthermore, parthenolide reduced Akt phosphorylation and activated mitochondrial signalling, suggesting that the antitumour function of parthenolide may be mediated not only by the inhibition of NF-kappaB but also by the inhibition of Akt signalling and the activation of apoptotic proteins. parthenolide 137-149 AKT serine/threonine kinase 1 Homo sapiens 34-37 23039130-11 2012 Furthermore, parthenolide reduced Akt phosphorylation and activated mitochondrial signalling, suggesting that the antitumour function of parthenolide may be mediated not only by the inhibition of NF-kappaB but also by the inhibition of Akt signalling and the activation of apoptotic proteins. parthenolide 137-149 nuclear factor kappa B subunit 1 Homo sapiens 196-205 23039130-11 2012 Furthermore, parthenolide reduced Akt phosphorylation and activated mitochondrial signalling, suggesting that the antitumour function of parthenolide may be mediated not only by the inhibition of NF-kappaB but also by the inhibition of Akt signalling and the activation of apoptotic proteins. parthenolide 137-149 AKT serine/threonine kinase 1 Homo sapiens 236-239 22895542-5 2012 Using the human colorectal cancer cell lines HT-29, SW620 and LS174T, we demonstrated that treatment of these cancer cells with PT induces apoptosis using MTT, Annexin V assay and Hoechst 33258 staining. parthenolide 128-130 annexin A5 Homo sapiens 160-169 22433057-7 2012 The results suggest that parthenolide may potentiate the apoptotic effect of geldanamycin on ovarian carcinoma cell lines by the activation of the caspase-8- and Bid-dependent pathway and the mitochondria-mediated apoptotic pathway. parthenolide 25-37 caspase 8 Homo sapiens 147-165 22683888-8 2012 Consistent with a role for NF-kappaB in the changes caused by TNF-alpha, treatment with the NF-kappaB inhibitor parthenolide restored PPAR DNA-binding activity, the expression of PPARbeta/delta-target genes and the expression of SIRT1 and PPARbeta/delta. parthenolide 112-124 tumor necrosis factor Homo sapiens 62-71 22683888-8 2012 Consistent with a role for NF-kappaB in the changes caused by TNF-alpha, treatment with the NF-kappaB inhibitor parthenolide restored PPAR DNA-binding activity, the expression of PPARbeta/delta-target genes and the expression of SIRT1 and PPARbeta/delta. parthenolide 112-124 nuclear factor kappa B subunit 1 Homo sapiens 92-101 22683888-8 2012 Consistent with a role for NF-kappaB in the changes caused by TNF-alpha, treatment with the NF-kappaB inhibitor parthenolide restored PPAR DNA-binding activity, the expression of PPARbeta/delta-target genes and the expression of SIRT1 and PPARbeta/delta. parthenolide 112-124 peroxisome proliferator activated receptor alpha Homo sapiens 134-138 22683888-8 2012 Consistent with a role for NF-kappaB in the changes caused by TNF-alpha, treatment with the NF-kappaB inhibitor parthenolide restored PPAR DNA-binding activity, the expression of PPARbeta/delta-target genes and the expression of SIRT1 and PPARbeta/delta. parthenolide 112-124 peroxisome proliferator activated receptor delta Homo sapiens 179-187 22683888-8 2012 Consistent with a role for NF-kappaB in the changes caused by TNF-alpha, treatment with the NF-kappaB inhibitor parthenolide restored PPAR DNA-binding activity, the expression of PPARbeta/delta-target genes and the expression of SIRT1 and PPARbeta/delta. parthenolide 112-124 sirtuin 1 Homo sapiens 229-234 22683888-8 2012 Consistent with a role for NF-kappaB in the changes caused by TNF-alpha, treatment with the NF-kappaB inhibitor parthenolide restored PPAR DNA-binding activity, the expression of PPARbeta/delta-target genes and the expression of SIRT1 and PPARbeta/delta. parthenolide 112-124 peroxisome proliferator activated receptor delta Homo sapiens 179-193 22278019-3 2012 Exogenous TWEAK increased mouse kidney CXCL16 expression and T-lymphocyte infiltration in vivo, processes inhibited by the NF-kappaB inhibitor parthenolide. parthenolide 143-155 tumor necrosis factor (ligand) superfamily, member 12 Mus musculus 10-15 22238372-6 2012 Pretreatment of trophoblasts with selective inhibitors of I-kB kinase activity (parthenolide and TPCA-1) reduced oxysterol- and LPS-stimulated inflammatory responses, consistent with the involvement of the nuclear factor kappa B (NF-kappaB) pathway downstream of TLR4 signalling. parthenolide 80-92 nuclear factor kappa B subunit 1 Homo sapiens 230-239 22238372-6 2012 Pretreatment of trophoblasts with selective inhibitors of I-kB kinase activity (parthenolide and TPCA-1) reduced oxysterol- and LPS-stimulated inflammatory responses, consistent with the involvement of the nuclear factor kappa B (NF-kappaB) pathway downstream of TLR4 signalling. parthenolide 80-92 toll like receptor 4 Homo sapiens 263-267 22884152-9 2012 Parthenolide decreased the levels of the angiogenic factors MMP-9, VEGF, and IL-8 secreted by the MDA-MB-231 cells. parthenolide 0-12 matrix metallopeptidase 9 Homo sapiens 60-65 22884152-9 2012 Parthenolide decreased the levels of the angiogenic factors MMP-9, VEGF, and IL-8 secreted by the MDA-MB-231 cells. parthenolide 0-12 vascular endothelial growth factor A Homo sapiens 67-71 22884152-9 2012 Parthenolide decreased the levels of the angiogenic factors MMP-9, VEGF, and IL-8 secreted by the MDA-MB-231 cells. parthenolide 0-12 C-X-C motif chemokine ligand 8 Homo sapiens 77-81 22661925-8 2012 Blockade of IL-1beta synthesis with inflammasome inhibitors Parthenolide and Bay11708 significantly reversed ethanol inhibited neurogenesis. parthenolide 60-72 interleukin 1 beta Homo sapiens 12-20 22278019-3 2012 Exogenous TWEAK increased mouse kidney CXCL16 expression and T-lymphocyte infiltration in vivo, processes inhibited by the NF-kappaB inhibitor parthenolide. parthenolide 143-155 chemokine (C-X-C motif) ligand 16 Mus musculus 39-45 22155272-0 2012 Bcl-XL, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis. parthenolide 68-80 BCL2 like 1 Homo sapiens 0-6 22369858-8 2012 In the taxol resistant cell lines, the IC50 values of paclitaxel and parthenolide were 233nM and 32muM, respectively, while the combination had an IC(50) of 128nM. parthenolide 69-81 latexin Homo sapiens 99-102 22155272-2 2012 We show that parthenolide inhibited NF-kappaB transcription factor c-Rel (REL). parthenolide 13-25 nuclear factor kappa B subunit 1 Homo sapiens 36-45 22155272-2 2012 We show that parthenolide inhibited NF-kappaB transcription factor c-Rel (REL). parthenolide 13-25 REL proto-oncogene, NF-kB subunit Homo sapiens 67-72 22155272-3 2012 In addition, the sensitivity of several human B-lymphoma cell lines to parthenolide-induced apoptosis inversely correlated with their levels of anti-apoptosis protein Bcl-X(L). parthenolide 71-83 BCL2 like 1 Homo sapiens 167-175 22155272-4 2012 Furthermore, ectopic expression of Bcl-X(L) (but not Bcl-2) in two B-lymphoma cell lines decreased their sensitivity to parthenolide-induced apoptosis. parthenolide 120-132 BCL2 like 1 Homo sapiens 35-43 22155272-5 2012 Finally, over-expression of a transforming mutant of REL, which increased expression of endogenous Bcl-X(L), decreased the sensitivity of BJAB B-lymphoma cells to parthenolide-induced apoptosis. parthenolide 163-175 BCL2 like 1 Homo sapiens 99-107 22724024-8 2012 Inhibition of both routes through selected molecules (SB203580, quercetin, artemisinin, parthenolide) prevented HZ-dependent lysozyme release. parthenolide 88-100 lysozyme Homo sapiens 125-133 22301094-6 2012 The capacity of rosiglitazone, resveratrol and parthenolide to influence the action of Tat was also assessed. parthenolide 47-59 tyrosine aminotransferase Homo sapiens 87-90 22155740-2 2012 Parthenolide, a sesquiterpene lactone compound isolated from extracts of the herb Feverfew (Tanacetum parthenium), has been demonstrated to be a potent inhibitor of NF-kappaB activation. parthenolide 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 165-174 22155740-9 2012 RESULTS: Administration of parthenolide significantly reduced the severity of DSS-induced colitis as assessed by DAI and histological score, and resulted in downregulation of MPO activity and phospho-NF-kappaB p65 expression by the blockade of phosphorylation and subsequent degradation of IkappaB protein, strikingly reduced the production of TNF-alpha and IL-1beta. parthenolide 27-39 myeloperoxidase Mus musculus 175-178 22155740-9 2012 RESULTS: Administration of parthenolide significantly reduced the severity of DSS-induced colitis as assessed by DAI and histological score, and resulted in downregulation of MPO activity and phospho-NF-kappaB p65 expression by the blockade of phosphorylation and subsequent degradation of IkappaB protein, strikingly reduced the production of TNF-alpha and IL-1beta. parthenolide 27-39 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 200-209 22155740-9 2012 RESULTS: Administration of parthenolide significantly reduced the severity of DSS-induced colitis as assessed by DAI and histological score, and resulted in downregulation of MPO activity and phospho-NF-kappaB p65 expression by the blockade of phosphorylation and subsequent degradation of IkappaB protein, strikingly reduced the production of TNF-alpha and IL-1beta. parthenolide 27-39 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 210-213 22155740-9 2012 RESULTS: Administration of parthenolide significantly reduced the severity of DSS-induced colitis as assessed by DAI and histological score, and resulted in downregulation of MPO activity and phospho-NF-kappaB p65 expression by the blockade of phosphorylation and subsequent degradation of IkappaB protein, strikingly reduced the production of TNF-alpha and IL-1beta. parthenolide 27-39 tumor necrosis factor Mus musculus 344-353 22155740-9 2012 RESULTS: Administration of parthenolide significantly reduced the severity of DSS-induced colitis as assessed by DAI and histological score, and resulted in downregulation of MPO activity and phospho-NF-kappaB p65 expression by the blockade of phosphorylation and subsequent degradation of IkappaB protein, strikingly reduced the production of TNF-alpha and IL-1beta. parthenolide 27-39 interleukin 1 beta Mus musculus 358-366 23554728-7 2012 The expressions of NF-kappaB p50, IkappaBalpha and p-IkappaBalpha were inhibited in both PTN and PTN+LPS group at end of 6 and 12 h and no effects at 24 h. In summary, myocardial NF-kappaB expression occurs 1 h after the administration of LPS. parthenolide 89-92 NFKB inhibitor alpha Rattus norvegicus 34-46 23554728-7 2012 The expressions of NF-kappaB p50, IkappaBalpha and p-IkappaBalpha were inhibited in both PTN and PTN+LPS group at end of 6 and 12 h and no effects at 24 h. In summary, myocardial NF-kappaB expression occurs 1 h after the administration of LPS. parthenolide 89-92 NFKB inhibitor alpha Rattus norvegicus 53-65 22105338-9 2012 In conclusion, the pharmacological inhibitors of the NFkappaB pathway Bay 11-7082 and parthenolide interfere with the survival of erythrocytes involving mechanisms other than disruption of NFkappaB-dependent gene expression. parthenolide 86-98 nuclear factor kappa B subunit 1 Homo sapiens 53-61 22324945-12 2012 Signal transducer and activator of transcription 3 (STAT3) inhibitor parthenolide inhibited the effect of IL-6/sIL-6R on ADAMTS-4, and downregulated ADAMTS-5 expression. parthenolide 69-81 signal transducer and activator of transcription 3 Homo sapiens 0-50 22324945-12 2012 Signal transducer and activator of transcription 3 (STAT3) inhibitor parthenolide inhibited the effect of IL-6/sIL-6R on ADAMTS-4, and downregulated ADAMTS-5 expression. parthenolide 69-81 signal transducer and activator of transcription 3 Homo sapiens 52-57 22324945-12 2012 Signal transducer and activator of transcription 3 (STAT3) inhibitor parthenolide inhibited the effect of IL-6/sIL-6R on ADAMTS-4, and downregulated ADAMTS-5 expression. parthenolide 69-81 interleukin 6 Homo sapiens 106-110 22324945-12 2012 Signal transducer and activator of transcription 3 (STAT3) inhibitor parthenolide inhibited the effect of IL-6/sIL-6R on ADAMTS-4, and downregulated ADAMTS-5 expression. parthenolide 69-81 ADAM metallopeptidase with thrombospondin type 1 motif 4 Homo sapiens 121-129 22324945-12 2012 Signal transducer and activator of transcription 3 (STAT3) inhibitor parthenolide inhibited the effect of IL-6/sIL-6R on ADAMTS-4, and downregulated ADAMTS-5 expression. parthenolide 69-81 ADAM metallopeptidase with thrombospondin type 1 motif 5 Homo sapiens 149-157 21992677-0 2011 Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cells. parthenolide 0-12 mitogen-activated protein kinase 1 Homo sapiens 22-25 22004922-4 2011 The initial hypothermia was exaggerated; the second phase of the biphasic LPS-induced fever and circulating interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFalpha) were significantly attenuated only in parthenolide-pretreated animals. parthenolide 210-222 interleukin 6 Rattus norvegicus 108-121 22004922-4 2011 The initial hypothermia was exaggerated; the second phase of the biphasic LPS-induced fever and circulating interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFalpha) were significantly attenuated only in parthenolide-pretreated animals. parthenolide 210-222 tumor necrosis factor Rattus norvegicus 133-160 22004922-4 2011 The initial hypothermia was exaggerated; the second phase of the biphasic LPS-induced fever and circulating interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFalpha) were significantly attenuated only in parthenolide-pretreated animals. parthenolide 210-222 tumor necrosis factor Rattus norvegicus 162-170 22004922-8 2011 In summary, pretreatment with parthenolide attenuates the febrile response during LPS-induced systemic inflammation by reducing circulating IL-6 and TNFalpha and decreasing hypothalamic NFkappaB/NF-IL6 activation, oxidative stress and expression of COX2. parthenolide 30-42 interleukin 6 Rattus norvegicus 140-144 22004922-8 2011 In summary, pretreatment with parthenolide attenuates the febrile response during LPS-induced systemic inflammation by reducing circulating IL-6 and TNFalpha and decreasing hypothalamic NFkappaB/NF-IL6 activation, oxidative stress and expression of COX2. parthenolide 30-42 tumor necrosis factor Rattus norvegicus 149-157 22004922-8 2011 In summary, pretreatment with parthenolide attenuates the febrile response during LPS-induced systemic inflammation by reducing circulating IL-6 and TNFalpha and decreasing hypothalamic NFkappaB/NF-IL6 activation, oxidative stress and expression of COX2. parthenolide 30-42 CCAAT/enhancer binding protein beta Rattus norvegicus 195-201 22004922-8 2011 In summary, pretreatment with parthenolide attenuates the febrile response during LPS-induced systemic inflammation by reducing circulating IL-6 and TNFalpha and decreasing hypothalamic NFkappaB/NF-IL6 activation, oxidative stress and expression of COX2. parthenolide 30-42 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 249-253 20605167-6 2011 RESULTS: Both parthenolide and resveratrol treatment led to early significant increases in plasma levels of IL-6. parthenolide 14-26 interleukin 6 Rattus norvegicus 108-112 21805026-2 2011 Modification of thermosensitivity by treatment with PTL prior to hyperthermia was investigated in the human prostate cancer androgen-independent cell lines PC3 and DU145. parthenolide 52-55 proprotein convertase subtilisin/kexin type 1 Homo sapiens 156-159 21992677-0 2011 Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cells. parthenolide 0-12 JunB proto-oncogene, AP-1 transcription factor subunit Homo sapiens 30-34 21992677-0 2011 Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cells. parthenolide 0-12 C-X-C motif chemokine ligand 8 Homo sapiens 86-90 21992677-11 2011 Since we previously showed that parthenolide inhibits excessive IL-8 production by CF cells, we evaluated its effects on MAPK and AP-1 activation and showed that parthenolide inhibited ERK and AP-1 activation. parthenolide 32-44 C-X-C motif chemokine ligand 8 Homo sapiens 64-68 21992677-11 2011 Since we previously showed that parthenolide inhibits excessive IL-8 production by CF cells, we evaluated its effects on MAPK and AP-1 activation and showed that parthenolide inhibited ERK and AP-1 activation. parthenolide 32-44 mitogen-activated protein kinase 1 Homo sapiens 185-188 21992677-11 2011 Since we previously showed that parthenolide inhibits excessive IL-8 production by CF cells, we evaluated its effects on MAPK and AP-1 activation and showed that parthenolide inhibited ERK and AP-1 activation. parthenolide 162-174 C-X-C motif chemokine ligand 8 Homo sapiens 64-68 21992677-11 2011 Since we previously showed that parthenolide inhibits excessive IL-8 production by CF cells, we evaluated its effects on MAPK and AP-1 activation and showed that parthenolide inhibited ERK and AP-1 activation. parthenolide 162-174 JunB proto-oncogene, AP-1 transcription factor subunit Homo sapiens 130-134 21992677-11 2011 Since we previously showed that parthenolide inhibits excessive IL-8 production by CF cells, we evaluated its effects on MAPK and AP-1 activation and showed that parthenolide inhibited ERK and AP-1 activation. parthenolide 162-174 mitogen-activated protein kinase 1 Homo sapiens 185-188 21992677-11 2011 Since we previously showed that parthenolide inhibits excessive IL-8 production by CF cells, we evaluated its effects on MAPK and AP-1 activation and showed that parthenolide inhibited ERK and AP-1 activation. parthenolide 162-174 JunB proto-oncogene, AP-1 transcription factor subunit Homo sapiens 193-197 21992677-12 2011 Using a luciferase promoter assay, our studies showed that parthenolide decreased activation of the IL-8 promoter in CF cells stimulated with TNFalpha/IL-1beta. parthenolide 59-71 C-X-C motif chemokine ligand 8 Homo sapiens 100-104 21992677-12 2011 Using a luciferase promoter assay, our studies showed that parthenolide decreased activation of the IL-8 promoter in CF cells stimulated with TNFalpha/IL-1beta. parthenolide 59-71 tumor necrosis factor Homo sapiens 142-150 21992677-12 2011 Using a luciferase promoter assay, our studies showed that parthenolide decreased activation of the IL-8 promoter in CF cells stimulated with TNFalpha/IL-1beta. parthenolide 59-71 interleukin 1 beta Homo sapiens 151-159 21992677-14 2011 Parthenolide inhibited both NFkappaB and MAPK/AP-1 pathways contributing to the inhibition of IL-8 production. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 28-36 21992677-14 2011 Parthenolide inhibited both NFkappaB and MAPK/AP-1 pathways contributing to the inhibition of IL-8 production. parthenolide 0-12 JunB proto-oncogene, AP-1 transcription factor subunit Homo sapiens 46-50 21992677-14 2011 Parthenolide inhibited both NFkappaB and MAPK/AP-1 pathways contributing to the inhibition of IL-8 production. parthenolide 0-12 C-X-C motif chemokine ligand 8 Homo sapiens 94-98 21829151-5 2011 Treatment with parthenolide led to G1 phase cell cycle arrest in 5637 cells by modulation of cyclin D1 and phosphorylated cyclin-dependent kinase 2. parthenolide 15-27 cyclin D1 Homo sapiens 93-102 21829151-5 2011 Treatment with parthenolide led to G1 phase cell cycle arrest in 5637 cells by modulation of cyclin D1 and phosphorylated cyclin-dependent kinase 2. parthenolide 15-27 cyclin dependent kinase 2 Homo sapiens 122-147 21515313-7 2011 In the presence of parthenolide, an inhibitor of NFkappaB, but not of SR-11302, a selective AP-1 inhibitor, thrombin-mediated TFPI2 induction was blunted. parthenolide 19-31 tissue factor pathway inhibitor 2 Homo sapiens 126-131 20870895-13 2011 The NF-kappaB inhibitors gliotoxin and parthenolide increased apoptosis and decreased IL-8 and CXCR2 expression. parthenolide 39-51 nuclear factor kappa B subunit 1 Homo sapiens 4-13 20870895-13 2011 The NF-kappaB inhibitors gliotoxin and parthenolide increased apoptosis and decreased IL-8 and CXCR2 expression. parthenolide 39-51 C-X-C motif chemokine ligand 8 Homo sapiens 86-90 20870895-13 2011 The NF-kappaB inhibitors gliotoxin and parthenolide increased apoptosis and decreased IL-8 and CXCR2 expression. parthenolide 39-51 C-X-C motif chemokine receptor 2 Homo sapiens 95-100 21719790-7 2011 Furthermore, inhibition of NFkappaB with parthenolide prevented TWEAK- or TNFalpha-induced downregulation of Klotho. parthenolide 41-53 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 27-35 21719790-7 2011 Furthermore, inhibition of NFkappaB with parthenolide prevented TWEAK- or TNFalpha-induced downregulation of Klotho. parthenolide 41-53 tumor necrosis factor (ligand) superfamily, member 12 Mus musculus 64-70 21719790-7 2011 Furthermore, inhibition of NFkappaB with parthenolide prevented TWEAK- or TNFalpha-induced downregulation of Klotho. parthenolide 41-53 tumor necrosis factor Mus musculus 74-82 21719790-7 2011 Furthermore, inhibition of NFkappaB with parthenolide prevented TWEAK- or TNFalpha-induced downregulation of Klotho. parthenolide 41-53 klotho Mus musculus 109-115 21703019-6 2011 RESULTS: Treatment of inflamed ECs with the inhibitors actinomycin, parthenolide or with AG-480 resulted in complete blockade of F11R- mRNA expression, indicating the involvement of NF-kappaB and JAK/STAT pathways in this induction. parthenolide 68-80 F11 receptor Homo sapiens 129-133 21631512-5 2011 Similarly, curcumin, parthenolide, and helenalin, but not resveratrol and (-)-epigallocatechin-3-gallate (EGCG), also inhibit NOD2 activation by interfering with NOD2 dimerization. parthenolide 21-33 nucleotide binding oligomerization domain containing 2 Homo sapiens 126-130 21413021-0 2011 Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. parthenolide 0-12 TNF superfamily member 10 Homo sapiens 58-63 21413021-0 2011 Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. parthenolide 0-12 signal transducer and activator of transcription 3 Homo sapiens 132-137 21413021-4 2011 In order to explain these effects we ascertained that parthenolide increased either at protein or mRNA level the total content of death receptors TRAIL-R1 and -R2 as well as their surface expression. parthenolide 54-66 TNF receptor superfamily member 10a Homo sapiens 146-162 21413021-6 2011 We suggest that the effects of parthenolide on death receptors depend on the decrease in the level of phosphorylated and active forms of STAT proteins, an event which could be a consequence of the inhibitory effect exerted by parthenolide on the activation of JAK proteins. parthenolide 31-43 signal transducer and activator of transcription 3 Homo sapiens 137-141 21413021-6 2011 We suggest that the effects of parthenolide on death receptors depend on the decrease in the level of phosphorylated and active forms of STAT proteins, an event which could be a consequence of the inhibitory effect exerted by parthenolide on the activation of JAK proteins. parthenolide 226-238 signal transducer and activator of transcription 3 Homo sapiens 137-141 21413021-7 2011 In agreement with this hypothesis treatment with STAT3 siRNA increased in HCC cells the effect of parthenolide on the expression of death receptors. parthenolide 98-110 signal transducer and activator of transcription 3 Homo sapiens 49-54 21413021-8 2011 Sensitization by parthenolide to TRAIL stimulated in the three cell lines the extrinsic mechanism of apoptosis with the activation of both caspases 8 and 3, whereas mitochondria were not involved in the process. parthenolide 17-29 TNF superfamily member 10 Homo sapiens 33-38 21413021-8 2011 Sensitization by parthenolide to TRAIL stimulated in the three cell lines the extrinsic mechanism of apoptosis with the activation of both caspases 8 and 3, whereas mitochondria were not involved in the process. parthenolide 17-29 caspase 8 Homo sapiens 139-155 21631512-5 2011 Similarly, curcumin, parthenolide, and helenalin, but not resveratrol and (-)-epigallocatechin-3-gallate (EGCG), also inhibit NOD2 activation by interfering with NOD2 dimerization. parthenolide 21-33 nucleotide binding oligomerization domain containing 2 Homo sapiens 162-166 21289336-0 2011 Parthenolide, an NF-kappaB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 17-26 21223972-0 2011 Parthenolide inhibits STAT3 signaling and attenuates angiotensin II-induced left ventricular hypertrophy via modulation of fibroblast activity. parthenolide 0-12 signal transducer and activator of transcription 3 Rattus norvegicus 22-27 21223972-0 2011 Parthenolide inhibits STAT3 signaling and attenuates angiotensin II-induced left ventricular hypertrophy via modulation of fibroblast activity. parthenolide 0-12 angiotensinogen Rattus norvegicus 53-67 21223972-1 2011 Parthenolide has shown promise in treatment of various cancers via inhibition of the transcription factor signal transducer and activator of transcription 3 (STAT3). parthenolide 0-12 signal transducer and activator of transcription 3 Rattus norvegicus 106-156 21223972-1 2011 Parthenolide has shown promise in treatment of various cancers via inhibition of the transcription factor signal transducer and activator of transcription 3 (STAT3). parthenolide 0-12 signal transducer and activator of transcription 3 Rattus norvegicus 158-163 21223972-6 2011 Parthenolide treatment had no effect on ejection fraction, but abolished the activation of STAT3 and reduced the Ang II-induced LVH (LV posterior wall thickness in end-diastole: 2.28 +- 0.12 mm vs. 1.80 +- 0.06 mm, P<0.001). parthenolide 0-12 signal transducer and activator of transcription 3 Rattus norvegicus 91-96 21223972-6 2011 Parthenolide treatment had no effect on ejection fraction, but abolished the activation of STAT3 and reduced the Ang II-induced LVH (LV posterior wall thickness in end-diastole: 2.28 +- 0.12 mm vs. 1.80 +- 0.06 mm, P<0.001). parthenolide 0-12 angiotensinogen Rattus norvegicus 113-119 21223972-8 2011 Parthenolide treatment almost completely abolished the Ang II-induced increase in the number of cells positive for prolyl-4-hydroxylase, a marker for collagen-synthesizing cells, as well as Ang II-induced interstitial fibrosis in the left ventricles. parthenolide 0-12 angiotensinogen Rattus norvegicus 55-61 21223972-8 2011 Parthenolide treatment almost completely abolished the Ang II-induced increase in the number of cells positive for prolyl-4-hydroxylase, a marker for collagen-synthesizing cells, as well as Ang II-induced interstitial fibrosis in the left ventricles. parthenolide 0-12 angiotensinogen Rattus norvegicus 190-196 21223972-10 2011 Moreover, parthenolide attenuated the Ang II-induced expression of interleukin-6, a potent pro-hypertrophic fibroblast-derived factor. parthenolide 10-22 angiotensinogen Rattus norvegicus 38-44 21223972-10 2011 Moreover, parthenolide attenuated the Ang II-induced expression of interleukin-6, a potent pro-hypertrophic fibroblast-derived factor. parthenolide 10-22 interleukin 6 Rattus norvegicus 67-80 21223972-11 2011 We conclude that pharmacological inhibition of STAT3 signaling by parthenolide has favorable effects on pressure overload-induced LVH through attenuation of fibroblast activation. parthenolide 66-78 signal transducer and activator of transcription 3 Rattus norvegicus 47-52 21040770-2 2011 MATERIALS AND METHODS: Dwarf elder leaf extract was subjected to activity guided fractionation using inhibition of TNFalpha induced expression of vascular cell adhesion molecule 1 (VCAM-1) on the surface of human umbilical vein endothelial cells (HUVECs) as monitoring tool (positive control: parthenolide 10muM, VCAM-1 expression (% of control): 5.35+-0.38%). parthenolide 293-305 vascular cell adhesion molecule 1 Homo sapiens 181-187 21289336-7 2011 The phosphorylation of NF-kappaB was down-regulated by the treatment of parthenolide. parthenolide 72-84 nuclear factor kappa B subunit 1 Homo sapiens 23-32 21289336-11 2011 CONCLUSION: The NF-kappaB inhibitor, parthenolide, may enhance chemosensitivity to paclitaxel in the treatment of patients with gastric cancer. parthenolide 37-49 nuclear factor kappa B subunit 1 Homo sapiens 16-25 21325821-2 2011 The substances interfere with the activation and nuclear translocation of nuclear factor NFkappaB, by inhibiting NFkappaB directly (parthenolide) or by interfering with the inactivation of the NFkappaB inhibitory protein IkappaB-alpha (Bay 11-7082). parthenolide 132-144 nuclear factor kappa B subunit 1 Homo sapiens 89-97 21289336-1 2011 AIM: This study evaluated the sesquiterpene lactone parthenolide, an inhibitor of transcription factor nuclear factor-kappaB (NF-kappaB), in the treatment of gastric cancer in vitro and in vivo. parthenolide 52-64 nuclear factor kappa B subunit 1 Homo sapiens 103-124 21325821-2 2011 The substances interfere with the activation and nuclear translocation of nuclear factor NFkappaB, by inhibiting NFkappaB directly (parthenolide) or by interfering with the inactivation of the NFkappaB inhibitory protein IkappaB-alpha (Bay 11-7082). parthenolide 132-144 nuclear factor kappa B subunit 1 Homo sapiens 113-121 21325821-2 2011 The substances interfere with the activation and nuclear translocation of nuclear factor NFkappaB, by inhibiting NFkappaB directly (parthenolide) or by interfering with the inactivation of the NFkappaB inhibitory protein IkappaB-alpha (Bay 11-7082). parthenolide 132-144 nuclear factor kappa B subunit 1 Homo sapiens 113-121 21289336-1 2011 AIM: This study evaluated the sesquiterpene lactone parthenolide, an inhibitor of transcription factor nuclear factor-kappaB (NF-kappaB), in the treatment of gastric cancer in vitro and in vivo. parthenolide 52-64 nuclear factor kappa B subunit 1 Homo sapiens 126-135 21325821-8 2011 Targeting the NFkappaB pathway by Bay 11-7082 (IC(50) 10 muM) and parthenolide (IC(50) 30 muM) triggered suicidal erythrocyte death as shown by annexin V binding and decrease of forward scatter. parthenolide 68-80 nuclear factor kappa B subunit 1 Homo sapiens 14-22 21325821-8 2011 Targeting the NFkappaB pathway by Bay 11-7082 (IC(50) 10 muM) and parthenolide (IC(50) 30 muM) triggered suicidal erythrocyte death as shown by annexin V binding and decrease of forward scatter. parthenolide 68-80 latexin Homo sapiens 94-97 20938215-0 2010 Enhancement of parthenolide-induced apoptosis by a PKC-alpha inhibition through heme oxygenase-1 blockage in cholangiocarcinoma cells. parthenolide 15-27 protein kinase C alpha Homo sapiens 51-60 21325821-8 2011 Targeting the NFkappaB pathway by Bay 11-7082 (IC(50) 10 muM) and parthenolide (IC(50) 30 muM) triggered suicidal erythrocyte death as shown by annexin V binding and decrease of forward scatter. parthenolide 68-80 annexin A5 Homo sapiens 148-157 21325821-10 2011 The effects of Bay 11-7082 and parthenolide on annexin V binding could be fully reversed by the antioxidant N-acetylcysteine. parthenolide 31-43 annexin A5 Homo sapiens 47-56 21325821-11 2011 In conclusion, the pharmacological inhibitors of NFkappaB, Bay 11-7082 and parthenolide, interfere with the survival of erythrocytes involving mechanisms other than disruption of NFkappaB-dependent gene expression. parthenolide 75-87 nuclear factor kappa B subunit 1 Homo sapiens 49-57 20889920-0 2010 Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. parthenolide 53-65 mechanistic target of rapamycin kinase Homo sapiens 104-108 20678173-5 2010 All HZ/trophozoite/15-HETE effects on MMP-9 activity and TNF/IL-1beta production were abrogated by quercetin, artemisinin and parthenolide, inhibitors of IkappaBalpha phosphorylation and subsequent degradation, NF-kappaB nuclear translocation, and NF-kappaB-p65 binding to DNA respectively. parthenolide 126-138 matrix metallopeptidase 9 Homo sapiens 38-43 20678173-5 2010 All HZ/trophozoite/15-HETE effects on MMP-9 activity and TNF/IL-1beta production were abrogated by quercetin, artemisinin and parthenolide, inhibitors of IkappaBalpha phosphorylation and subsequent degradation, NF-kappaB nuclear translocation, and NF-kappaB-p65 binding to DNA respectively. parthenolide 126-138 tumor necrosis factor Homo sapiens 57-60 20678173-5 2010 All HZ/trophozoite/15-HETE effects on MMP-9 activity and TNF/IL-1beta production were abrogated by quercetin, artemisinin and parthenolide, inhibitors of IkappaBalpha phosphorylation and subsequent degradation, NF-kappaB nuclear translocation, and NF-kappaB-p65 binding to DNA respectively. parthenolide 126-138 interleukin 1 beta Homo sapiens 61-69 20678173-5 2010 All HZ/trophozoite/15-HETE effects on MMP-9 activity and TNF/IL-1beta production were abrogated by quercetin, artemisinin and parthenolide, inhibitors of IkappaBalpha phosphorylation and subsequent degradation, NF-kappaB nuclear translocation, and NF-kappaB-p65 binding to DNA respectively. parthenolide 126-138 NFKB inhibitor alpha Homo sapiens 154-166 20926142-3 2011 Both mRNA and protein levels were reduced in THP-1 upon LPS challenge, and it was found that transcriptional down-regulation was mediated by a direct mechanism dependent on NF-kappaB as its specific inhibitor parthenolide prevented the reduction in the alpha7dup transcript. parthenolide 209-221 GLI family zinc finger 2 Homo sapiens 45-50 21625432-4 2011 However, addition of the NF-kappaB inhibitor parthenolide to these cells prevents the downregulation of PDK4 expression but not ERRalpha and PPARbeta/delta DNA binding activity, thus suggesting that additional transcription factors are regulating PDK4. parthenolide 45-57 nuclear factor kappa B subunit 1 Homo sapiens 25-34 21625432-4 2011 However, addition of the NF-kappaB inhibitor parthenolide to these cells prevents the downregulation of PDK4 expression but not ERRalpha and PPARbeta/delta DNA binding activity, thus suggesting that additional transcription factors are regulating PDK4. parthenolide 45-57 pyruvate dehydrogenase kinase 4 Homo sapiens 104-108 21625432-4 2011 However, addition of the NF-kappaB inhibitor parthenolide to these cells prevents the downregulation of PDK4 expression but not ERRalpha and PPARbeta/delta DNA binding activity, thus suggesting that additional transcription factors are regulating PDK4. parthenolide 45-57 pyruvate dehydrogenase kinase 4 Homo sapiens 247-251 21625432-9 2011 Interestingly, the NF-kappaB inhibitor parthenolide prevented the inhibition of E2F1, while E2F1 overexpression reduced interleukin expression in stimulated cardiac cells. parthenolide 39-51 nuclear factor kappa B subunit 1 Homo sapiens 19-28 21625432-9 2011 Interestingly, the NF-kappaB inhibitor parthenolide prevented the inhibition of E2F1, while E2F1 overexpression reduced interleukin expression in stimulated cardiac cells. parthenolide 39-51 E2F transcription factor 1 Homo sapiens 80-84 21179282-8 2010 Treatment with inhibitors of nuclear factor-kappaB (NF-kappaB), i.e., pyrrolidine dithiocarbamate and parthenolide, abrogated the stimulatory effect of poly (I:C) on the production of VEGF and IL-8 in RA FLS. parthenolide 102-114 vascular endothelial growth factor A Homo sapiens 184-188 21179282-8 2010 Treatment with inhibitors of nuclear factor-kappaB (NF-kappaB), i.e., pyrrolidine dithiocarbamate and parthenolide, abrogated the stimulatory effect of poly (I:C) on the production of VEGF and IL-8 in RA FLS. parthenolide 102-114 C-X-C motif chemokine ligand 8 Homo sapiens 193-197 20938215-5 2010 Low PTL concentrations (5 to 10 microM) led to Nrf2-dependent HO-1 induction, which attenuated the apoptogenic effect of PTL in Choi-CK and SCK cells. parthenolide 4-7 NFE2 like bZIP transcription factor 2 Homo sapiens 47-51 20938215-5 2010 Low PTL concentrations (5 to 10 microM) led to Nrf2-dependent HO-1 induction, which attenuated the apoptogenic effect of PTL in Choi-CK and SCK cells. parthenolide 4-7 heme oxygenase 1 Homo sapiens 62-66 20938215-5 2010 Low PTL concentrations (5 to 10 microM) led to Nrf2-dependent HO-1 induction, which attenuated the apoptogenic effect of PTL in Choi-CK and SCK cells. parthenolide 121-124 NFE2 like bZIP transcription factor 2 Homo sapiens 47-51 20938215-5 2010 Low PTL concentrations (5 to 10 microM) led to Nrf2-dependent HO-1 induction, which attenuated the apoptogenic effect of PTL in Choi-CK and SCK cells. parthenolide 121-124 heme oxygenase 1 Homo sapiens 62-66 20578985-5 2010 An examination of pathways common to Paclitaxel and parthenolide signaling revealed that this synergy was related to modulation of the NF-kappaB/ I-kappaB kinase (IKK) signal cascade through IKKbeta. parthenolide 52-64 inhibitor of nuclear factor kappa B kinase subunit beta Homo sapiens 191-198 20699435-2 2010 We evaluated the role of myeloperoxidase (MPO) in determining the sensitivity of leukemia cells to PTL-induced apoptosis. parthenolide 99-102 myeloperoxidase Homo sapiens 42-45 20699435-0 2010 Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. parthenolide 57-69 myeloperoxidase Homo sapiens 0-15 20649582-5 2010 KEY RESULTS: Two IKKbeta inhibitors were found to be highly effective and non-toxic inhibitors of choriodecidual cytokine production: parthenolide and [5-(p-fluorophenyl)-2-ureido] thiophene-3-carboxamide (TPCA-1). parthenolide 134-146 inhibitor of nuclear factor kappa B kinase subunit beta Homo sapiens 17-24 20699435-2 2010 We evaluated the role of myeloperoxidase (MPO) in determining the sensitivity of leukemia cells to PTL-induced apoptosis. parthenolide 99-102 myeloperoxidase Homo sapiens 25-40 20718930-7 2010 However, inhibition of IkappaB (IKK) kinase by parthenolide by stopping NF-kappaB release from the complex with IkappaB did not prevent onset of resistance, but it invoked some resistance even in groups with shorter, 1 h dark pause. parthenolide 47-59 nuclear factor kappa B subunit 1 Homo sapiens 72-81 20702415-6 2010 Interestingly, the recruitment of both MTA1 and MyD88 expression is effectively blocked by NF-kappaB inhibitor parthenolide. parthenolide 111-123 metastasis associated 1 Homo sapiens 39-43 20702415-6 2010 Interestingly, the recruitment of both MTA1 and MyD88 expression is effectively blocked by NF-kappaB inhibitor parthenolide. parthenolide 111-123 MYD88 innate immune signal transduction adaptor Homo sapiens 48-53 20702415-6 2010 Interestingly, the recruitment of both MTA1 and MyD88 expression is effectively blocked by NF-kappaB inhibitor parthenolide. parthenolide 111-123 nuclear factor kappa B subunit 1 Homo sapiens 91-100 20554912-7 2010 The activation of NF-kappaB was blocked by using the inhibitors parthenolide or p65 small interfering RNA (siRNA) which both led to a decrease in AT(1)R expression. parthenolide 64-76 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 18-27 20554912-7 2010 The activation of NF-kappaB was blocked by using the inhibitors parthenolide or p65 small interfering RNA (siRNA) which both led to a decrease in AT(1)R expression. parthenolide 64-76 angiotensin II, type I receptor-associated protein Mus musculus 146-152 20554912-9 2010 p65-DNA binding was assessed using electrophoretic mobility shift assay, and it was shown that there was a time-dependent increased binding that was inhibited by means of parthenolide pretreatment or siRNA-mediated p65 gene silencing. parthenolide 171-183 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 0-3 20699435-3 2010 In this study, the level of PTL-induced generation of reactive oxygen species (ROS) and apoptosis was significantly higher in the MPO-high leukemia cell lines compared with the MPO-low leukemia cell lines. parthenolide 28-31 myeloperoxidase Homo sapiens 130-133 20699435-6 2010 The extent of PTL-induced apoptosis of the CD34+CD38- cell fraction was significantly greater in the MPO-high AML cases, compared with the MPO-low AML (P < 0.01) and normal CD34+ marrow cells (P < 0.01). parthenolide 14-17 CD34 molecule Homo sapiens 43-47 20699435-6 2010 The extent of PTL-induced apoptosis of the CD34+CD38- cell fraction was significantly greater in the MPO-high AML cases, compared with the MPO-low AML (P < 0.01) and normal CD34+ marrow cells (P < 0.01). parthenolide 14-17 CD38 molecule Homo sapiens 48-52 20699435-6 2010 The extent of PTL-induced apoptosis of the CD34+CD38- cell fraction was significantly greater in the MPO-high AML cases, compared with the MPO-low AML (P < 0.01) and normal CD34+ marrow cells (P < 0.01). parthenolide 14-17 myeloperoxidase Homo sapiens 101-104 20699435-6 2010 The extent of PTL-induced apoptosis of the CD34+CD38- cell fraction was significantly greater in the MPO-high AML cases, compared with the MPO-low AML (P < 0.01) and normal CD34+ marrow cells (P < 0.01). parthenolide 14-17 myeloperoxidase Homo sapiens 139-142 20699435-6 2010 The extent of PTL-induced apoptosis of the CD34+CD38- cell fraction was significantly greater in the MPO-high AML cases, compared with the MPO-low AML (P < 0.01) and normal CD34+ marrow cells (P < 0.01). parthenolide 14-17 CD34 molecule Homo sapiens 176-180 20701602-0 2010 The NF (Nuclear factor)-kappaB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. parthenolide 41-53 mitogen-activated protein kinase kinase 7 Homo sapiens 110-114 20701602-0 2010 The NF (Nuclear factor)-kappaB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. parthenolide 41-53 mitogen-activated protein kinase 8 Homo sapiens 115-119 20701602-1 2010 Interactions between the nuclear factor (NF)-kappaB inhibitor parthenolide and the pan-histone deacetylase inhibitors (HDACIs) vorinostat and LBH589 were investigated in human acute myeloid leukaemia (AML) cells, including primary AML blasts. parthenolide 62-74 nuclear factor kappa B subunit 1 Homo sapiens 25-51 20701602-2 2010 Co-administration of parthenolide blocked HDACI-mediated phosphorylation/activation of IKK and RelA/p65 in association with increased JNK1 activation in various AML cell types. parthenolide 21-33 RELA proto-oncogene, NF-kB subunit Homo sapiens 95-99 20701602-2 2010 Co-administration of parthenolide blocked HDACI-mediated phosphorylation/activation of IKK and RelA/p65 in association with increased JNK1 activation in various AML cell types. parthenolide 21-33 RELA proto-oncogene, NF-kB subunit Homo sapiens 100-103 20701602-2 2010 Co-administration of parthenolide blocked HDACI-mediated phosphorylation/activation of IKK and RelA/p65 in association with increased JNK1 activation in various AML cell types. parthenolide 21-33 mitogen-activated protein kinase 8 Homo sapiens 134-138 20701602-4 2010 Significantly, parthenolide also increased HDACI-mediated cell death in haematopoietic cells transduced with the MLL-MLLT1 fusion gene, which exhibit certain leukaemia-initiating cell characteristics, as well as primary AML blasts. parthenolide 15-27 lysine methyltransferase 2A Homo sapiens 113-116 20701602-4 2010 Significantly, parthenolide also increased HDACI-mediated cell death in haematopoietic cells transduced with the MLL-MLLT1 fusion gene, which exhibit certain leukaemia-initiating cell characteristics, as well as primary AML blasts. parthenolide 15-27 MLLT1 super elongation complex subunit Homo sapiens 117-122 20701602-6 2010 Notably, blockade of c-Jun N-terminal kinase (JNK) signalling by either pharmacological inhibitors or genetic means (e.g. dominant-negative JNK1 or JNK1 shRNA) diminished parthenolide/HDACI-mediated lethality. parthenolide 171-183 mitogen-activated protein kinase 8 Homo sapiens 21-44 20701602-6 2010 Notably, blockade of c-Jun N-terminal kinase (JNK) signalling by either pharmacological inhibitors or genetic means (e.g. dominant-negative JNK1 or JNK1 shRNA) diminished parthenolide/HDACI-mediated lethality. parthenolide 171-183 mitogen-activated protein kinase 8 Homo sapiens 46-49 20701602-6 2010 Notably, blockade of c-Jun N-terminal kinase (JNK) signalling by either pharmacological inhibitors or genetic means (e.g. dominant-negative JNK1 or JNK1 shRNA) diminished parthenolide/HDACI-mediated lethality. parthenolide 171-183 mitogen-activated protein kinase 8 Homo sapiens 140-144 20701602-6 2010 Notably, blockade of c-Jun N-terminal kinase (JNK) signalling by either pharmacological inhibitors or genetic means (e.g. dominant-negative JNK1 or JNK1 shRNA) diminished parthenolide/HDACI-mediated lethality. parthenolide 171-183 mitogen-activated protein kinase 8 Homo sapiens 148-152 20701602-7 2010 Moreover, dominant-negative MKK7, but not dominant-negative MKK4/SEK1, blocked JNK1 activation and apoptosis induced by parthenolide/HDACI regimens. parthenolide 120-132 mitogen-activated protein kinase kinase 7 Homo sapiens 28-32 20701602-7 2010 Moreover, dominant-negative MKK7, but not dominant-negative MKK4/SEK1, blocked JNK1 activation and apoptosis induced by parthenolide/HDACI regimens. parthenolide 120-132 mitogen-activated protein kinase 8 Homo sapiens 79-83 20701602-8 2010 Together, these findings indicate that parthenolide potentiates HDACI lethality in human AML cells through a process involving NF-kappaB inhibition and subsequent MKK7-dependent activation of the SAPK/JNK pathway. parthenolide 39-51 mitogen-activated protein kinase kinase 7 Homo sapiens 163-167 20701602-8 2010 Together, these findings indicate that parthenolide potentiates HDACI lethality in human AML cells through a process involving NF-kappaB inhibition and subsequent MKK7-dependent activation of the SAPK/JNK pathway. parthenolide 39-51 mitogen-activated protein kinase 8 Homo sapiens 201-204 20582811-5 2010 The natural products curcumin, resveratrol and parthenolide are known inhibitors of the activation of NF-kappaB. parthenolide 47-59 nuclear factor kappa B subunit 1 Homo sapiens 102-111 20434582-4 2010 Thus, secretion of IL-1beta decreased significantly when cells were depleted of NLRP3 or treated with the anti-inflammatory inhibitors parthenolide or Bay 11-7082, which inhibit inflammasomes and the transcription factor NF-kappaB. parthenolide 135-147 interleukin 1 beta Homo sapiens 19-27 20434582-4 2010 Thus, secretion of IL-1beta decreased significantly when cells were depleted of NLRP3 or treated with the anti-inflammatory inhibitors parthenolide or Bay 11-7082, which inhibit inflammasomes and the transcription factor NF-kappaB. parthenolide 135-147 nuclear factor kappa B subunit 1 Homo sapiens 221-230 20590608-2 2010 Here, we report the effects of parthenolide on either untreated, cisplatin- or TNFalpha-treated melanoma cell lines A375, 1205Lu and WM793, exhibiting different levels of constitutive NF-kappaB activity. parthenolide 31-43 tumor necrosis factor Homo sapiens 79-87 20590608-7 2010 KEY RESULTS: Parthenolide suppressed both constitutive and induced NF-kappaB activity in melanoma cells. parthenolide 13-25 nuclear factor kappa B subunit 1 Homo sapiens 67-76 20590608-10 2010 These findings not only reflected differences between melanoma cell lines in basal expression of NF-kappaB-regulated genes, but also suggested other parthenolide targets involved in cell cycle progression, migration, invasiveness and survival. parthenolide 149-161 nuclear factor kappa B subunit 1 Homo sapiens 97-106 20590608-11 2010 CONCLUSIONS: Inhibition of constitutive and therapeutically induced NF-kappaB pathway by parthenolide might be useful in the treatment of melanoma, although the diversity of changes induced in melanoma cells with different genetic backgrounds indicate context-dependent poly-pharmacological properties of this compound. parthenolide 89-101 nuclear factor kappa B subunit 1 Homo sapiens 68-77 19432816-8 2010 Treatment of resistant cells with parthenolide, an inhibitor of inhibitor of kappaB (I-kappaB), eliminated TRAIL-induced NF-kappaB activity but not TRAIL resistance. parthenolide 34-46 TNF superfamily member 10 Homo sapiens 107-112 20209491-0 2010 A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species. parthenolide 16-28 nuclear factor kappa B subunit 1 Homo sapiens 93-101 20540695-9 2010 We found that either parthenolide or magnolol could effectively inhibit the gene expression mediated by NF-kappaB and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-kappaB. parthenolide 21-33 nuclear factor kappa B subunit 1 Homo sapiens 104-113 20540695-9 2010 We found that either parthenolide or magnolol could effectively inhibit the gene expression mediated by NF-kappaB and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-kappaB. parthenolide 21-33 fibroblast growth factor 2 Homo sapiens 136-140 20540695-9 2010 We found that either parthenolide or magnolol could effectively inhibit the gene expression mediated by NF-kappaB and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-kappaB. parthenolide 21-33 matrix metallopeptidase 1 Homo sapiens 145-150 20540695-9 2010 We found that either parthenolide or magnolol could effectively inhibit the gene expression mediated by NF-kappaB and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-kappaB. parthenolide 21-33 RELA proto-oncogene, NF-kB subunit Homo sapiens 177-180 20540695-9 2010 We found that either parthenolide or magnolol could effectively inhibit the gene expression mediated by NF-kappaB and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-kappaB. parthenolide 21-33 nuclear factor kappa B subunit 1 Homo sapiens 201-210 20233868-5 2010 In PC3 but not PrEC cells, parthenolide activates NADPH oxidase, leading to a decrease in the level of reduced thioredoxin, activation of phosphoinositide 3-kinase/Akt, and consequent FOXO3a phosphorylation, which results in the downregulation of FOXO3a targets antioxidant enzyme manganese superoxide dismutase and catalase. parthenolide 27-39 thioredoxin Homo sapiens 111-122 20151982-6 2010 Inhibition of HIF-1alpha by chetomin and NF-kappaB by parthenolide reduced mRNA and protein expression of the studied molecules and prevented invasion of hypoxic MCF-7 cells. parthenolide 54-66 hypoxia inducible factor 1 subunit alpha Homo sapiens 14-24 19821157-5 2010 Parthenolide was added as NF-kappaB inhibitor. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 26-35 19821157-9 2010 The levels of NF-kappaB and API-5, as well as NF-kappaB activity and API-5 phosphorylation level, were in accordance with Pim-2 level, but could be reversed by Parthenolide. parthenolide 160-172 nuclear factor kappa B subunit 1 Homo sapiens 14-23 19821157-9 2010 The levels of NF-kappaB and API-5, as well as NF-kappaB activity and API-5 phosphorylation level, were in accordance with Pim-2 level, but could be reversed by Parthenolide. parthenolide 160-172 apoptosis inhibitor 5 Homo sapiens 28-33 19821157-9 2010 The levels of NF-kappaB and API-5, as well as NF-kappaB activity and API-5 phosphorylation level, were in accordance with Pim-2 level, but could be reversed by Parthenolide. parthenolide 160-172 nuclear factor kappa B subunit 1 Homo sapiens 46-55 19821157-9 2010 The levels of NF-kappaB and API-5, as well as NF-kappaB activity and API-5 phosphorylation level, were in accordance with Pim-2 level, but could be reversed by Parthenolide. parthenolide 160-172 apoptosis inhibitor 5 Homo sapiens 69-74 19821157-9 2010 The levels of NF-kappaB and API-5, as well as NF-kappaB activity and API-5 phosphorylation level, were in accordance with Pim-2 level, but could be reversed by Parthenolide. parthenolide 160-172 Pim-2 proto-oncogene, serine/threonine kinase Homo sapiens 122-127 20368435-9 2010 The alpha-beta unsaturated carbonyl containing compounds ethacrynic acid and parthenolide activated Nrf2 in normal peripheral blood mononuclear cells, but had a less potent effect in CLL cells. parthenolide 77-89 NFE2 like bZIP transcription factor 2 Homo sapiens 100-104 20233868-3 2010 Here, we show that parthenolide, a sesquiterpene lactone, selectively exhibits a radiosensitization effect on prostate cancer PC3 cells but not on normal prostate epithelial PrEC cells. parthenolide 19-31 chromobox 8 Homo sapiens 126-129 20233868-4 2010 Parthenolide causes oxidative stress in PC3 cells but not in PrEC cells, as determined by the oxidation of the ROS-sensitive probe H(2)DCFDA and intracellular reduced thiol and disulfide levels. parthenolide 0-12 chromobox 8 Homo sapiens 40-43 20233868-5 2010 In PC3 but not PrEC cells, parthenolide activates NADPH oxidase, leading to a decrease in the level of reduced thioredoxin, activation of phosphoinositide 3-kinase/Akt, and consequent FOXO3a phosphorylation, which results in the downregulation of FOXO3a targets antioxidant enzyme manganese superoxide dismutase and catalase. parthenolide 27-39 chromobox 8 Homo sapiens 3-6 20151982-6 2010 Inhibition of HIF-1alpha by chetomin and NF-kappaB by parthenolide reduced mRNA and protein expression of the studied molecules and prevented invasion of hypoxic MCF-7 cells. parthenolide 54-66 nuclear factor kappa B subunit 1 Homo sapiens 41-50 20233868-5 2010 In PC3 but not PrEC cells, parthenolide activates NADPH oxidase, leading to a decrease in the level of reduced thioredoxin, activation of phosphoinositide 3-kinase/Akt, and consequent FOXO3a phosphorylation, which results in the downregulation of FOXO3a targets antioxidant enzyme manganese superoxide dismutase and catalase. parthenolide 27-39 AKT serine/threonine kinase 1 Homo sapiens 164-167 20233868-5 2010 In PC3 but not PrEC cells, parthenolide activates NADPH oxidase, leading to a decrease in the level of reduced thioredoxin, activation of phosphoinositide 3-kinase/Akt, and consequent FOXO3a phosphorylation, which results in the downregulation of FOXO3a targets antioxidant enzyme manganese superoxide dismutase and catalase. parthenolide 27-39 forkhead box O3 Homo sapiens 184-190 20233868-5 2010 In PC3 but not PrEC cells, parthenolide activates NADPH oxidase, leading to a decrease in the level of reduced thioredoxin, activation of phosphoinositide 3-kinase/Akt, and consequent FOXO3a phosphorylation, which results in the downregulation of FOXO3a targets antioxidant enzyme manganese superoxide dismutase and catalase. parthenolide 27-39 forkhead box O3 Homo sapiens 247-253 20233868-5 2010 In PC3 but not PrEC cells, parthenolide activates NADPH oxidase, leading to a decrease in the level of reduced thioredoxin, activation of phosphoinositide 3-kinase/Akt, and consequent FOXO3a phosphorylation, which results in the downregulation of FOXO3a targets antioxidant enzyme manganese superoxide dismutase and catalase. parthenolide 27-39 catalase Homo sapiens 316-324 20233868-6 2010 Importantly, when combined with radiation, parthenolide further increases ROS levels in PC3 cells whereas it decreases radiation-induced oxidative stress in PrEC cells, possibly by increasing reduced glutathione levels. parthenolide 43-55 chromobox 8 Homo sapiens 88-91 19774508-0 2010 Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-kappaB activation and induction of apoptosis. parthenolide 22-34 nuclear factor kappa B subunit 1 Homo sapiens 127-136 19949351-11 2010 Cell death accompanied by mitochondrial membrane depolarization and caspase-3 activation was observed as the result of parthenolide application. parthenolide 119-131 caspase 3 Homo sapiens 68-77 20093358-4 2010 Here, we show that the herbal NF-kappaB inhibitory compound parthenolide inhibits the activity of multiple inflammasomes in macrophages by directly inhibiting the protease activity of caspase-1. parthenolide 60-72 caspase 1 Homo sapiens 184-193 20093358-6 2010 In vitro assays of the effect of parthenolide and Bay 11-7082 on the ATPase activity of NLRP3 demonstrated that both compounds inhibit the ATPase activity of NLRP3, suggesting that the inhibitory effect of these compounds on inflammasome activity could be mediated in part through their effect on the ATPase activity of NLRP3. parthenolide 33-45 NLR family pyrin domain containing 3 Homo sapiens 88-93 20093358-6 2010 In vitro assays of the effect of parthenolide and Bay 11-7082 on the ATPase activity of NLRP3 demonstrated that both compounds inhibit the ATPase activity of NLRP3, suggesting that the inhibitory effect of these compounds on inflammasome activity could be mediated in part through their effect on the ATPase activity of NLRP3. parthenolide 33-45 NLR family pyrin domain containing 3 Homo sapiens 158-163 20093358-6 2010 In vitro assays of the effect of parthenolide and Bay 11-7082 on the ATPase activity of NLRP3 demonstrated that both compounds inhibit the ATPase activity of NLRP3, suggesting that the inhibitory effect of these compounds on inflammasome activity could be mediated in part through their effect on the ATPase activity of NLRP3. parthenolide 33-45 NLR family pyrin domain containing 3 Homo sapiens 158-163 20093358-7 2010 Our results thus elucidate the molecular mechanism for the therapeutic anti-inflammatory activity of parthenolide and identify vinyl sulfones as a new class of potential therapeutics that target the NLRP3 inflammasome. parthenolide 101-113 NLR family pyrin domain containing 3 Homo sapiens 199-204 19774508-8 2010 These findings indicate that parthenolide could markedly enhance sensitivity of A549 cells to low-dose oxaliplatin by inhibiting NF-kappaB activation and inducing apoptosis. parthenolide 29-41 nuclear factor kappa B subunit 1 Homo sapiens 129-138 19774508-3 2010 Thus, this study was performed to explore the effect of parthenolide, a natural NF-kappaB inhibitor, on human lung cancer A549 cells treated with low-dose oxaliplatin, as well as to determine the potential mechanisms involved. parthenolide 56-68 nuclear factor kappa B subunit 1 Homo sapiens 80-89 19943112-6 2010 Interestingly, selective inactivation of NF-kappaB using either an NF-kappaB decoy or parthenolide, a blocker of IKK-dependent NF-kappaB activation, reduced, rather then increased, apoptosis and p53 levels in FC1-depleted cells. parthenolide 86-98 nuclear factor kappa B subunit 1 Homo sapiens 41-50 19900478-7 2010 The expression of RANKL mRNA and protein was blocked completely by inhibitors of NF-kappaB (parthenolide) or of the JAK II-STAT3 pathway (AG490), showing that the RANKL expression pathway is mediated by NF-kappaB and STAT3. parthenolide 92-104 TNF superfamily member 11 Homo sapiens 18-23 19900478-7 2010 The expression of RANKL mRNA and protein was blocked completely by inhibitors of NF-kappaB (parthenolide) or of the JAK II-STAT3 pathway (AG490), showing that the RANKL expression pathway is mediated by NF-kappaB and STAT3. parthenolide 92-104 TNF superfamily member 11 Homo sapiens 163-168 19943112-6 2010 Interestingly, selective inactivation of NF-kappaB using either an NF-kappaB decoy or parthenolide, a blocker of IKK-dependent NF-kappaB activation, reduced, rather then increased, apoptosis and p53 levels in FC1-depleted cells. parthenolide 86-98 tumor protein p53 Homo sapiens 195-198 19584059-6 2009 An inhibition of NF-kappaB activity by parthenolide significantly increased the transcriptional activity of the F-promoter. parthenolide 39-51 nuclear factor kappa B subunit 1 Homo sapiens 17-26 19900365-7 2009 Parthenolide suppressed the expression of TNF-alpha and enhances the proliferation of newborn cells in the ischemic striatum. parthenolide 0-12 tumor necrosis factor Rattus norvegicus 42-51 19333555-5 2010 When ECs were pre-treated with a nuclear factor-kappaB (NF-kappaB) inhibitor, i.e., parthenolide, their TNF-alpha-mediated down-regulation of TM expression was inhibited. parthenolide 84-96 tumor necrosis factor Homo sapiens 104-113 19956548-5 2009 In addition, we used immuno-precipitation techniques to identify the central redox regulator thioredoxin, as one of the surface protein thiol targets modified by parthenolide. parthenolide 162-174 thioredoxin Homo sapiens 93-104 19956548-8 2009 Together these data support the likelihood that GSH inhibits the effect of parthenolide on JNK, NFkappaB and cell death through its direct inhibition of parthenolide"s modulation of exofacial thiols. parthenolide 75-87 mitogen-activated protein kinase 8 Homo sapiens 91-94 19956548-8 2009 Together these data support the likelihood that GSH inhibits the effect of parthenolide on JNK, NFkappaB and cell death through its direct inhibition of parthenolide"s modulation of exofacial thiols. parthenolide 75-87 nuclear factor kappa B subunit 1 Homo sapiens 96-104 19759193-6 2009 Caffeic acid phenethyl ester and parthenolide inhibited NF-kappaB activation, as seen by gel shift assays and immunoblotting for p65 in nuclear fractions, as well as decreased production of IL-6 and MCP-1. parthenolide 33-45 RELA proto-oncogene, NF-kB subunit Homo sapiens 129-132 19759193-6 2009 Caffeic acid phenethyl ester and parthenolide inhibited NF-kappaB activation, as seen by gel shift assays and immunoblotting for p65 in nuclear fractions, as well as decreased production of IL-6 and MCP-1. parthenolide 33-45 interleukin 6 Homo sapiens 190-194 19759193-6 2009 Caffeic acid phenethyl ester and parthenolide inhibited NF-kappaB activation, as seen by gel shift assays and immunoblotting for p65 in nuclear fractions, as well as decreased production of IL-6 and MCP-1. parthenolide 33-45 C-C motif chemokine ligand 2 Homo sapiens 199-204 19067767-2 2009 We also found that parthenolide could target IKK activity and then inhibit NF-kappaB; this promoted cytochrome c release and activation of caspases 3 and 9. parthenolide 19-31 cytochrome c, somatic Homo sapiens 100-112 19067767-2 2009 We also found that parthenolide could target IKK activity and then inhibit NF-kappaB; this promoted cytochrome c release and activation of caspases 3 and 9. parthenolide 19-31 caspase 3 Homo sapiens 139-155 19067767-3 2009 Inhibition of caspase activity blocked the activation of caspase cascade, implying that the observed synergy was related to caspases 3 and 9 activation of parthenolide. parthenolide 155-167 caspase 9 Homo sapiens 14-21 19067767-3 2009 Inhibition of caspase activity blocked the activation of caspase cascade, implying that the observed synergy was related to caspases 3 and 9 activation of parthenolide. parthenolide 155-167 caspase 9 Homo sapiens 57-64 19067767-3 2009 Inhibition of caspase activity blocked the activation of caspase cascade, implying that the observed synergy was related to caspases 3 and 9 activation of parthenolide. parthenolide 155-167 caspase 9 Homo sapiens 124-140 19067767-5 2009 Finally, exposure to parthenolide resulted in the inhibition of several NF-kappaB transcript anti-apoptotic proteins such as c-IAP1 and Bcl-xl. parthenolide 21-33 PYD and CARD domain containing Homo sapiens 122-126 19067767-5 2009 Finally, exposure to parthenolide resulted in the inhibition of several NF-kappaB transcript anti-apoptotic proteins such as c-IAP1 and Bcl-xl. parthenolide 21-33 baculoviral IAP repeat containing 3 Homo sapiens 127-131 19067767-5 2009 Finally, exposure to parthenolide resulted in the inhibition of several NF-kappaB transcript anti-apoptotic proteins such as c-IAP1 and Bcl-xl. parthenolide 21-33 BCL2 like 1 Homo sapiens 136-142 19067767-6 2009 These data strengthen the rationale for using parthenolide to decrease the apoptotic threshold via caspase-dependent processes for treatment of non-small cell lung cancer with paclitaxel chemoresistance. parthenolide 46-58 caspase 9 Homo sapiens 99-106 20134045-7 2009 Inhibition of NF-kappaB with curcumin or parthenolide resulted in a decrease of IL-8 secretion. parthenolide 41-53 C-X-C motif chemokine ligand 8 Homo sapiens 80-84 19584264-3 2009 In A549 cells, inhibition of nuclear factor-kappaB by parthenolide resulted in activation of the mitochondrial death pathway to promote cytochrome c release and caspase 3 and 9 activation. parthenolide 54-66 caspase 3 Mus musculus 161-170 19659784-9 2009 PAR-induced apoptosis was associated with intracellular events including the decline of mitochondrial potential, increased release of cytochrome C from the mitochondria, decreased expression of Bcl-2, increased expression of Bax, Bid and tBid and activation of caspase 3 and 8. parthenolide 0-3 cytochrome c, somatic Homo sapiens 134-146 19659784-9 2009 PAR-induced apoptosis was associated with intracellular events including the decline of mitochondrial potential, increased release of cytochrome C from the mitochondria, decreased expression of Bcl-2, increased expression of Bax, Bid and tBid and activation of caspase 3 and 8. parthenolide 0-3 BCL2 apoptosis regulator Homo sapiens 194-199 19659784-9 2009 PAR-induced apoptosis was associated with intracellular events including the decline of mitochondrial potential, increased release of cytochrome C from the mitochondria, decreased expression of Bcl-2, increased expression of Bax, Bid and tBid and activation of caspase 3 and 8. parthenolide 0-3 BCL2 associated X, apoptosis regulator Homo sapiens 225-228 19659784-9 2009 PAR-induced apoptosis was associated with intracellular events including the decline of mitochondrial potential, increased release of cytochrome C from the mitochondria, decreased expression of Bcl-2, increased expression of Bax, Bid and tBid and activation of caspase 3 and 8. parthenolide 0-3 BH3 interacting domain death agonist Homo sapiens 230-233 19659784-9 2009 PAR-induced apoptosis was associated with intracellular events including the decline of mitochondrial potential, increased release of cytochrome C from the mitochondria, decreased expression of Bcl-2, increased expression of Bax, Bid and tBid and activation of caspase 3 and 8. parthenolide 0-3 caspase 3 Homo sapiens 261-270 19671767-6 2009 Celastrol and parthenolide but not BMS-345541 prevented the activation of both IKKalpha and IKKbeta, and celastrol inhibited IKKalpha/beta activation by preventing the phosphorylation of TAK1, a key receptor-associated factor upstream of IKK. parthenolide 14-26 inhibitor of nuclear factor kappa B kinase subunit beta Rattus norvegicus 92-99 19671767-6 2009 Celastrol and parthenolide but not BMS-345541 prevented the activation of both IKKalpha and IKKbeta, and celastrol inhibited IKKalpha/beta activation by preventing the phosphorylation of TAK1, a key receptor-associated factor upstream of IKK. parthenolide 14-26 mitogen activated protein kinase kinase kinase 7 Rattus norvegicus 187-241 19671767-7 2009 Celastrol and parthenolide markedly reduced the mRNA expression of matrix metalloproteinase 9 and urinary plasminogen activator, and inhibited W256 migration. parthenolide 14-26 matrix metallopeptidase 9 Rattus norvegicus 67-93 19423687-7 2009 Treatment with a NF-kappaB inhibitor, parthenolide, inhibited CTGF-induced renal inflammatory responses, including the up-regulation of chemokines and cytokines. parthenolide 38-50 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 17-26 19423687-7 2009 Treatment with a NF-kappaB inhibitor, parthenolide, inhibited CTGF-induced renal inflammatory responses, including the up-regulation of chemokines and cytokines. parthenolide 38-50 cellular communication network factor 2 Mus musculus 62-66 19585671-7 2009 Addition of parthenolide also increased cell population at G(0)/G(1) phase by 19.2%~65.7% (P<0.05) and decreased cell population at S phase by 50.7%~84.8% (P<0.05), which is consistent with its stimulatory effects on p21 and p27. parthenolide 12-24 KRAS proto-oncogene, GTPase Rattus norvegicus 223-226 19585671-7 2009 Addition of parthenolide also increased cell population at G(0)/G(1) phase by 19.2%~65.7% (P<0.05) and decreased cell population at S phase by 50.7%~84.8% (P<0.05), which is consistent with its stimulatory effects on p21 and p27. parthenolide 12-24 cyclin-dependent kinase inhibitor 1B Rattus norvegicus 231-234 19585671-8 2009 In addition, parthenolide also increased IkappaBalpha expression and reduced Cox-2 expression in a time-dependent manner. parthenolide 13-25 NFKB inhibitor alpha Rattus norvegicus 41-53 19585671-8 2009 In addition, parthenolide also increased IkappaBalpha expression and reduced Cox-2 expression in a time-dependent manner. parthenolide 13-25 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 77-82 19585671-10 2009 IkappaBalpha and Cox-2 are likely involved in such inhibitory effect of parthenolide on VSMC proliferation. parthenolide 72-84 NFKB inhibitor alpha Rattus norvegicus 0-12 19585671-10 2009 IkappaBalpha and Cox-2 are likely involved in such inhibitory effect of parthenolide on VSMC proliferation. parthenolide 72-84 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 17-22 19426154-7 2009 TWEAK-induced proliferation was prevented by inhibitors of these protein kinases and by the NF-kappaB inhibitor parthenolide. parthenolide 112-124 tumor necrosis factor (ligand) superfamily, member 12 Mus musculus 0-5 19555300-4 2009 OBJECTIVES: To highlight the caution necessary with this therapeutic approach, we review our investigations in a mouse sepsis model with parthenolide and ethyl pyruvate, two NF-kappaB inhibitors proposed for clinical study. parthenolide 137-149 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 174-183 19555300-5 2009 RESULTS: Consistent with published studies, parthenolide decreased NF-kappaB binding activity and inflammatory cytokine release from lipopolysaccharide (LPS) stimulated RAW 264.7 cells in vitro. parthenolide 44-56 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 67-76 19671767-5 2009 Celastrol, BMS-345541, and parthenolide abolished IL1beta and tumor necrosis factor alpha-induced IkappaB phosphorylation and prevented nuclear translocation of NF-kappaB and DNA binding. parthenolide 27-39 interleukin 1 beta Rattus norvegicus 50-57 19671767-5 2009 Celastrol, BMS-345541, and parthenolide abolished IL1beta and tumor necrosis factor alpha-induced IkappaB phosphorylation and prevented nuclear translocation of NF-kappaB and DNA binding. parthenolide 27-39 tumor necrosis factor Rattus norvegicus 62-89 19671767-6 2009 Celastrol and parthenolide but not BMS-345541 prevented the activation of both IKKalpha and IKKbeta, and celastrol inhibited IKKalpha/beta activation by preventing the phosphorylation of TAK1, a key receptor-associated factor upstream of IKK. parthenolide 14-26 component of inhibitor of nuclear factor kappa B kinase complex Rattus norvegicus 79-87 19204913-2 2009 In this study, we show that the sesquiterpene lactone parthenolide (PTL) is cytotoxic to prostate TICs isolated from prostate cancer cell lines: DU145, PC3, VCAP, and LAPC4, as well as primary prostate TICs. parthenolide 68-71 proprotein convertase subtilisin/kexin type 1 Mus musculus 152-155 19247368-3 2009 After exposure to hydrogen peroxide (H(2)O(2)) or a strong ROS inducer parthenolide, loss of mitochondrial membrane potential (MMP) and subsequent cell death occurred more extensively in XBP1-deficient cells than wild-type mouse embryonic fibroblast cells, whereas two other anticancer agents induced death similarly in both cells. parthenolide 71-83 X-box binding protein 1 Mus musculus 187-191 19201992-6 2009 In this article, we report that parthenolide 1) inhibits DNA methyltransferase 1 (DNMT1) with an IC(50) of 3.5 microM, possibly through alkylation of the proximal thiolate of Cys(1226) of the catalytic domain by its gamma-methylene lactone, and 2) down-regulates DNMT1 expression possibly associated with its SubG(1) cell-cycle arrest or the interruption of transcriptional factor Sp1 binding to the promoter of DNMT1. parthenolide 32-44 DNA methyltransferase 1 Homo sapiens 57-80 19204913-2 2009 In this study, we show that the sesquiterpene lactone parthenolide (PTL) is cytotoxic to prostate TICs isolated from prostate cancer cell lines: DU145, PC3, VCAP, and LAPC4, as well as primary prostate TICs. parthenolide 54-66 proprotein convertase subtilisin/kexin type 1 Mus musculus 152-155 19201992-8 2009 Furthermore, parthenolide has been shown to reactivate tumor suppressor HIN-1 gene in vitro possibly associated with its promoter hypomethylation. parthenolide 13-25 OTU deubiquitinase 4 Homo sapiens 72-77 19201992-6 2009 In this article, we report that parthenolide 1) inhibits DNA methyltransferase 1 (DNMT1) with an IC(50) of 3.5 microM, possibly through alkylation of the proximal thiolate of Cys(1226) of the catalytic domain by its gamma-methylene lactone, and 2) down-regulates DNMT1 expression possibly associated with its SubG(1) cell-cycle arrest or the interruption of transcriptional factor Sp1 binding to the promoter of DNMT1. parthenolide 32-44 DNA methyltransferase 1 Homo sapiens 82-87 19201992-9 2009 Hence, our study established parthenolide as an effective DNA methylation inhibitor, representing a novel prototype for DNMT1 inhibitor discovery and development from natural structural-diversified sesquiterpene lactones. parthenolide 29-41 DNA methyltransferase 1 Homo sapiens 120-125 19201992-6 2009 In this article, we report that parthenolide 1) inhibits DNA methyltransferase 1 (DNMT1) with an IC(50) of 3.5 microM, possibly through alkylation of the proximal thiolate of Cys(1226) of the catalytic domain by its gamma-methylene lactone, and 2) down-regulates DNMT1 expression possibly associated with its SubG(1) cell-cycle arrest or the interruption of transcriptional factor Sp1 binding to the promoter of DNMT1. parthenolide 32-44 DNA methyltransferase 1 Homo sapiens 263-268 19201992-6 2009 In this article, we report that parthenolide 1) inhibits DNA methyltransferase 1 (DNMT1) with an IC(50) of 3.5 microM, possibly through alkylation of the proximal thiolate of Cys(1226) of the catalytic domain by its gamma-methylene lactone, and 2) down-regulates DNMT1 expression possibly associated with its SubG(1) cell-cycle arrest or the interruption of transcriptional factor Sp1 binding to the promoter of DNMT1. parthenolide 32-44 DNA methyltransferase 1 Homo sapiens 263-268 19303104-12 2009 Parthenolide dose dependently suppressed tumor necrosis factor-alpha induced cyclooxygenase-2 expression and prevented nuclear factor-kappaB phosphorylation as well as nuclear factor-kappaB nuclear translocation and IkappaBalpha phosphorylation/degradation. parthenolide 0-12 tumor necrosis factor Rattus norvegicus 41-68 19404004-8 2009 Parthenolide is one of the main sesquiterpense lactones responsible for the bioactivities of feverfew and recently reported to inhibit NFkappaB activation. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 135-143 19303104-12 2009 Parthenolide dose dependently suppressed tumor necrosis factor-alpha induced cyclooxygenase-2 expression and prevented nuclear factor-kappaB phosphorylation as well as nuclear factor-kappaB nuclear translocation and IkappaBalpha phosphorylation/degradation. parthenolide 0-12 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 77-93 19303104-12 2009 Parthenolide dose dependently suppressed tumor necrosis factor-alpha induced cyclooxygenase-2 expression and prevented nuclear factor-kappaB phosphorylation as well as nuclear factor-kappaB nuclear translocation and IkappaBalpha phosphorylation/degradation. parthenolide 0-12 NFKB inhibitor alpha Rattus norvegicus 216-228 19269818-1 2009 Semisynthetic derivatives of parthenolide (1) were tested on NF-kB driven transcription and metalloproteinase-9 (MMP-9) expression and secretion. parthenolide 29-41 matrix metallopeptidase 9 Homo sapiens 113-118 19298255-2 2009 As the sesquiterpene lactone thapsigargin, a known inhibitor of mammalian SERCA, enhances the expression of P-glycoprotein (Pgp) by increasing the intracellular Ca(++) ([Ca(++)](i)) level, we investigated whether artemisinin and its structural homologue parthenolide could inhibit SERCA in human colon carcinoma HT29 cells and induce a resistance to doxorubicin. parthenolide 254-266 ATP binding cassette subfamily B member 1 Homo sapiens 108-122 19298255-2 2009 As the sesquiterpene lactone thapsigargin, a known inhibitor of mammalian SERCA, enhances the expression of P-glycoprotein (Pgp) by increasing the intracellular Ca(++) ([Ca(++)](i)) level, we investigated whether artemisinin and its structural homologue parthenolide could inhibit SERCA in human colon carcinoma HT29 cells and induce a resistance to doxorubicin. parthenolide 254-266 ATP binding cassette subfamily B member 1 Homo sapiens 124-127 19298255-8 2009 In HT29 cells, artemisinin and parthenolide induced the phosphorylation of HIF-1alpha, which was inhibited by KN93. parthenolide 31-43 hypoxia inducible factor 1 subunit alpha Homo sapiens 75-85 19298255-9 2009 CONCLUSIONS AND IMPLICATIONS: Our results suggest that artemisinin and parthenolide may act as SERCA inhibitors and, like other SERCA inhibitors, induce resistance to doxorubicin in human colon cancer cells, via the CaMKII-dependent activation of HIF-1alpha and the induction of Pgp. parthenolide 71-83 calcium/calmodulin dependent protein kinase II gamma Homo sapiens 216-222 19298255-9 2009 CONCLUSIONS AND IMPLICATIONS: Our results suggest that artemisinin and parthenolide may act as SERCA inhibitors and, like other SERCA inhibitors, induce resistance to doxorubicin in human colon cancer cells, via the CaMKII-dependent activation of HIF-1alpha and the induction of Pgp. parthenolide 71-83 hypoxia inducible factor 1 subunit alpha Homo sapiens 247-257 19298255-9 2009 CONCLUSIONS AND IMPLICATIONS: Our results suggest that artemisinin and parthenolide may act as SERCA inhibitors and, like other SERCA inhibitors, induce resistance to doxorubicin in human colon cancer cells, via the CaMKII-dependent activation of HIF-1alpha and the induction of Pgp. parthenolide 71-83 ATP binding cassette subfamily B member 1 Homo sapiens 279-282 19428548-8 2009 LY294002 and SP600125 inhibited the parthenolide-induced phosphorylation of c-Jun. parthenolide 36-48 Jun proto-oncogene, AP-1 transcription factor subunit Homo sapiens 76-81 19397439-0 2009 Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells. parthenolide 37-49 nuclear factor kappa B subunit 1 Homo sapiens 15-24 19397439-0 2009 Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells. parthenolide 37-49 tumor protein p53 Homo sapiens 119-123 19397439-1 2009 We have shown that parthenolide, a sesquiterpene lactone, is a radiation sensitizer for human CGL1 hybrid cells that have constitutively activated NF-kappaB and wild-type p53. parthenolide 19-31 granzyme B Homo sapiens 94-98 19397439-1 2009 We have shown that parthenolide, a sesquiterpene lactone, is a radiation sensitizer for human CGL1 hybrid cells that have constitutively activated NF-kappaB and wild-type p53. parthenolide 19-31 nuclear factor kappa B subunit 1 Homo sapiens 147-156 19397439-1 2009 We have shown that parthenolide, a sesquiterpene lactone, is a radiation sensitizer for human CGL1 hybrid cells that have constitutively activated NF-kappaB and wild-type p53. parthenolide 19-31 tumor protein p53 Homo sapiens 171-174 19397439-4 2009 Cell cycle analysis of PC-3 cells treated with parthenolide showed only small alterations in G1 and G2/M cells, and these appeared to be insufficient to explain the observed radiosensitization. parthenolide 47-59 proprotein convertase subtilisin/kexin type 1 Homo sapiens 23-27 19397439-5 2009 Split-dose studies using clinically relevant 2- and 4-Gy fractions demonstrated that parthenolide completely inhibited split-dose repair in PC-3 cells. parthenolide 85-97 proprotein convertase subtilisin/kexin type 1 Homo sapiens 140-144 19397439-6 2009 We hypothesized that inhibition of NF-kappaB activity by parthenolide was responsible for the observed X-ray sensitization and inhibition of split-dose repair. parthenolide 57-69 nuclear factor kappa B subunit 1 Homo sapiens 35-44 19397439-8 2009 Inhibition of NF-kappaB activity by knockdown of p65 increased radiation sensitivity and completely inhibited split-dose repair in both cell lines in a nearly identical manner as parthenolide treatment alone. parthenolide 179-191 nuclear factor kappa B subunit 1 Homo sapiens 14-23 19397439-9 2009 Treating p65-depleted PC-3 cells with 5 microM parthenolide did not further increase their radiation sensitivity or the inhibition of split-dose repair. parthenolide 47-59 RELA proto-oncogene, NF-kB subunit Homo sapiens 9-12 19397439-9 2009 Treating p65-depleted PC-3 cells with 5 microM parthenolide did not further increase their radiation sensitivity or the inhibition of split-dose repair. parthenolide 47-59 proprotein convertase subtilisin/kexin type 1 Homo sapiens 22-26 19397439-10 2009 We propose that the suppression of radiation-induced NF-kappaB activity by parthenolide leads to X-ray sensitization through inhibition of split-dose repair in p53 null PC-3 prostate cancer cells. parthenolide 75-87 nuclear factor kappa B subunit 1 Homo sapiens 53-62 19397439-10 2009 We propose that the suppression of radiation-induced NF-kappaB activity by parthenolide leads to X-ray sensitization through inhibition of split-dose repair in p53 null PC-3 prostate cancer cells. parthenolide 75-87 tumor protein p53 Homo sapiens 160-163 19397439-10 2009 We propose that the suppression of radiation-induced NF-kappaB activity by parthenolide leads to X-ray sensitization through inhibition of split-dose repair in p53 null PC-3 prostate cancer cells. parthenolide 75-87 proprotein convertase subtilisin/kexin type 1 Homo sapiens 169-173 19066964-9 2009 Because parthenolide has been reported to be a COX-2 inhibitor, we hypothesize that COX-2 might be a key factor that promotes resistance of cholangiocarcinoma cancer cells to parthenolide-induced apoptosis. parthenolide 8-20 COX2 Clonorchis sinensis 47-52 19066964-9 2009 Because parthenolide has been reported to be a COX-2 inhibitor, we hypothesize that COX-2 might be a key factor that promotes resistance of cholangiocarcinoma cancer cells to parthenolide-induced apoptosis. parthenolide 8-20 COX2 Clonorchis sinensis 84-89 19066964-9 2009 Because parthenolide has been reported to be a COX-2 inhibitor, we hypothesize that COX-2 might be a key factor that promotes resistance of cholangiocarcinoma cancer cells to parthenolide-induced apoptosis. parthenolide 175-187 COX2 Clonorchis sinensis 84-89 19428548-10 2009 N-acetylcysteine, an antioxidant precursor of glutathione, inhibited the parthenolide-induced and H(2)O(2)-induced secretion of MIF. parthenolide 73-85 macrophage migration inhibitory factor Homo sapiens 128-131 19276167-0 2009 Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. parthenolide 0-12 tumor protein p53 Homo sapiens 63-66 19276167-4 2009 We found that the natural product, small-molecule anti-inflammatory agent parthenolide (PN), which is actively being investigated as a potential therapeutic for many human cancers, induces ubiquitination of MDM2 in treated cells, resulting in the activation of p53 and other MDM2-regulated tumor-suppressor proteins. parthenolide 74-86 tumor protein p53 Homo sapiens 261-264 19276167-4 2009 We found that the natural product, small-molecule anti-inflammatory agent parthenolide (PN), which is actively being investigated as a potential therapeutic for many human cancers, induces ubiquitination of MDM2 in treated cells, resulting in the activation of p53 and other MDM2-regulated tumor-suppressor proteins. parthenolide 74-86 MDM2 proto-oncogene Homo sapiens 207-211 19276167-4 2009 We found that the natural product, small-molecule anti-inflammatory agent parthenolide (PN), which is actively being investigated as a potential therapeutic for many human cancers, induces ubiquitination of MDM2 in treated cells, resulting in the activation of p53 and other MDM2-regulated tumor-suppressor proteins. parthenolide 88-90 tumor protein p53 Homo sapiens 261-264 19276167-4 2009 We found that the natural product, small-molecule anti-inflammatory agent parthenolide (PN), which is actively being investigated as a potential therapeutic for many human cancers, induces ubiquitination of MDM2 in treated cells, resulting in the activation of p53 and other MDM2-regulated tumor-suppressor proteins. parthenolide 88-90 MDM2 proto-oncogene Homo sapiens 207-211 18463201-7 2008 Parthenolide and artemisinin prevented all of the statin effects by inducing RhoA/Rho kinase activation. parthenolide 0-12 ras homolog family member A Homo sapiens 77-81 19187601-10 2008 Because parthenolide could inhibit CT-1 induced ICAM-1 expression NFkappaB activation is required in this pathway. parthenolide 8-20 cardiotrophin 1 Homo sapiens 35-39 19187601-10 2008 Because parthenolide could inhibit CT-1 induced ICAM-1 expression NFkappaB activation is required in this pathway. parthenolide 8-20 intercellular adhesion molecule 1 Homo sapiens 48-54 18662886-7 2008 We also detected a different response of HT-29 and FHC cells after the pre-treatment with the NF-kappaB inhibitor parthenolide. parthenolide 114-126 low density lipoprotein receptor Homo sapiens 51-54 19095747-10 2009 When JP-8-treated mice, or JP-8-treated keratinocytes were treated with a selective NF-kappabeta inhibitor, parthenolide, COX-2 expression, and immune suppression were abrogated. parthenolide 108-120 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 84-96 20224758-8 2009 Parthenolide inhibited both NFkappaB translocation and TNFalpha protein expression indicating that NFkappaB seems to be necessary. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 28-36 20224758-8 2009 Parthenolide inhibited both NFkappaB translocation and TNFalpha protein expression indicating that NFkappaB seems to be necessary. parthenolide 0-12 tumor necrosis factor Homo sapiens 55-63 20224758-8 2009 Parthenolide inhibited both NFkappaB translocation and TNFalpha protein expression indicating that NFkappaB seems to be necessary. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 99-107 18652825-7 2008 A cotreatment of HT29 cells with a NFkappaB inhibitor (parthenolide) significantly inhibited the TSA-induced cellular levels of acetyl NFkappaB p65 and abolished the stimulation of STC1 gene expression. parthenolide 55-67 nuclear factor kappa B subunit 1 Homo sapiens 35-43 18652825-7 2008 A cotreatment of HT29 cells with a NFkappaB inhibitor (parthenolide) significantly inhibited the TSA-induced cellular levels of acetyl NFkappaB p65 and abolished the stimulation of STC1 gene expression. parthenolide 55-67 nuclear factor kappa B subunit 1 Homo sapiens 135-143 18652825-7 2008 A cotreatment of HT29 cells with a NFkappaB inhibitor (parthenolide) significantly inhibited the TSA-induced cellular levels of acetyl NFkappaB p65 and abolished the stimulation of STC1 gene expression. parthenolide 55-67 RELA proto-oncogene, NF-kB subunit Homo sapiens 144-147 18652825-7 2008 A cotreatment of HT29 cells with a NFkappaB inhibitor (parthenolide) significantly inhibited the TSA-induced cellular levels of acetyl NFkappaB p65 and abolished the stimulation of STC1 gene expression. parthenolide 55-67 stanniocalcin 1 Homo sapiens 181-185 18652825-8 2008 ChIP assay also demonstrated that TSA treatment increased while TSA/parthenolide cotreatment decreased NFkappaB p65 binding to STC1 gene promoter. parthenolide 68-80 nuclear factor kappa B subunit 1 Homo sapiens 103-111 18652825-8 2008 ChIP assay also demonstrated that TSA treatment increased while TSA/parthenolide cotreatment decreased NFkappaB p65 binding to STC1 gene promoter. parthenolide 68-80 RELA proto-oncogene, NF-kB subunit Homo sapiens 112-115 18652825-8 2008 ChIP assay also demonstrated that TSA treatment increased while TSA/parthenolide cotreatment decreased NFkappaB p65 binding to STC1 gene promoter. parthenolide 68-80 stanniocalcin 1 Homo sapiens 127-131 18652825-11 2008 Consistent with the STC1mRNA expression data, TSA/parthenolide cotreatment also significantly inhibited the TSA-induced STC1 promoter-driven luciferase activity. parthenolide 50-62 stanniocalcin 1 Homo sapiens 20-24 18652825-11 2008 Consistent with the STC1mRNA expression data, TSA/parthenolide cotreatment also significantly inhibited the TSA-induced STC1 promoter-driven luciferase activity. parthenolide 50-62 stanniocalcin 1 Homo sapiens 120-124 18298650-8 2008 Parthenolide, a STAT3 inhibitor, completely abolished the beneficial effects of G-CSF on cardiac function and remodelling with loss of effect on both anti-cardiomyocyte degeneration and anti-fibrosis. parthenolide 0-12 signal transducer and activator of transcription 3 Mus musculus 16-21 18298650-8 2008 Parthenolide, a STAT3 inhibitor, completely abolished the beneficial effects of G-CSF on cardiac function and remodelling with loss of effect on both anti-cardiomyocyte degeneration and anti-fibrosis. parthenolide 0-12 colony stimulating factor 3 (granulocyte) Mus musculus 80-85 18425350-1 2008 The thermo-enhancement effects of the sesquiterpene lactone parthenolide (PTL), which targets the transcription factor nuclear factor-kappaB (NF-kappaB), and hyperthermia at 40, 42 and 44 degrees C on the human lung adenocarcinoma A549 cell line were investigated in vitro. parthenolide 60-72 nuclear factor kappa B subunit 1 Homo sapiens 119-140 18425350-1 2008 The thermo-enhancement effects of the sesquiterpene lactone parthenolide (PTL), which targets the transcription factor nuclear factor-kappaB (NF-kappaB), and hyperthermia at 40, 42 and 44 degrees C on the human lung adenocarcinoma A549 cell line were investigated in vitro. parthenolide 60-72 nuclear factor kappa B subunit 1 Homo sapiens 142-151 18425350-1 2008 The thermo-enhancement effects of the sesquiterpene lactone parthenolide (PTL), which targets the transcription factor nuclear factor-kappaB (NF-kappaB), and hyperthermia at 40, 42 and 44 degrees C on the human lung adenocarcinoma A549 cell line were investigated in vitro. parthenolide 74-77 nuclear factor kappa B subunit 1 Homo sapiens 119-140 18425350-1 2008 The thermo-enhancement effects of the sesquiterpene lactone parthenolide (PTL), which targets the transcription factor nuclear factor-kappaB (NF-kappaB), and hyperthermia at 40, 42 and 44 degrees C on the human lung adenocarcinoma A549 cell line were investigated in vitro. parthenolide 74-77 nuclear factor kappa B subunit 1 Homo sapiens 142-151 18425350-11 2008 Our results suggested that the PTL-induced apoptosis of A549 cells was due to the direct suppression of NF-kappaB activity in a p53- and hsp72-independent manner based on NF-kappaB signaling. parthenolide 31-34 nuclear factor kappa B subunit 1 Homo sapiens 104-113 18425350-11 2008 Our results suggested that the PTL-induced apoptosis of A549 cells was due to the direct suppression of NF-kappaB activity in a p53- and hsp72-independent manner based on NF-kappaB signaling. parthenolide 31-34 tumor protein p53 Homo sapiens 128-131 18425350-11 2008 Our results suggested that the PTL-induced apoptosis of A549 cells was due to the direct suppression of NF-kappaB activity in a p53- and hsp72-independent manner based on NF-kappaB signaling. parthenolide 31-34 heat shock protein family A (Hsp70) member 1A Homo sapiens 137-142 18425350-11 2008 Our results suggested that the PTL-induced apoptosis of A549 cells was due to the direct suppression of NF-kappaB activity in a p53- and hsp72-independent manner based on NF-kappaB signaling. parthenolide 31-34 nuclear factor kappa B subunit 1 Homo sapiens 171-180 17594095-1 2008 PURPOSE: To possibly increase the in vitro cytotoxic activity of arsenic trioxide (ATO) by combining it with Parthenolide (PRT), a known NF-kappaB inhibitor and buthionine sulfoximine (BSO), an inhibitor of gamma-glutamylcysteine synthetase. parthenolide 109-121 glutamate-cysteine ligase catalytic subunit Homo sapiens 207-240 18235096-6 2008 Parthenolide, which prevents IkappaB-alpha degradation, inhibited TWEAK-induced NF-kappaB activation and prevented the aforementioned changes in vitro and in vivo. parthenolide 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 29-42 18235096-6 2008 Parthenolide, which prevents IkappaB-alpha degradation, inhibited TWEAK-induced NF-kappaB activation and prevented the aforementioned changes in vitro and in vivo. parthenolide 0-12 tumor necrosis factor (ligand) superfamily, member 12 Mus musculus 66-71 18235096-6 2008 Parthenolide, which prevents IkappaB-alpha degradation, inhibited TWEAK-induced NF-kappaB activation and prevented the aforementioned changes in vitro and in vivo. parthenolide 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 80-89 18217751-6 2008 Finally, we demonstrate the value of in situ profiling of HDACs by comparing the activity and expression of HDAC1 in cancer cells treated with the cytotoxic agent parthenolide. parthenolide 163-175 histone deacetylase 1 Homo sapiens 108-113 18347184-2 2008 The sesquiterpene lactone parthenolide targets NF-kappaB. parthenolide 26-38 nuclear factor kappa B subunit 1 Homo sapiens 47-56 18347184-6 2008 Parthenolide overcame the proliferative effects of cytokines interleukin-6 and insulin-like growth factor I, whereas the adhesion of MM cells to bone marrow stromal cells partially protected MM cells against parthenolide effect. parthenolide 0-12 interleukin 6 Homo sapiens 61-107 18347184-7 2008 In addition, parthenolide blocked interleukin-6 secretion from bone marrow stromal cells triggered by the adhesion of MM cells. parthenolide 13-25 interleukin 6 Homo sapiens 34-47 18347184-9 2008 Parthenolide rapidly induced caspase activation and cleavage of PARP, MCL-1, X-linked inhibitor of apoptosis protein, and BID. parthenolide 0-12 poly(ADP-ribose) polymerase 1 Homo sapiens 64-68 18347184-9 2008 Parthenolide rapidly induced caspase activation and cleavage of PARP, MCL-1, X-linked inhibitor of apoptosis protein, and BID. parthenolide 0-12 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 70-75 18347184-9 2008 Parthenolide rapidly induced caspase activation and cleavage of PARP, MCL-1, X-linked inhibitor of apoptosis protein, and BID. parthenolide 0-12 BH3 interacting domain death agonist Homo sapiens 77-125 18347184-10 2008 Parthenolide rapidly down-regulated cellular FADD-like IL-1beta-converting enzyme inhibitory protein, and direct targeting of cellular FADD-like IL-1beta-converting enzyme inhibitory protein using small interfering RNA oligonucleotides inhibited MM cell growth and lowered the parthenolide concentration required for growth inhibition. parthenolide 0-12 Fas associated via death domain Homo sapiens 45-49 18683686-0 2008 [Parthenolide inhibits tumor necrosis factor-alpha induced catabolism of aggrecan in chondrocytes in osteoarthritis: in vitro experiment with cultured human chondrocytes]. parthenolide 1-13 tumor necrosis factor Homo sapiens 23-50 18683686-1 2008 OBJECTIVE: To investigate the effect of parthenolide (PAR) on the tumor necrosis factor (TNF)-alpha induced aggrecan catabolism of chondrocytes in osteoarthritis (OA). parthenolide 40-52 tumor necrosis factor Homo sapiens 66-99 18507007-6 2008 Western blot analyses showed that the levels of the stress proteins, Grp 78 and Gadd 153 were reduced in the parthenolide-treated Y8 cells, but not in those co-treated with NAC. parthenolide 109-121 heat shock protein 5 Mus musculus 69-75 18507007-6 2008 Western blot analyses showed that the levels of the stress proteins, Grp 78 and Gadd 153 were reduced in the parthenolide-treated Y8 cells, but not in those co-treated with NAC. parthenolide 109-121 DNA-damage inducible transcript 3 Mus musculus 80-88 19116667-5 2008 Pretreatment with the NF-kappaB inhibitor parthenolide provided evidence that Tat+/-morphine-induced release of MCP-1, IL-6 and TNF-alpha by astrocytes is NF-kappaB dependent. parthenolide 42-54 nuclear factor kappa B subunit 1 Homo sapiens 22-31 19023456-7 2008 This anti-apoptotic effect was lost when cells were pretreated with parthenolide, an inhibitor of NFkappaB activation. parthenolide 68-80 nuclear factor kappa B subunit 1 Homo sapiens 98-106 18055523-8 2008 CT-1-mediated upregulation of ICAM-1 and MCP-1 was suppressed by PD-98059, SB-203580, LY-294002, and parthenolide. parthenolide 101-113 cardiotrophin 1 Homo sapiens 0-4 18055523-8 2008 CT-1-mediated upregulation of ICAM-1 and MCP-1 was suppressed by PD-98059, SB-203580, LY-294002, and parthenolide. parthenolide 101-113 intercellular adhesion molecule 1 Homo sapiens 30-36 18055523-8 2008 CT-1-mediated upregulation of ICAM-1 and MCP-1 was suppressed by PD-98059, SB-203580, LY-294002, and parthenolide. parthenolide 101-113 C-C motif chemokine ligand 2 Homo sapiens 41-46 17275007-7 2008 An inhibitor of NF-kappaB action, namely parthenolide (0.1 microM), BAY 11-7082 (5 microM) and SN50 (1 microM), significantly blocked high glucose-mediated PAI-1 expression to a level with low glucose (5.7 mM). parthenolide 41-53 serpin family E member 1 Bos taurus 156-161 17986299-0 2008 The lipophilic hapten parthenolide induces interferon-gamma and interleukin-13 production by peripheral blood-derived CD8+ T cells from contact allergic subjects in vitro. parthenolide 22-34 interferon gamma Homo sapiens 43-59 17986299-0 2008 The lipophilic hapten parthenolide induces interferon-gamma and interleukin-13 production by peripheral blood-derived CD8+ T cells from contact allergic subjects in vitro. parthenolide 22-34 interleukin 13 Homo sapiens 64-78 17986299-5 2008 RESULTS: The allergic group, but not the control group, responded to parthenolide with increased numbers of cells producing interferon (IFN)-gamma, interleukin (IL)-2, IL-4, IL-5 (P < 0.05 for all) and IL-13 (P < 0.01). parthenolide 69-81 interferon gamma Homo sapiens 124-146 17986299-5 2008 RESULTS: The allergic group, but not the control group, responded to parthenolide with increased numbers of cells producing interferon (IFN)-gamma, interleukin (IL)-2, IL-4, IL-5 (P < 0.05 for all) and IL-13 (P < 0.01). parthenolide 69-81 interleukin 4 Homo sapiens 168-172 17986299-5 2008 RESULTS: The allergic group, but not the control group, responded to parthenolide with increased numbers of cells producing interferon (IFN)-gamma, interleukin (IL)-2, IL-4, IL-5 (P < 0.05 for all) and IL-13 (P < 0.01). parthenolide 69-81 interleukin 5 Homo sapiens 174-178 17986299-5 2008 RESULTS: The allergic group, but not the control group, responded to parthenolide with increased numbers of cells producing interferon (IFN)-gamma, interleukin (IL)-2, IL-4, IL-5 (P < 0.05 for all) and IL-13 (P < 0.01). parthenolide 69-81 interleukin 13 Homo sapiens 205-210 17986299-8 2008 In contrast to the CD4+ T cell-mediated peripheral reactivity induced by nickel, cell depletion experiments identified the parthenolide-reactive IFN-gamma- and IL-13-producing cells as CD8+ T cells. parthenolide 123-135 interferon gamma Homo sapiens 145-154 19116667-5 2008 Pretreatment with the NF-kappaB inhibitor parthenolide provided evidence that Tat+/-morphine-induced release of MCP-1, IL-6 and TNF-alpha by astrocytes is NF-kappaB dependent. parthenolide 42-54 tyrosine aminotransferase Homo sapiens 78-81 19116667-5 2008 Pretreatment with the NF-kappaB inhibitor parthenolide provided evidence that Tat+/-morphine-induced release of MCP-1, IL-6 and TNF-alpha by astrocytes is NF-kappaB dependent. parthenolide 42-54 C-C motif chemokine ligand 2 Homo sapiens 112-117 19116667-5 2008 Pretreatment with the NF-kappaB inhibitor parthenolide provided evidence that Tat+/-morphine-induced release of MCP-1, IL-6 and TNF-alpha by astrocytes is NF-kappaB dependent. parthenolide 42-54 interleukin 6 Homo sapiens 119-123 19116667-5 2008 Pretreatment with the NF-kappaB inhibitor parthenolide provided evidence that Tat+/-morphine-induced release of MCP-1, IL-6 and TNF-alpha by astrocytes is NF-kappaB dependent. parthenolide 42-54 tumor necrosis factor Homo sapiens 128-137 19116667-5 2008 Pretreatment with the NF-kappaB inhibitor parthenolide provided evidence that Tat+/-morphine-induced release of MCP-1, IL-6 and TNF-alpha by astrocytes is NF-kappaB dependent. parthenolide 42-54 nuclear factor kappa B subunit 1 Homo sapiens 155-164 18088190-0 2007 Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 82-91 18088190-3 2007 We investigated whether parthenolide would enhance X-ray-induced cell killing in radiation resistant, NF-kappaB-activated CGL1 cells. parthenolide 24-36 nuclear factor kappa B subunit 1 Homo sapiens 102-111 18088190-3 2007 We investigated whether parthenolide would enhance X-ray-induced cell killing in radiation resistant, NF-kappaB-activated CGL1 cells. parthenolide 24-36 granzyme B Homo sapiens 122-126 18088190-4 2007 Treatment with 5 microM parthenolide for 48 to 72 h inhibited constitutive NF-kappaB binding and cell growth, reduced plating efficiency, and induced apoptosis through stabilization of p53 (TP53), induction of the pro-apoptosis protein BAX, and phosphorylation of BID. parthenolide 24-36 nuclear factor kappa B subunit 1 Homo sapiens 75-84 18088190-4 2007 Treatment with 5 microM parthenolide for 48 to 72 h inhibited constitutive NF-kappaB binding and cell growth, reduced plating efficiency, and induced apoptosis through stabilization of p53 (TP53), induction of the pro-apoptosis protein BAX, and phosphorylation of BID. parthenolide 24-36 tumor protein p53 Homo sapiens 185-188 18088190-4 2007 Treatment with 5 microM parthenolide for 48 to 72 h inhibited constitutive NF-kappaB binding and cell growth, reduced plating efficiency, and induced apoptosis through stabilization of p53 (TP53), induction of the pro-apoptosis protein BAX, and phosphorylation of BID. parthenolide 24-36 tumor protein p53 Homo sapiens 190-194 18088190-4 2007 Treatment with 5 microM parthenolide for 48 to 72 h inhibited constitutive NF-kappaB binding and cell growth, reduced plating efficiency, and induced apoptosis through stabilization of p53 (TP53), induction of the pro-apoptosis protein BAX, and phosphorylation of BID. parthenolide 24-36 BCL2 associated X, apoptosis regulator Homo sapiens 236-239 18088190-5 2007 Parthenolide also enhanced radiation-induced cell killing, increasing the X-ray sensitivity of CGL1 cells by a dose modification factor of 1.6. parthenolide 0-12 granzyme B Homo sapiens 95-99 18088190-6 2007 Flow cytometry revealed that parthenolide reduced the percentage of X-ray-resistant S-phase cells due to induction of p21 waf1/cip1 (CDKN1A) and the onset of G1/S and G2/M blocks, but depletion of radioresistant S-phase cells does not explain the observed X-ray sensitization. parthenolide 29-41 cyclin dependent kinase inhibitor 1A Homo sapiens 118-131 18088190-6 2007 Flow cytometry revealed that parthenolide reduced the percentage of X-ray-resistant S-phase cells due to induction of p21 waf1/cip1 (CDKN1A) and the onset of G1/S and G2/M blocks, but depletion of radioresistant S-phase cells does not explain the observed X-ray sensitization. parthenolide 29-41 cyclin dependent kinase inhibitor 1A Homo sapiens 133-139 17637508-11 2007 AG490 as well as SB 203580 and parthenolide blocked CT-1 induced IL-6 expression completely. parthenolide 31-43 cardiotrophin 1 Homo sapiens 52-56 17916596-6 2007 The effect of TNF-alpha on CAFs is inhibited by the nuclear factor-kappaB inhibitor parthenolide. parthenolide 84-96 tumor necrosis factor Homo sapiens 14-23 17516915-9 2007 Induction of PTGS2 protein by 4beta-PMA in the absence of a PPAR ligand was decreased by the NF-kappaB (nuclear factor kappaB) inhibitors MG132 and parthenolide, suggesting that PKC acted through NF-kappaB in addition to PPAR phosphorylation. parthenolide 148-160 prostaglandin-endoperoxide synthase 2 Bos taurus 13-18 17385713-0 2007 Evidence that IL-6-type cytokine signaling in cardiomyocytes is inhibited by oxidative stress: parthenolide targets JAK1 activation by generating ROS. parthenolide 95-107 interleukin 6 Homo sapiens 14-18 17385713-0 2007 Evidence that IL-6-type cytokine signaling in cardiomyocytes is inhibited by oxidative stress: parthenolide targets JAK1 activation by generating ROS. parthenolide 95-107 Janus kinase 1 Homo sapiens 116-120 17385713-1 2007 Parthenolide, an anti-inflammatory compound, was reported to inhibit signal transducer and activator of transcription 3 (STAT3) activation by the interleukin (IL)-6-type cytokines by an undefined process, which was the focus of our study. parthenolide 0-12 signal transducer and activator of transcription 3 Homo sapiens 69-119 17385713-1 2007 Parthenolide, an anti-inflammatory compound, was reported to inhibit signal transducer and activator of transcription 3 (STAT3) activation by the interleukin (IL)-6-type cytokines by an undefined process, which was the focus of our study. parthenolide 0-12 signal transducer and activator of transcription 3 Homo sapiens 121-126 17385713-2 2007 Here we report that parthenolide reduced both basal and leukemia inhibitory factor (LIF)-induced STAT3 tyrosine 705 (Y705) phosphorylation in cardiomyocytes in a dose-dependent manner, but stimulated the MAP kinase signaling pathways. parthenolide 20-32 LIF interleukin 6 family cytokine Homo sapiens 56-82 17385713-2 2007 Here we report that parthenolide reduced both basal and leukemia inhibitory factor (LIF)-induced STAT3 tyrosine 705 (Y705) phosphorylation in cardiomyocytes in a dose-dependent manner, but stimulated the MAP kinase signaling pathways. parthenolide 20-32 LIF interleukin 6 family cytokine Homo sapiens 84-87 17385713-2 2007 Here we report that parthenolide reduced both basal and leukemia inhibitory factor (LIF)-induced STAT3 tyrosine 705 (Y705) phosphorylation in cardiomyocytes in a dose-dependent manner, but stimulated the MAP kinase signaling pathways. parthenolide 20-32 signal transducer and activator of transcription 3 Homo sapiens 97-102 17385713-3 2007 Activation of Janus kinase 1 (JAK1) tyrosine kinase was markedly reduced by parthenolide. parthenolide 76-88 Janus kinase 1 Homo sapiens 14-28 17385713-3 2007 Activation of Janus kinase 1 (JAK1) tyrosine kinase was markedly reduced by parthenolide. parthenolide 76-88 Janus kinase 1 Homo sapiens 30-34 17385713-4 2007 Pretreatment with parthenolide inhibited JAK1-mediated phosphorylation of the LIF receptor subunits LIF receptor (LIFR) alpha and glycoprotein 130 (gp130), and reduced the LIF-induced increase in JAK1 association with both components. parthenolide 18-30 Janus kinase 1 Homo sapiens 41-45 17385713-4 2007 Pretreatment with parthenolide inhibited JAK1-mediated phosphorylation of the LIF receptor subunits LIF receptor (LIFR) alpha and glycoprotein 130 (gp130), and reduced the LIF-induced increase in JAK1 association with both components. parthenolide 18-30 LIF receptor subunit alpha Homo sapiens 78-90 17385713-4 2007 Pretreatment with parthenolide inhibited JAK1-mediated phosphorylation of the LIF receptor subunits LIF receptor (LIFR) alpha and glycoprotein 130 (gp130), and reduced the LIF-induced increase in JAK1 association with both components. parthenolide 18-30 LIF receptor subunit alpha Homo sapiens 100-112 17385713-4 2007 Pretreatment with parthenolide inhibited JAK1-mediated phosphorylation of the LIF receptor subunits LIF receptor (LIFR) alpha and glycoprotein 130 (gp130), and reduced the LIF-induced increase in JAK1 association with both components. parthenolide 18-30 LIF receptor subunit alpha Homo sapiens 114-118 17385713-4 2007 Pretreatment with parthenolide inhibited JAK1-mediated phosphorylation of the LIF receptor subunits LIF receptor (LIFR) alpha and glycoprotein 130 (gp130), and reduced the LIF-induced increase in JAK1 association with both components. parthenolide 18-30 interleukin 6 cytokine family signal transducer Homo sapiens 130-146 17385713-4 2007 Pretreatment with parthenolide inhibited JAK1-mediated phosphorylation of the LIF receptor subunits LIF receptor (LIFR) alpha and glycoprotein 130 (gp130), and reduced the LIF-induced increase in JAK1 association with both components. parthenolide 18-30 interleukin 6 cytokine family signal transducer Homo sapiens 148-153 17385713-4 2007 Pretreatment with parthenolide inhibited JAK1-mediated phosphorylation of the LIF receptor subunits LIF receptor (LIFR) alpha and glycoprotein 130 (gp130), and reduced the LIF-induced increase in JAK1 association with both components. parthenolide 18-30 LIF interleukin 6 family cytokine Homo sapiens 78-81 17385713-4 2007 Pretreatment with parthenolide inhibited JAK1-mediated phosphorylation of the LIF receptor subunits LIF receptor (LIFR) alpha and glycoprotein 130 (gp130), and reduced the LIF-induced increase in JAK1 association with both components. parthenolide 18-30 Janus kinase 1 Homo sapiens 196-200 17385713-7 2007 Pretreatment with the antioxidant, N-acetyl-L-cysteine, completely suppressed the effect of parthenolide on JAK1 and STAT3. parthenolide 92-104 Janus kinase 1 Homo sapiens 108-112 17385713-7 2007 Pretreatment with the antioxidant, N-acetyl-L-cysteine, completely suppressed the effect of parthenolide on JAK1 and STAT3. parthenolide 92-104 signal transducer and activator of transcription 3 Homo sapiens 117-122 17656318-0 2007 Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. parthenolide 0-12 histone deacetylase 1 Homo sapiens 35-56 17656318-4 2007 We have identified a small molecule, the sesquiterpene lactone parthenolide (PN), which specifically depletes HDAC1 protein without affecting other class I/II HDACs. parthenolide 63-75 histone deacetylase 1 Homo sapiens 110-115 17656318-4 2007 We have identified a small molecule, the sesquiterpene lactone parthenolide (PN), which specifically depletes HDAC1 protein without affecting other class I/II HDACs. parthenolide 77-79 histone deacetylase 1 Homo sapiens 110-115 17290398-7 2007 Localization of NF-kappaB in response to parthenolide treatment was examined of by immunofluorostaining of OUR-10 cells with antibody against NF-kappaB p65 and by Western blot analysis of OUR-10 cell and tumor nuclear and cytosol fraction. parthenolide 41-53 nuclear factor kappa B subunit 1 Homo sapiens 16-25 17290398-7 2007 Localization of NF-kappaB in response to parthenolide treatment was examined of by immunofluorostaining of OUR-10 cells with antibody against NF-kappaB p65 and by Western blot analysis of OUR-10 cell and tumor nuclear and cytosol fraction. parthenolide 41-53 nuclear factor kappa B subunit 1 Homo sapiens 142-151 17290398-7 2007 Localization of NF-kappaB in response to parthenolide treatment was examined of by immunofluorostaining of OUR-10 cells with antibody against NF-kappaB p65 and by Western blot analysis of OUR-10 cell and tumor nuclear and cytosol fraction. parthenolide 41-53 RELA proto-oncogene, NF-kB subunit Homo sapiens 152-155 17290398-9 2007 Subcutaneous injection or oral administration of parthenolide showed significant tumor growth inhibition in the xenograft model via decreased production of interleukin-8 (IL-8) or vascular endothelial growth factor (VEGF). parthenolide 49-61 C-X-C motif chemokine ligand 8 Homo sapiens 156-169 17290398-9 2007 Subcutaneous injection or oral administration of parthenolide showed significant tumor growth inhibition in the xenograft model via decreased production of interleukin-8 (IL-8) or vascular endothelial growth factor (VEGF). parthenolide 49-61 C-X-C motif chemokine ligand 8 Homo sapiens 171-175 17290398-9 2007 Subcutaneous injection or oral administration of parthenolide showed significant tumor growth inhibition in the xenograft model via decreased production of interleukin-8 (IL-8) or vascular endothelial growth factor (VEGF). parthenolide 49-61 vascular endothelial growth factor A Homo sapiens 180-214 17290398-9 2007 Subcutaneous injection or oral administration of parthenolide showed significant tumor growth inhibition in the xenograft model via decreased production of interleukin-8 (IL-8) or vascular endothelial growth factor (VEGF). parthenolide 49-61 vascular endothelial growth factor A Homo sapiens 216-220 17290398-10 2007 Immunohistochemistry and Western blot analysis showed decreased nuclear localization of NF-kappaB and phosphorylated NF-kappaB protein and subsequently expression of MMP-9, Bcl-xL and Cox-2 in response to parthenolide treatment. parthenolide 205-217 nuclear factor kappa B subunit 1 Homo sapiens 88-97 17290398-10 2007 Immunohistochemistry and Western blot analysis showed decreased nuclear localization of NF-kappaB and phosphorylated NF-kappaB protein and subsequently expression of MMP-9, Bcl-xL and Cox-2 in response to parthenolide treatment. parthenolide 205-217 nuclear factor kappa B subunit 1 Homo sapiens 117-126 17290398-10 2007 Immunohistochemistry and Western blot analysis showed decreased nuclear localization of NF-kappaB and phosphorylated NF-kappaB protein and subsequently expression of MMP-9, Bcl-xL and Cox-2 in response to parthenolide treatment. parthenolide 205-217 matrix metallopeptidase 9 Homo sapiens 166-171 17290398-10 2007 Immunohistochemistry and Western blot analysis showed decreased nuclear localization of NF-kappaB and phosphorylated NF-kappaB protein and subsequently expression of MMP-9, Bcl-xL and Cox-2 in response to parthenolide treatment. parthenolide 205-217 BCL2 like 1 Homo sapiens 173-179 17290398-10 2007 Immunohistochemistry and Western blot analysis showed decreased nuclear localization of NF-kappaB and phosphorylated NF-kappaB protein and subsequently expression of MMP-9, Bcl-xL and Cox-2 in response to parthenolide treatment. parthenolide 205-217 mitochondrially encoded cytochrome c oxidase II Homo sapiens 184-189 17290398-11 2007 These results indicate that parthenolide is a useful in the treatment of renal cell carcinoma and acts via inhibition of NF-kappaB. parthenolide 28-40 nuclear factor kappa B subunit 1 Homo sapiens 121-130 17272824-7 2007 Parthenolide significantly inhibited IL-8 secretion induced by these cytokines and prevented NF-kappaB activation, IkappaBalpha degradation, and IkappaB Kinase complex activity. parthenolide 0-12 chemokine (C-X-C motif) ligand 15 Mus musculus 37-41 17272824-7 2007 Parthenolide significantly inhibited IL-8 secretion induced by these cytokines and prevented NF-kappaB activation, IkappaBalpha degradation, and IkappaB Kinase complex activity. parthenolide 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 115-127 17272824-8 2007 CFTR-KO and wild-type mice were pretreated with parthenolide or vehicle alone then challenged intratracheally with LPS. parthenolide 48-60 cystic fibrosis transmembrane conductance regulator Mus musculus 0-4 17272824-12 2007 We thus conclude that parthenolide inhibits IkappaB kinase, resulting in stabilization of cytoplasmic IkappaBalpha, which in turn leads to inhibition of NF-kappaB translocation and attenuation of subsequent inflammatory responses. parthenolide 22-34 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 102-114 17339884-0 2007 Parthenolide protects human lens epithelial cells from oxidative stress-induced apoptosis via inhibition of activation of caspase-3 and caspase-9. parthenolide 0-12 caspase 9 Homo sapiens 136-145 17339884-6 2007 The expression of caspase-3 and caspase-9 induced by H(2)O(2) in HLE cells was significantly reduced by parthenolide both at the protein and mRNA levels, and the activation of caspase-3 and caspase-9 was also suppressed by parthenolide in a dose-dependent manner. parthenolide 104-116 caspase 3 Homo sapiens 18-27 17339884-6 2007 The expression of caspase-3 and caspase-9 induced by H(2)O(2) in HLE cells was significantly reduced by parthenolide both at the protein and mRNA levels, and the activation of caspase-3 and caspase-9 was also suppressed by parthenolide in a dose-dependent manner. parthenolide 104-116 caspase 9 Homo sapiens 32-41 17339884-6 2007 The expression of caspase-3 and caspase-9 induced by H(2)O(2) in HLE cells was significantly reduced by parthenolide both at the protein and mRNA levels, and the activation of caspase-3 and caspase-9 was also suppressed by parthenolide in a dose-dependent manner. parthenolide 223-235 caspase 3 Homo sapiens 18-27 17339884-6 2007 The expression of caspase-3 and caspase-9 induced by H(2)O(2) in HLE cells was significantly reduced by parthenolide both at the protein and mRNA levels, and the activation of caspase-3 and caspase-9 was also suppressed by parthenolide in a dose-dependent manner. parthenolide 223-235 caspase 9 Homo sapiens 32-41 17339884-6 2007 The expression of caspase-3 and caspase-9 induced by H(2)O(2) in HLE cells was significantly reduced by parthenolide both at the protein and mRNA levels, and the activation of caspase-3 and caspase-9 was also suppressed by parthenolide in a dose-dependent manner. parthenolide 223-235 caspase 3 Homo sapiens 176-185 17339884-6 2007 The expression of caspase-3 and caspase-9 induced by H(2)O(2) in HLE cells was significantly reduced by parthenolide both at the protein and mRNA levels, and the activation of caspase-3 and caspase-9 was also suppressed by parthenolide in a dose-dependent manner. parthenolide 223-235 caspase 9 Homo sapiens 190-199 17339884-7 2007 In conclusion, parthenolide prevents HLE cells from oxidative stress-induced apoptosis through inhibition of the activation of caspase-3 and caspase-9, suggesting a potential protective effect against cataract formation. parthenolide 15-27 caspase 3 Homo sapiens 127-136 17339884-7 2007 In conclusion, parthenolide prevents HLE cells from oxidative stress-induced apoptosis through inhibition of the activation of caspase-3 and caspase-9, suggesting a potential protective effect against cataract formation. parthenolide 15-27 caspase 9 Homo sapiens 141-150 17947709-4 2007 Hsp72 induced a dose-dependent increase in IL-8 expression, which was inhibited by the NF-kappaB inhibitor parthenolide. parthenolide 107-119 heat shock protein 1A Mus musculus 0-5 17947709-4 2007 Hsp72 induced a dose-dependent increase in IL-8 expression, which was inhibited by the NF-kappaB inhibitor parthenolide. parthenolide 107-119 chemokine (C-X-C motif) ligand 15 Mus musculus 43-47 17947709-4 2007 Hsp72 induced a dose-dependent increase in IL-8 expression, which was inhibited by the NF-kappaB inhibitor parthenolide. parthenolide 107-119 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 87-96 17876045-0 2007 The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. parthenolide 33-45 phosphatase and tensin homolog Homo sapiens 151-155 17876045-3 2007 In this study, we show that inhibition of the nuclear factor-kappaB (NF-kappaB) pathway is a common mechanism for the radiosensitization effect of parthenolide in prostate cancer cells LNCaP, DU 145, and PC3. parthenolide 147-159 chromobox 8 Homo sapiens 204-207 17876045-4 2007 Parthenolide inhibits radiation-induced NF-kappaB DNA-binding activity and the expression of its downstream target sod2, the gene coding for an important antiapoptotic and antioxidant enzyme (manganese superoxide dismutase) in the three prostate cancer cells. parthenolide 0-12 superoxide dismutase 2 Homo sapiens 115-119 17876045-5 2007 Different susceptibilities to parthenolide"s effect are observed in two radioresistant cancer cells, DU 145 and PC3, with DU 145 cells showing higher sensitivity. parthenolide 30-42 chromobox 8 Homo sapiens 112-115 17876045-6 2007 This differential susceptibility to parthenolide is due, in part, to the fact that in addition to NF-kappaB inhibition, parthenolide activates the phosphatidylinositol-3-kinase/Akt prosurvival pathway in both cell lines. parthenolide 36-48 AKT serine/threonine kinase 1 Homo sapiens 177-180 17876045-6 2007 This differential susceptibility to parthenolide is due, in part, to the fact that in addition to NF-kappaB inhibition, parthenolide activates the phosphatidylinositol-3-kinase/Akt prosurvival pathway in both cell lines. parthenolide 120-132 AKT serine/threonine kinase 1 Homo sapiens 177-180 17876045-8 2007 Transfection of wild-type PTEN into PTEN-null cells, PC3, confers the enhanced radiosensitization effect of parthenolide in PTEN-expressing cells. parthenolide 108-120 phosphatase and tensin homolog Homo sapiens 26-30 17876045-8 2007 Transfection of wild-type PTEN into PTEN-null cells, PC3, confers the enhanced radiosensitization effect of parthenolide in PTEN-expressing cells. parthenolide 108-120 phosphatase and tensin homolog Homo sapiens 36-40 17876045-8 2007 Transfection of wild-type PTEN into PTEN-null cells, PC3, confers the enhanced radiosensitization effect of parthenolide in PTEN-expressing cells. parthenolide 108-120 chromobox 8 Homo sapiens 53-56 17876045-8 2007 Transfection of wild-type PTEN into PTEN-null cells, PC3, confers the enhanced radiosensitization effect of parthenolide in PTEN-expressing cells. parthenolide 108-120 phosphatase and tensin homolog Homo sapiens 36-40 17876045-9 2007 When PTEN expression is knocked down in DU 145 cells, the cells become more resistant to parthenolide"s effect. parthenolide 89-101 phosphatase and tensin homolog Homo sapiens 5-9 17876045-10 2007 Taken together, these results suggest that parthenolide inhibits the NF-kappaB pathway and activates the phosphatidylinositol-3-kinase/Akt pathway in prostate cancer cells. parthenolide 43-55 AKT serine/threonine kinase 1 Homo sapiens 135-138 17876045-12 2007 The presence of PTEN enhances the radiosensitization effect of parthenolide, in part, by suppressing the absolute amount of activated p-Akt. parthenolide 63-75 phosphatase and tensin homolog Homo sapiens 16-20 17876045-12 2007 The presence of PTEN enhances the radiosensitization effect of parthenolide, in part, by suppressing the absolute amount of activated p-Akt. parthenolide 63-75 AKT serine/threonine kinase 1 Homo sapiens 136-139 17290398-0 2007 Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. parthenolide 22-34 nuclear factor kappa B subunit 1 Homo sapiens 136-145 17290398-3 2007 The sesquiterpene lactone parthenolide, an inhibition of NF-kappaB, has been used conventionally to treat migraines and inflammation. parthenolide 26-38 nuclear factor kappa B subunit 1 Homo sapiens 57-66 17637508-11 2007 AG490 as well as SB 203580 and parthenolide blocked CT-1 induced IL-6 expression completely. parthenolide 31-43 interleukin 6 Homo sapiens 65-69 17208315-6 2007 Parthenolide, a signal transducer and activator of transcription (STAT1 and STAT3) phosphorylation inhibitor, reduced OSM-induced ADAMTS-4 and MMP-13 gene expression and prevented STAT1/3 DNA binding activity. parthenolide 0-12 signal transducer and activator of transcription 1 Homo sapiens 66-71 17339884-0 2007 Parthenolide protects human lens epithelial cells from oxidative stress-induced apoptosis via inhibition of activation of caspase-3 and caspase-9. parthenolide 0-12 caspase 3 Homo sapiens 122-131 17343877-2 2007 Here we report on the change in the gene expression profile in TNF-alpha stimulated human 293 cells after treatment with parthenolide using a cDNA microarray analysis. parthenolide 121-133 tumor necrosis factor Homo sapiens 63-72 17208315-6 2007 Parthenolide, a signal transducer and activator of transcription (STAT1 and STAT3) phosphorylation inhibitor, reduced OSM-induced ADAMTS-4 and MMP-13 gene expression and prevented STAT1/3 DNA binding activity. parthenolide 0-12 signal transducer and activator of transcription 3 Homo sapiens 76-81 17208315-6 2007 Parthenolide, a signal transducer and activator of transcription (STAT1 and STAT3) phosphorylation inhibitor, reduced OSM-induced ADAMTS-4 and MMP-13 gene expression and prevented STAT1/3 DNA binding activity. parthenolide 0-12 ADAM metallopeptidase with thrombospondin type 1 motif 4 Homo sapiens 130-138 17208315-6 2007 Parthenolide, a signal transducer and activator of transcription (STAT1 and STAT3) phosphorylation inhibitor, reduced OSM-induced ADAMTS-4 and MMP-13 gene expression and prevented STAT1/3 DNA binding activity. parthenolide 0-12 matrix metallopeptidase 13 Homo sapiens 143-149 17208315-6 2007 Parthenolide, a signal transducer and activator of transcription (STAT1 and STAT3) phosphorylation inhibitor, reduced OSM-induced ADAMTS-4 and MMP-13 gene expression and prevented STAT1/3 DNA binding activity. parthenolide 0-12 signal transducer and activator of transcription 1 Homo sapiens 180-187 17436572-4 2007 In this report we present data to show that fenretinide (a synthetic retinoid) potentiates the apoptotic effects of parthenolide (a drug that inhibits the activation of NF-kappa B) and BAY 11-7085 (an inhibitor of I-kappa B-alpha kinase). parthenolide 116-128 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 169-179 17436572-4 2007 In this report we present data to show that fenretinide (a synthetic retinoid) potentiates the apoptotic effects of parthenolide (a drug that inhibits the activation of NF-kappa B) and BAY 11-7085 (an inhibitor of I-kappa B-alpha kinase). parthenolide 116-128 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 214-229 17556802-6 2007 Parthenolide inhibited proliferation of all three types of cancer cells (A549, TE671, HT-29) and HUVEC with the following IC(50) values (in muM): 4.3, 6.5, 7.0 and 2.8, respectively. parthenolide 0-12 latexin Homo sapiens 140-143 17325184-8 2007 The impact of the NF-kappaB inhibition was assessed by using parthenolide. parthenolide 61-73 nuclear factor kappa B subunit 1 Homo sapiens 18-27 17325184-14 2007 RAGE-mediated upregulation of VEGF secretion by ARPE-19 cells was largely dependent on NF-kappaB, as indicated by studies with parthenolide. parthenolide 127-139 long intergenic non-protein coding RNA 914 Homo sapiens 0-4 17325184-14 2007 RAGE-mediated upregulation of VEGF secretion by ARPE-19 cells was largely dependent on NF-kappaB, as indicated by studies with parthenolide. parthenolide 127-139 vascular endothelial growth factor A Homo sapiens 30-34 17197193-11 2006 AG490, SB203580, piceatannol, parthenolide and cycloheximide inhibit CT-1 induced IL-6 mRNA and protein expression whereas wortmannin and PD98059 did not inhibit IL-6 expression. parthenolide 30-42 cardiotrophin 1 Homo sapiens 69-73 17349210-7 2007 Inhibition of NF-kappaB transactivation by inhibitors, BAY 11-7085 and parthenolide, reversed the suppression of Fas-mediated apoptosis by TNF-alpha. parthenolide 71-83 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 14-23 17349210-7 2007 Inhibition of NF-kappaB transactivation by inhibitors, BAY 11-7085 and parthenolide, reversed the suppression of Fas-mediated apoptosis by TNF-alpha. parthenolide 71-83 tumor necrosis factor Mus musculus 139-148 17341611-5 2006 Besides small peptides and oligonucleotides, numerous small molecules have been identified as blockers of STAT3 activation, including synthetic molecules (e.g., AG 490, decoy peptides, and oligonucleotides) and plant polyphenols (e.g., curcumin, resveratrol, flavopiridol, indirubin, magnolol, piceatannol, parthenolide, EGCG, and cucurbitacin). parthenolide 307-319 signal transducer and activator of transcription 3 Homo sapiens 106-111 17275679-6 2007 At concentrations >5 microM, parthenolide decreased cell viability in a dose-and time-dependent manner, and activated the stress MAP kinases JNK and p38. parthenolide 32-44 mitogen activated protein kinase 14 Rattus norvegicus 152-155 17200339-0 2007 Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells. parthenolide 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 37-58 17200339-2 2007 Parthenolide, a sesquiterpene lactone, was reported to inhibit the DNA binding of NF-kappaB. parthenolide 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 82-91 17200339-11 2007 This supports our notion that the metastasis-preventing effect of parthenolide is mediated at least in part by inhibition of NF-kappaB activity. parthenolide 66-78 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 125-134 17259561-8 2006 Based on our promising studies selectively inhibiting EGFR (gefitinib), NFkappaB (parthenolide) or CD59 (neutralising antibody) together with antioestrogens, we propose that co-targeting strategies could markedly improve anti-tumour activity (notably enhancing cell kill) during the antihormone-responsive phase. parthenolide 82-94 nuclear factor kappa B subunit 1 Homo sapiens 72-80 17197193-11 2006 AG490, SB203580, piceatannol, parthenolide and cycloheximide inhibit CT-1 induced IL-6 mRNA and protein expression whereas wortmannin and PD98059 did not inhibit IL-6 expression. parthenolide 30-42 interleukin 6 Homo sapiens 82-86 16921510-1 2006 BACKGROUND: Nuclear Factor kappa B (NFkappaB) is a eukaryotic transcription factor that is constitutively active in human cancers and can be inhibited by the naturally occurring sesquiterpene lactone, parthenolide (P). parthenolide 201-213 nuclear factor kappa B subunit 1 Homo sapiens 12-34 17003343-8 2006 Furthermore, nuclear factor-kappaB (NF-kappaB) activation was also involved in palmitate-mediated PGC-1alpha downregulation, since the NF-kappaB inhibitor parthenolide prevented a decrease in PGC-1alpha expression. parthenolide 155-167 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 98-108 17003343-8 2006 Furthermore, nuclear factor-kappaB (NF-kappaB) activation was also involved in palmitate-mediated PGC-1alpha downregulation, since the NF-kappaB inhibitor parthenolide prevented a decrease in PGC-1alpha expression. parthenolide 155-167 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 192-202 16921510-1 2006 BACKGROUND: Nuclear Factor kappa B (NFkappaB) is a eukaryotic transcription factor that is constitutively active in human cancers and can be inhibited by the naturally occurring sesquiterpene lactone, parthenolide (P). parthenolide 201-213 nuclear factor kappa B subunit 1 Homo sapiens 36-44 16921510-4 2006 RESULTS: Parthenolide at low micromolar concentration inhibited proliferation of CWR22Rv1 and HUVEC cells, promoted apoptosis and abrogated NFkappaB-DNA binding. parthenolide 9-21 nuclear factor kappa B subunit 1 Homo sapiens 140-148 16921510-5 2006 Parthenolide downregulated anti-apoptotic genes under NFkappaB control, TRAF 1 and 2, and promoted sustained activation of c-jun-NH2 kinase (JNK). parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 54-62 16921510-5 2006 Parthenolide downregulated anti-apoptotic genes under NFkappaB control, TRAF 1 and 2, and promoted sustained activation of c-jun-NH2 kinase (JNK). parthenolide 0-12 TNF receptor associated factor 1 Homo sapiens 72-84 16921510-5 2006 Parthenolide downregulated anti-apoptotic genes under NFkappaB control, TRAF 1 and 2, and promoted sustained activation of c-jun-NH2 kinase (JNK). parthenolide 0-12 mitogen-activated protein kinase 8 Homo sapiens 123-139 16921510-5 2006 Parthenolide downregulated anti-apoptotic genes under NFkappaB control, TRAF 1 and 2, and promoted sustained activation of c-jun-NH2 kinase (JNK). parthenolide 0-12 mitogen-activated protein kinase 8 Homo sapiens 141-144 16741149-0 2006 Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. parthenolide 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 27-36 16741149-3 2006 In this work we analyzed the effects of the natural compound parthenolide (PTN), an NF-kappaB inhibitor. parthenolide 61-73 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 84-93 16741149-3 2006 In this work we analyzed the effects of the natural compound parthenolide (PTN), an NF-kappaB inhibitor. parthenolide 75-78 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 84-93 16741149-4 2006 METHODS AND RESULTS: In vascular smooth muscle cells (VSMCs) and monocytes stimulated with lipopolysaccharide (LPS), nontoxic doses of PTN reduced IkappaBalpha degradation, NF-kappaB activation, and MCP-1 expression, without inhibiting AP-1 and MAPK. parthenolide 135-138 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 147-159 16741149-4 2006 METHODS AND RESULTS: In vascular smooth muscle cells (VSMCs) and monocytes stimulated with lipopolysaccharide (LPS), nontoxic doses of PTN reduced IkappaBalpha degradation, NF-kappaB activation, and MCP-1 expression, without inhibiting AP-1 and MAPK. parthenolide 135-138 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 173-182 16741149-4 2006 METHODS AND RESULTS: In vascular smooth muscle cells (VSMCs) and monocytes stimulated with lipopolysaccharide (LPS), nontoxic doses of PTN reduced IkappaBalpha degradation, NF-kappaB activation, and MCP-1 expression, without inhibiting AP-1 and MAPK. parthenolide 135-138 mast cell protease 1 Mus musculus 199-204 16741149-4 2006 METHODS AND RESULTS: In vascular smooth muscle cells (VSMCs) and monocytes stimulated with lipopolysaccharide (LPS), nontoxic doses of PTN reduced IkappaBalpha degradation, NF-kappaB activation, and MCP-1 expression, without inhibiting AP-1 and MAPK. parthenolide 135-138 jun proto-oncogene Mus musculus 236-240 16741149-8 2006 CONCLUSIONS: NF-kappaB inhibition by PTN retards atherosclerotic lesions in apoE mice, by reducing lesion size and changing plaque composition. parthenolide 37-40 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 13-22 16878028-9 2006 To assess the NF-kappaB contribution to PIC-modulated inflammatory responses to septic shock, we treated with parthenolide, an NF-kappaB inhibitor before PIC and septic shock. parthenolide 110-122 nuclear factor kappa B subunit 1 Homo sapiens 127-136 16733051-12 2006 Perturbation of nuclear factor (NF)-kappaB signaling was strongly suggested by the fact that the wild-type Fhit expressants of SW480 cells tended to be sensitive to sulfasarazine or parthenolide, which are inhibitors of NF-kappaB. parthenolide 182-194 nuclear factor kappa B subunit 1 Homo sapiens 16-42 16733051-12 2006 Perturbation of nuclear factor (NF)-kappaB signaling was strongly suggested by the fact that the wild-type Fhit expressants of SW480 cells tended to be sensitive to sulfasarazine or parthenolide, which are inhibitors of NF-kappaB. parthenolide 182-194 fragile histidine triad diadenosine triphosphatase Homo sapiens 107-111 16878028-11 2006 Inhibition of NF-kappaB by parthenolide did reduce IFN-alpha-mediated potentiation of the cytokine response and lethality from septic shock. parthenolide 27-39 nuclear factor kappa B subunit 1 Homo sapiens 14-23 16878028-11 2006 Inhibition of NF-kappaB by parthenolide did reduce IFN-alpha-mediated potentiation of the cytokine response and lethality from septic shock. parthenolide 27-39 interferon alpha 1 Homo sapiens 51-60 16263740-15 2006 Parthenolide and mithramycin A, inhibitors of NF-kappaB and Sp1, respectively, abolished CML-induced MCP-1 gene expression in a dose-dependent manner. parthenolide 0-12 chemokine (C-C motif) ligand 2 Mus musculus 101-106 17081402-8 2006 U-0126 increased the GATA4 mRNA expression and enhanced the GATA4 binding activity and these effects could be partially attenuated with addition of Parthenolide. parthenolide 148-160 GATA binding protein 4 Rattus norvegicus 21-26 17081402-8 2006 U-0126 increased the GATA4 mRNA expression and enhanced the GATA4 binding activity and these effects could be partially attenuated with addition of Parthenolide. parthenolide 148-160 GATA binding protein 4 Rattus norvegicus 60-65 16212965-8 2006 In cytokine-treated cultured THP-1, the NF-kappaB inhibitors parthenolide, Bay 11-7082 and PDTC reduced COX-2, mPGES-1 and EP-1/EP-3/EP-4 expression as well as PGE2 levels. parthenolide 61-73 GLI family zinc finger 2 Homo sapiens 29-34 16212965-8 2006 In cytokine-treated cultured THP-1, the NF-kappaB inhibitors parthenolide, Bay 11-7082 and PDTC reduced COX-2, mPGES-1 and EP-1/EP-3/EP-4 expression as well as PGE2 levels. parthenolide 61-73 prostaglandin-endoperoxide synthase 2 Homo sapiens 104-109 16212965-8 2006 In cytokine-treated cultured THP-1, the NF-kappaB inhibitors parthenolide, Bay 11-7082 and PDTC reduced COX-2, mPGES-1 and EP-1/EP-3/EP-4 expression as well as PGE2 levels. parthenolide 61-73 prostaglandin E synthase Mus musculus 111-118 16212965-8 2006 In cytokine-treated cultured THP-1, the NF-kappaB inhibitors parthenolide, Bay 11-7082 and PDTC reduced COX-2, mPGES-1 and EP-1/EP-3/EP-4 expression as well as PGE2 levels. parthenolide 61-73 prostaglandin E receptor 4 Homo sapiens 128-137 16873071-8 2006 Moreover, this research suggests that combined treatment approaches involving the use of tamoxifen in conjunction with agents that inhibit NFkappaB pathway signaling, such as parthenolide and genistein, warrant further study. parthenolide 175-187 nuclear factor kappa B subunit 1 Homo sapiens 139-147 16628188-6 2006 The mechanism of cell killing was via PTL-induced generation of reactive oxygen species, resulting in turn in a proapoptotic Bax conformational change, release of mitochondrial cytochrome c and caspase activation. parthenolide 38-41 BCL2 associated X, apoptosis regulator Homo sapiens 125-128 16628188-6 2006 The mechanism of cell killing was via PTL-induced generation of reactive oxygen species, resulting in turn in a proapoptotic Bax conformational change, release of mitochondrial cytochrome c and caspase activation. parthenolide 38-41 cytochrome c, somatic Homo sapiens 177-189 16778086-8 2006 The combination of parthenolide/NS398 inhibited phosphorylation of the NF-kappaB-inhibitory protein IkappaBalpha and increased total IkappaBalpha levels. parthenolide 19-31 NFKB inhibitor alpha Homo sapiens 100-112 16778086-8 2006 The combination of parthenolide/NS398 inhibited phosphorylation of the NF-kappaB-inhibitory protein IkappaBalpha and increased total IkappaBalpha levels. parthenolide 19-31 NFKB inhibitor alpha Homo sapiens 133-145 16778086-11 2006 The combination of parthenolide/NS398 increased apoptosis only in PLC cells, suggesting that the combination may decrease the apoptotic threshold in these cells. parthenolide 19-31 heparan sulfate proteoglycan 2 Homo sapiens 66-69 16705314-2 2006 We have previously demonstrated that either Calphostin C (CC) (a protein kinase C (PKC) inhibitor) or Parthenolide (an NF-kappaB inhibitor) abrogates HDACI-induced transcriptional activation of NF-kappaB and p21, which is associated with profound potentiation of HDACI-mediated induction of apoptosis. parthenolide 102-114 nuclear factor kappa B subunit 1 Homo sapiens 119-128 16705314-2 2006 We have previously demonstrated that either Calphostin C (CC) (a protein kinase C (PKC) inhibitor) or Parthenolide (an NF-kappaB inhibitor) abrogates HDACI-induced transcriptional activation of NF-kappaB and p21, which is associated with profound potentiation of HDACI-mediated induction of apoptosis. parthenolide 102-114 nuclear factor kappa B subunit 1 Homo sapiens 194-203 16705314-2 2006 We have previously demonstrated that either Calphostin C (CC) (a protein kinase C (PKC) inhibitor) or Parthenolide (an NF-kappaB inhibitor) abrogates HDACI-induced transcriptional activation of NF-kappaB and p21, which is associated with profound potentiation of HDACI-mediated induction of apoptosis. parthenolide 102-114 H3 histone pseudogene 16 Homo sapiens 208-211 16705314-9 2006 Kinase inhibitor-mediated suppression of NF-kappaB transcriptional activity played an important role in sensitising cancer cells to VA as direct inhibition of NF-kappaB by Parthenolide drastically synergised with VA to induce apoptosis (VA+Parthenolide: 60-90% compared to <20% following single-drug treatments). parthenolide 172-184 nuclear factor kappa B subunit 1 Homo sapiens 41-50 16705314-9 2006 Kinase inhibitor-mediated suppression of NF-kappaB transcriptional activity played an important role in sensitising cancer cells to VA as direct inhibition of NF-kappaB by Parthenolide drastically synergised with VA to induce apoptosis (VA+Parthenolide: 60-90% compared to <20% following single-drug treatments). parthenolide 172-184 nuclear factor kappa B subunit 1 Homo sapiens 159-168 16705314-9 2006 Kinase inhibitor-mediated suppression of NF-kappaB transcriptional activity played an important role in sensitising cancer cells to VA as direct inhibition of NF-kappaB by Parthenolide drastically synergised with VA to induce apoptosis (VA+Parthenolide: 60-90% compared to <20% following single-drug treatments). parthenolide 240-252 nuclear factor kappa B subunit 1 Homo sapiens 41-50 16705314-11 2006 The weak VA-mediated induction of apoptosis of thoracic cancer cells can be profoundly enhanced either by Parthenolide, a pharmacologic inhibitor of NF-kappaB, or by UCN-01 a kinase inhibitor that has already undergone phase I clinical development. parthenolide 106-118 nuclear factor kappa B subunit 1 Homo sapiens 149-158 16651419-3 2006 A selective nuclear factor-kappaB (NF-kappaB) inhibitor, parthenolide, inhibited the effects of PAF. parthenolide 57-69 patchy fur Mus musculus 96-99 16720096-2 2006 We investigated whether increased survival with parthenolide was associated directly with inhibition of NF-kappabeta and cytokines in LPS challenged C57BL/6J mice. parthenolide 48-60 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 104-116 16720096-3 2006 In RAW 264.7 cells, parthenolide inhibited LPS-stimulated NF-kappabeta and cytokines (interleukin [IL]-1alpha, -1beta, -2, -4, -6, and -10, interferon-gamma, tumor necrosis factor-alpha, granulocyte macrophage-colony stimulating factor, migratory inhibitory protein-1 and -2alpha, JE, and RANTES). parthenolide 20-32 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 58-70 16720096-3 2006 In RAW 264.7 cells, parthenolide inhibited LPS-stimulated NF-kappabeta and cytokines (interleukin [IL]-1alpha, -1beta, -2, -4, -6, and -10, interferon-gamma, tumor necrosis factor-alpha, granulocyte macrophage-colony stimulating factor, migratory inhibitory protein-1 and -2alpha, JE, and RANTES). parthenolide 20-32 interferon gamma Mus musculus 140-185 16720096-3 2006 In RAW 264.7 cells, parthenolide inhibited LPS-stimulated NF-kappabeta and cytokines (interleukin [IL]-1alpha, -1beta, -2, -4, -6, and -10, interferon-gamma, tumor necrosis factor-alpha, granulocyte macrophage-colony stimulating factor, migratory inhibitory protein-1 and -2alpha, JE, and RANTES). parthenolide 20-32 chemokine (C-C motif) ligand 5 Mus musculus 289-295 16720096-10 2006 With lethal LPS, compared to placebo, parthenolide (1 mg/kg) decreased NF-kappabeta and 10 of 13 cytokines early and increased NF-kappabeta and 11 of 13 cytokines late (p < or = 0.02 for early vs. late). parthenolide 38-50 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 71-83 16720096-10 2006 With lethal LPS, compared to placebo, parthenolide (1 mg/kg) decreased NF-kappabeta and 10 of 13 cytokines early and increased NF-kappabeta and 11 of 13 cytokines late (p < or = 0.02 for early vs. late). parthenolide 38-50 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 127-139 16720096-11 2006 Although parthenolide inhibits NF-kappabeta and cytokines in vitro, its effects on these mediators and survival in animal sepsis models vary. parthenolide 9-21 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 31-43 16002075-4 2006 In addition, parthenolide, a nuclear factor kappaB (NF-kappaB) inhibitor, abolished VCAM-1 induction. parthenolide 13-25 nuclear factor kappa B subunit 1 Homo sapiens 52-61 16002075-4 2006 In addition, parthenolide, a nuclear factor kappaB (NF-kappaB) inhibitor, abolished VCAM-1 induction. parthenolide 13-25 vascular cell adhesion molecule 1 Homo sapiens 84-90 16461558-0 2006 Suppressive effects of dehydroepiandrosterone and the nuclear factor-kappaB inhibitor parthenolide on corticotroph tumor cell growth and function in vitro and in vivo. parthenolide 86-98 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 54-75 17081402-9 2006 Parthenolide also prevented the increase of GATA4 mRNA and binding activity induced by CT-1. parthenolide 0-12 GATA binding protein 4 Rattus norvegicus 44-49 17081402-9 2006 Parthenolide also prevented the increase of GATA4 mRNA and binding activity induced by CT-1. parthenolide 0-12 cardiotrophin 1 Rattus norvegicus 87-91 16427785-13 2006 Parthenolide-a blocker of NFkappaB-inhibited CT-1 induced MCP-1 expression, completely. parthenolide 0-12 cardiotrophin 1 Homo sapiens 45-49 16427785-13 2006 Parthenolide-a blocker of NFkappaB-inhibited CT-1 induced MCP-1 expression, completely. parthenolide 0-12 C-C motif chemokine ligand 2 Homo sapiens 58-63 16043032-6 2005 Parthenolide blocked NF-kappaB activation to a greater extent in EPA-treated cells and also decreased CP induced by NF-kappaB activation. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 21-30 16027228-0 2005 Prevention of the ultraviolet B-mediated skin photoaging by a nuclear factor kappaB inhibitor, parthenolide. parthenolide 95-107 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 77-83 16027228-6 2005 In this experiment, we examined if parthenolide, an NF-kappaB inhibitor, could block the UVB-mediated skin changes. parthenolide 35-47 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 52-61 16027228-7 2005 We found that parthenolide could effectively inhibit the gene expression mediated by NF-kappaB and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-kappaB. parthenolide 14-26 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 85-94 16027228-7 2005 We found that parthenolide could effectively inhibit the gene expression mediated by NF-kappaB and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-kappaB. parthenolide 14-26 fibroblast growth factor 2 Mus musculus 117-121 16027228-7 2005 We found that parthenolide could effectively inhibit the gene expression mediated by NF-kappaB and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-kappaB. parthenolide 14-26 matrix metallopeptidase 13 Mus musculus 126-131 16027228-7 2005 We found that parthenolide could effectively inhibit the gene expression mediated by NF-kappaB and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-kappaB. parthenolide 14-26 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 158-161 16027228-7 2005 We found that parthenolide could effectively inhibit the gene expression mediated by NF-kappaB and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-kappaB. parthenolide 14-26 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 182-191 16139565-3 2005 Embryonic rat heart-derived H9c2 cells stimulated with lipopolysaccharide (LPS) showed a reduction (38%, P<0.05) in the mRNA levels of the PPARbeta/delta-target gene pyruvatedehydrogenase kinase 4 (PDK4) that was prevented in the presence of the NF-kappaB inhibitors parthenolide (10 microM) and atorvastatin (10 microM). parthenolide 270-282 peroxisome proliferator-activated receptor delta Rattus norvegicus 142-150 16139565-8 2005 Finally, electrophoretic mobility shift assay revealed that parthenolide and atorvastatin prevented LPS-mediated reduction in PPARbeta/delta binding activity in H9c2 cardiac cells. parthenolide 60-72 peroxisome proliferator-activated receptor delta Rattus norvegicus 126-134 16223857-6 2006 Palmitate increased nuclear factor (NF)-kappaB activation and incubation of the cells with the NF-kappaB inhibitors pyrrolidine dithiocarbamate and parthenolide partially prevented TNF-alpha expression. parthenolide 148-160 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 20-46 16223857-6 2006 Palmitate increased nuclear factor (NF)-kappaB activation and incubation of the cells with the NF-kappaB inhibitors pyrrolidine dithiocarbamate and parthenolide partially prevented TNF-alpha expression. parthenolide 148-160 tumor necrosis factor Mus musculus 181-190 16783963-3 2006 In this study we investigated the molecular pathway involved, and showed that the addition of NF-kappaB inhibitors salicylate and parthenolide reduced the levels of TNF secreted into the culture supernatants induced with DMXAA (10 microg/ml) alone or in combination with LPS (10 microg/ml). parthenolide 130-142 tumor necrosis factor Mus musculus 165-168 16123329-12 2005 Parthenolide, SN50, and BAY 11-7082 (NF-kappaB inhibitors) significantly blocked CRP-mediated PAI-1 expression. parthenolide 0-12 C-reactive protein Homo sapiens 81-84 16123329-12 2005 Parthenolide, SN50, and BAY 11-7082 (NF-kappaB inhibitors) significantly blocked CRP-mediated PAI-1 expression. parthenolide 0-12 serpin family E member 1 Homo sapiens 94-99 16115031-5 2005 AngII-induced MCP-1 protein expression in mProx at 6 h was largely blocked by ROS (N-acetylcysteine; 82 +/- 14%), Ras (N-acetyl-S-trans,trans-farnesyl-L-cysteine; 82 +/- 13%), and nuclear factor-kappaB (NF-kappaB) (parthenolide; 89 +/- 7.9%) inhibitors. parthenolide 215-227 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 0-5 16115031-5 2005 AngII-induced MCP-1 protein expression in mProx at 6 h was largely blocked by ROS (N-acetylcysteine; 82 +/- 14%), Ras (N-acetyl-S-trans,trans-farnesyl-L-cysteine; 82 +/- 13%), and nuclear factor-kappaB (NF-kappaB) (parthenolide; 89 +/- 7.9%) inhibitors. parthenolide 215-227 chemokine (C-C motif) ligand 2 Mus musculus 14-19 16447874-3 2005 RESULTS: Parthenolide could inhibit proliferation of PGCL3 cells after 24h treatment, the IC50 value was 17.60 micromol/L; Parthenolide reduced significantly the activity of uPA secreted by PGCL3 cells and down-regulated the expression level of uPA protein. parthenolide 123-135 plasminogen activator, urokinase Homo sapiens 245-248 16447874-4 2005 CONCLUSION: The antitumor activity of Parthenolide is involved in the activity and expression of urokinase type plasminogen activator. parthenolide 38-50 plasminogen activator, urokinase Homo sapiens 97-133 16043032-6 2005 Parthenolide blocked NF-kappaB activation to a greater extent in EPA-treated cells and also decreased CP induced by NF-kappaB activation. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 116-125 16024633-7 2005 SCK cells, which stably express Bcl-X(L), were resistant to parthenolide, whereas Bcl-X(L)-positive Choi-CK cells transfected with the antisense Bcl-X(L) showed a higher parthenolide sensitivity than the vector control cells. parthenolide 170-182 BCL2 like 1 Homo sapiens 82-90 16024633-6 2005 The results showed that Bcl-2 family molecules, such as Bid, Bak, and Bax, are involved in the parthenolide-induced apoptosis and that the defective expression of Bcl-X(L) might contribute to the higher parthenolide sensitivity in the SCK cells than in the other adenomatous cholangiocarcinoma cells. parthenolide 95-107 BCL2 apoptosis regulator Homo sapiens 24-29 16024633-9 2005 These results suggest that parthenolide effectively induces oxidative stress-mediated apoptosis, and that the susceptibility to parthenolide in cholangiocarcinoma cells might be modulated by Bcl-X(L) expression in association with Bax translocation to the mitochondria. parthenolide 128-140 BCL2 like 1 Homo sapiens 191-199 16024633-6 2005 The results showed that Bcl-2 family molecules, such as Bid, Bak, and Bax, are involved in the parthenolide-induced apoptosis and that the defective expression of Bcl-X(L) might contribute to the higher parthenolide sensitivity in the SCK cells than in the other adenomatous cholangiocarcinoma cells. parthenolide 95-107 BH3 interacting domain death agonist Homo sapiens 56-59 15987517-4 2005 The objective of this study was to test the hypothesis that parthenolide suppresses lipopolysaccharide (LPS)-induced serum (interleukin) IL-6, tumor necrosis factor (TNF)-alpha, IL-1beta and cyclooxygenase (COX)-2 expression in mice as indicated by reduced splenic and liver mRNA levels. parthenolide 60-72 interleukin 6 Mus musculus 137-141 16024633-6 2005 The results showed that Bcl-2 family molecules, such as Bid, Bak, and Bax, are involved in the parthenolide-induced apoptosis and that the defective expression of Bcl-X(L) might contribute to the higher parthenolide sensitivity in the SCK cells than in the other adenomatous cholangiocarcinoma cells. parthenolide 95-107 BCL2 antagonist/killer 1 Homo sapiens 61-64 16024633-6 2005 The results showed that Bcl-2 family molecules, such as Bid, Bak, and Bax, are involved in the parthenolide-induced apoptosis and that the defective expression of Bcl-X(L) might contribute to the higher parthenolide sensitivity in the SCK cells than in the other adenomatous cholangiocarcinoma cells. parthenolide 95-107 BCL2 associated X, apoptosis regulator Homo sapiens 70-73 16024633-6 2005 The results showed that Bcl-2 family molecules, such as Bid, Bak, and Bax, are involved in the parthenolide-induced apoptosis and that the defective expression of Bcl-X(L) might contribute to the higher parthenolide sensitivity in the SCK cells than in the other adenomatous cholangiocarcinoma cells. parthenolide 203-215 BCL2 apoptosis regulator Homo sapiens 24-29 16024633-6 2005 The results showed that Bcl-2 family molecules, such as Bid, Bak, and Bax, are involved in the parthenolide-induced apoptosis and that the defective expression of Bcl-X(L) might contribute to the higher parthenolide sensitivity in the SCK cells than in the other adenomatous cholangiocarcinoma cells. parthenolide 203-215 BCL2 like 1 Homo sapiens 163-171 15987517-4 2005 The objective of this study was to test the hypothesis that parthenolide suppresses lipopolysaccharide (LPS)-induced serum (interleukin) IL-6, tumor necrosis factor (TNF)-alpha, IL-1beta and cyclooxygenase (COX)-2 expression in mice as indicated by reduced splenic and liver mRNA levels. parthenolide 60-72 tumor necrosis factor Mus musculus 143-176 15987517-4 2005 The objective of this study was to test the hypothesis that parthenolide suppresses lipopolysaccharide (LPS)-induced serum (interleukin) IL-6, tumor necrosis factor (TNF)-alpha, IL-1beta and cyclooxygenase (COX)-2 expression in mice as indicated by reduced splenic and liver mRNA levels. parthenolide 60-72 interleukin 1 beta Mus musculus 178-186 15987517-4 2005 The objective of this study was to test the hypothesis that parthenolide suppresses lipopolysaccharide (LPS)-induced serum (interleukin) IL-6, tumor necrosis factor (TNF)-alpha, IL-1beta and cyclooxygenase (COX)-2 expression in mice as indicated by reduced splenic and liver mRNA levels. parthenolide 60-72 cytochrome c oxidase II, mitochondrial Mus musculus 191-213 15987517-9 2005 RESULTS: LPS induced increases in serum IL-6 and TNF-alpha concentrations with only IL-6 being suppressed in parthenolide-treated mice. parthenolide 109-121 interleukin 6 Mus musculus 84-88 15987517-10 2005 Induction of IL-6 mRNA was reduced, TNF-alpha and COX-2 mRNAs unchanged, and IL-1beta mRNA increased in spleens of parthenolide plus LPS co-treated animals compared to LPS-only. parthenolide 115-127 interleukin 6 Mus musculus 13-17 15987517-10 2005 Induction of IL-6 mRNA was reduced, TNF-alpha and COX-2 mRNAs unchanged, and IL-1beta mRNA increased in spleens of parthenolide plus LPS co-treated animals compared to LPS-only. parthenolide 115-127 interleukin 1 beta Mus musculus 77-85 15987517-13 2005 CONCLUSION: In summary, only one gene, IL-6, was modestly suppressed by parthenolide co-exposure which contrasts with many in vitro studies suggesting anti-inflammatory effects of this compound. parthenolide 72-84 interleukin 6 Mus musculus 39-43 16447874-0 2005 [Effects of parthenolide on the activity and expression of urokinase type plasminogen activator in PGCL3 cells]. parthenolide 12-24 plasminogen activator, urokinase Homo sapiens 59-95 15956258-7 2005 In addition, nuclear NF-kappaB levels were lower in residual tumors and lung metastasis of animals treated with parthenolide, docetaxel, or both. parthenolide 112-124 nuclear factor kappa B subunit 1 Homo sapiens 21-30 16447874-1 2005 OBJECTIVE: To study the effect of Parthenolide on the activity and expression of urokinase type plasminogen activator (uPA) on PGCL3 cells and to investigate the antitumor mechanisms of Parthenolide. parthenolide 34-46 plasminogen activator, urokinase Homo sapiens 81-117 16447874-1 2005 OBJECTIVE: To study the effect of Parthenolide on the activity and expression of urokinase type plasminogen activator (uPA) on PGCL3 cells and to investigate the antitumor mechanisms of Parthenolide. parthenolide 34-46 plasminogen activator, urokinase Homo sapiens 119-122 16447874-2 2005 METHODS: MTT assay was used to determine the growth inhibition by Parthenolide in PGCL3 cells; Effect of Parthenolide on the activity of uPA secreted by PGCL3 cells was measured by chromogenic substrate assay;The expression level of uPA protein was assessed by Western blot analysis. parthenolide 105-117 plasminogen activator, urokinase Homo sapiens 137-140 16447874-3 2005 RESULTS: Parthenolide could inhibit proliferation of PGCL3 cells after 24h treatment, the IC50 value was 17.60 micromol/L; Parthenolide reduced significantly the activity of uPA secreted by PGCL3 cells and down-regulated the expression level of uPA protein. parthenolide 9-21 plasminogen activator, urokinase Homo sapiens 174-177 16447874-3 2005 RESULTS: Parthenolide could inhibit proliferation of PGCL3 cells after 24h treatment, the IC50 value was 17.60 micromol/L; Parthenolide reduced significantly the activity of uPA secreted by PGCL3 cells and down-regulated the expression level of uPA protein. parthenolide 9-21 plasminogen activator, urokinase Homo sapiens 245-248 16447874-3 2005 RESULTS: Parthenolide could inhibit proliferation of PGCL3 cells after 24h treatment, the IC50 value was 17.60 micromol/L; Parthenolide reduced significantly the activity of uPA secreted by PGCL3 cells and down-regulated the expression level of uPA protein. parthenolide 123-135 plasminogen activator, urokinase Homo sapiens 174-177 15935092-13 2005 TLR4 mRNA and protein expression were inhibited in the presence of BAPTA-AM, SN50 or parthenolide. parthenolide 85-97 toll-like receptor 4 Rattus norvegicus 0-4 15935092-14 2005 TNF-alpha and MIP-2 release was increased in type II cells in response to C. pneumoniae, whereas BAPTA-AM, SN50 or parthenolide decreased the C. pneumoniae-induced TNF-alpha and MIP-2 release. parthenolide 115-127 tumor necrosis factor Rattus norvegicus 164-173 15935092-14 2005 TNF-alpha and MIP-2 release was increased in type II cells in response to C. pneumoniae, whereas BAPTA-AM, SN50 or parthenolide decreased the C. pneumoniae-induced TNF-alpha and MIP-2 release. parthenolide 115-127 C-X-C motif chemokine ligand 2 Rattus norvegicus 178-183 15956258-1 2005 Parthenolide, a sesquiterpene lactone, shows antitumor activity in vitro, which correlates with its ability to inhibit the DNA binding of the antiapoptotic transcription factor nuclear factor kappaB (NF-kappaB) and activation of the c-Jun NH(2)-terminal kinase. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 192-198 15956258-1 2005 Parthenolide, a sesquiterpene lactone, shows antitumor activity in vitro, which correlates with its ability to inhibit the DNA binding of the antiapoptotic transcription factor nuclear factor kappaB (NF-kappaB) and activation of the c-Jun NH(2)-terminal kinase. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 200-209 15956258-4 2005 Parthenolide was effective either alone or in combination with docetaxel in reducing colony formation, inducing apoptosis and reducing the expression of prometastatic genes IL-8 and the antiapoptotic gene GADD45beta1 in vitro. parthenolide 0-12 C-X-C motif chemokine ligand 8 Homo sapiens 173-177 15956258-9 2005 These results for the first time reveal the significant in vivo chemosensitizing properties of parthenolide in the metastatic breast cancer setting and support the contention that metastases are very reliant on activation of NF-kappaB. parthenolide 95-107 nuclear factor kappa B subunit 1 Homo sapiens 225-234 15475494-9 2004 In addition, the sesquiterpene lactone parthenolide inhibited NF-kappaB activation following LPS exposure and blocked the LPS-induced increase in type II cells. parthenolide 39-51 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 62-71 15657351-2 2005 The purpose of this study was to elucidate the mechanism by which NFkappaB up-regulation contributes to Faslodex resistance and to determine whether pharmacologic inhibition of NFkappaB by the small molecule parthenolide could restore Faslodex-mediated suppression of cell growth. parthenolide 208-220 nuclear factor kappa B subunit 1 Homo sapiens 66-74 15657351-2 2005 The purpose of this study was to elucidate the mechanism by which NFkappaB up-regulation contributes to Faslodex resistance and to determine whether pharmacologic inhibition of NFkappaB by the small molecule parthenolide could restore Faslodex-mediated suppression of cell growth. parthenolide 208-220 nuclear factor kappa B subunit 1 Homo sapiens 177-185 15480428-6 2004 The RTKN-mediated antiapoptotic effect was blocked by the nuclear factor-kappaB (NF-kappaB) inhibitors, curcumin or parthenolide, but not by the phosphatidylinositol 3"-OH-kinase inhibitor, LY294002, or the MAP kinase inhibitor, PD98059. parthenolide 116-128 rhotekin Homo sapiens 4-8 15743683-3 2005 Oxidant (menadione 100 microMx30 min) activation of NFkappaB was prevented by pretreatment with various NFkappaB inhibitors, including the specific IkappaB kinase (IKK) inhibitor, parthenolide (PA), which was found to sensitize MCF-7/HER2 and BT474 but not MCF-7 cells to the antiestrogen tamoxifen. parthenolide 180-192 nuclear factor kappa B subunit 1 Homo sapiens 52-60 15743683-3 2005 Oxidant (menadione 100 microMx30 min) activation of NFkappaB was prevented by pretreatment with various NFkappaB inhibitors, including the specific IkappaB kinase (IKK) inhibitor, parthenolide (PA), which was found to sensitize MCF-7/HER2 and BT474 but not MCF-7 cells to the antiestrogen tamoxifen. parthenolide 180-192 nuclear factor kappa B subunit 1 Homo sapiens 104-112 15743683-3 2005 Oxidant (menadione 100 microMx30 min) activation of NFkappaB was prevented by pretreatment with various NFkappaB inhibitors, including the specific IkappaB kinase (IKK) inhibitor, parthenolide (PA), which was found to sensitize MCF-7/HER2 and BT474 but not MCF-7 cells to the antiestrogen tamoxifen. parthenolide 194-196 nuclear factor kappa B subunit 1 Homo sapiens 52-60 15743683-3 2005 Oxidant (menadione 100 microMx30 min) activation of NFkappaB was prevented by pretreatment with various NFkappaB inhibitors, including the specific IkappaB kinase (IKK) inhibitor, parthenolide (PA), which was found to sensitize MCF-7/HER2 and BT474 but not MCF-7 cells to the antiestrogen tamoxifen. parthenolide 194-196 nuclear factor kappa B subunit 1 Homo sapiens 104-112 15743683-3 2005 Oxidant (menadione 100 microMx30 min) activation of NFkappaB was prevented by pretreatment with various NFkappaB inhibitors, including the specific IkappaB kinase (IKK) inhibitor, parthenolide (PA), which was found to sensitize MCF-7/HER2 and BT474 but not MCF-7 cells to the antiestrogen tamoxifen. parthenolide 194-196 erb-b2 receptor tyrosine kinase 2 Homo sapiens 234-238 15805281-9 2005 These results suggest that ANKRD1 and the other genes, whose expressions were substantially modulated by the parthenolide-mediated inhibition of NF-kappaB activation, play roles in the enhanced drug-induced apoptosis. parthenolide 109-121 ankyrin repeat domain 1 Homo sapiens 27-33 15827332-0 2005 Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 82-104 15827332-2 2005 We evaluated the effect of a novel NF-kappa B inhibitor, parthenolide, a sesquiterpene lactone isolated from the herb feverfew, in three human pancreatic tumor cell lines (BxPC-3, PANC-1, and MIA PaCa-2). parthenolide 57-69 nuclear factor kappa B subunit 1 Homo sapiens 35-45 15827332-4 2005 Parthenolide treatment also dose-dependently increased the amount of the NF-kappa B inhibitory protein, I kappa B-alpha, and decreased NF-kappa B DNA binding activity. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 73-83 15827332-4 2005 Parthenolide treatment also dose-dependently increased the amount of the NF-kappa B inhibitory protein, I kappa B-alpha, and decreased NF-kappa B DNA binding activity. parthenolide 0-12 NFKB inhibitor alpha Homo sapiens 104-119 15827332-4 2005 Parthenolide treatment also dose-dependently increased the amount of the NF-kappa B inhibitory protein, I kappa B-alpha, and decreased NF-kappa B DNA binding activity. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 135-145 15827332-9 2005 Increased levels of I kappa B-alpha protein were detected, especially in MIA PaCa-2 cells, after treatment with parthenolide and sulindac compared with each agent alone. parthenolide 112-124 NFKB inhibitor alpha Homo sapiens 20-35 15475494-9 2004 In addition, the sesquiterpene lactone parthenolide inhibited NF-kappaB activation following LPS exposure and blocked the LPS-induced increase in type II cells. parthenolide 39-51 toll-like receptor 4 Mus musculus 93-96 15475494-9 2004 In addition, the sesquiterpene lactone parthenolide inhibited NF-kappaB activation following LPS exposure and blocked the LPS-induced increase in type II cells. parthenolide 39-51 toll-like receptor 4 Mus musculus 122-125 15256485-0 2004 Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. parthenolide 92-104 nuclear factor kappa B subunit 1 Homo sapiens 11-20 15256485-0 2004 Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. parthenolide 92-104 mitogen-activated protein kinase 8 Homo sapiens 35-38 15256485-0 2004 Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. parthenolide 92-104 tumor necrosis factor Homo sapiens 108-117 15286701-8 2004 Parthenolide through JNK increased the TRAIL-mediated degradation of the antiapoptotic protein X-linked inhibitor of apoptosis (XIAP). parthenolide 0-12 mitogen-activated protein kinase 8 Homo sapiens 21-24 15467918-9 2004 Parthenolide, an IkappaB kinase inhibitor, prevented up-regulation of MCP-1 by fibrinogen, linking this response to NF-kappaB activation. parthenolide 0-12 C-C motif chemokine ligand 2 Homo sapiens 70-75 15467918-9 2004 Parthenolide, an IkappaB kinase inhibitor, prevented up-regulation of MCP-1 by fibrinogen, linking this response to NF-kappaB activation. parthenolide 0-12 fibrinogen beta chain Homo sapiens 79-89 15467918-9 2004 Parthenolide, an IkappaB kinase inhibitor, prevented up-regulation of MCP-1 by fibrinogen, linking this response to NF-kappaB activation. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 116-125 15286701-0 2004 Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. parthenolide 16-28 TNF superfamily member 10 Homo sapiens 75-130 15286701-0 2004 Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. parthenolide 16-28 mitogen-activated protein kinase 8 Homo sapiens 163-186 15286701-1 2004 The antitumor activity of the sesquiterpene lactone parthenolide, an active ingredient of medicinal plants, is believed to be due to the inhibition of DNA binding of transcription factors NF-kappaB and STAT-3, reduction in MAP kinase activity and the generation of reactive oxygen. parthenolide 52-64 signal transducer and activator of transcription 3 Homo sapiens 202-208 15286701-2 2004 In this report, we show that parthenolide activates c-Jun N-terminal kinase (JNK), which is independent of inhibition of NF-kappaB DNA binding and generation of reactive oxygen species. parthenolide 29-41 mitogen-activated protein kinase 8 Homo sapiens 52-75 15286701-2 2004 In this report, we show that parthenolide activates c-Jun N-terminal kinase (JNK), which is independent of inhibition of NF-kappaB DNA binding and generation of reactive oxygen species. parthenolide 29-41 mitogen-activated protein kinase 8 Homo sapiens 77-80 15286701-3 2004 Parthenolide reversed resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. parthenolide 0-12 TNF superfamily member 10 Homo sapiens 59-114 15286701-3 2004 Parthenolide reversed resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. parthenolide 0-12 TNF superfamily member 10 Homo sapiens 116-121 15286701-5 2004 JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis. parthenolide 34-46 mitogen-activated protein kinase 8 Homo sapiens 0-3 15286701-5 2004 JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis. parthenolide 34-46 TNF superfamily member 10 Homo sapiens 72-77 15286701-5 2004 JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis. parthenolide 34-46 mitogen-activated protein kinase 8 Homo sapiens 106-109 15286701-5 2004 JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis. parthenolide 34-46 mitogen-activated protein kinase 8 Homo sapiens 106-109 15286701-5 2004 JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis. parthenolide 34-46 TNF superfamily member 10 Homo sapiens 148-153 15286701-5 2004 JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis. parthenolide 159-171 mitogen-activated protein kinase 8 Homo sapiens 0-3 15286701-5 2004 JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis. parthenolide 159-171 TNF superfamily member 10 Homo sapiens 72-77 15286701-5 2004 JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis. parthenolide 159-171 mitogen-activated protein kinase 8 Homo sapiens 106-109 15286701-5 2004 JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis. parthenolide 159-171 mitogen-activated protein kinase 8 Homo sapiens 106-109 15286701-6 2004 Parthenolide induced phosphorylation of Bid and increased TRAIL-dependent cleavage of Bid without affecting caspase 8 activities. parthenolide 0-12 BH3 interacting domain death agonist Homo sapiens 40-43 15286701-6 2004 Parthenolide induced phosphorylation of Bid and increased TRAIL-dependent cleavage of Bid without affecting caspase 8 activities. parthenolide 0-12 TNF superfamily member 10 Homo sapiens 58-63 15286701-6 2004 Parthenolide induced phosphorylation of Bid and increased TRAIL-dependent cleavage of Bid without affecting caspase 8 activities. parthenolide 0-12 BH3 interacting domain death agonist Homo sapiens 86-89 15286701-7 2004 Cytochrome c but not Smac/DIABLO was released from the mitochondria in cells treated with parthenolide alone. parthenolide 90-102 cytochrome c, somatic Homo sapiens 0-12 15339391-6 2004 Parthenolide, an inhibitor of STAT, suppressed CT-1-induced [3H]leucine incorporation by 88.3 % and protein-to-DNA ratio by 75.0 %. parthenolide 0-12 cardiotrophin 1 Rattus norvegicus 47-51 15328189-3 2004 The functional relevance of NF-kappaB DNA binding was assessed by both cDNA array analyses and proliferation assays of prostate cancer cells with and without exposure to an NF-kappaB inhibitor, parthenolide. parthenolide 194-206 nuclear factor kappa B subunit 1 Homo sapiens 28-37 15328189-3 2004 The functional relevance of NF-kappaB DNA binding was assessed by both cDNA array analyses and proliferation assays of prostate cancer cells with and without exposure to an NF-kappaB inhibitor, parthenolide. parthenolide 194-206 nuclear factor kappa B subunit 1 Homo sapiens 173-182 15328189-7 2004 The binding was inhibited by parthenolide, and this agent also decreased multiple gene transcripts under the control of NF-kappaB and inhibited proliferation of prostate cancer cells. parthenolide 29-41 nuclear factor kappa B subunit 1 Homo sapiens 120-129 15219941-0 2004 Involvement of proapoptotic Bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis. parthenolide 52-64 BCL2 apoptosis regulator Homo sapiens 28-33 15219941-3 2004 In the present study, we attempted to examine parthenolide-mediated cell death signaling pathway by focusing on the involvement of Bcl-2 family members. parthenolide 46-58 BCL2 apoptosis regulator Homo sapiens 131-136 15219941-4 2004 Using a human colorectal cancer cell line COLO205, we first demonstrated that parthenolide acted through the cell death receptor pathway to activate caspase 8. parthenolide 78-90 caspase 8 Homo sapiens 149-158 15219941-7 2004 All these alterations were found to be prerequisite for the subsequent release of proapopototic mitochondrial proteins, including cytochrome c and Samc, in parthenolide-treated cells. parthenolide 156-168 cytochrome c, somatic Homo sapiens 130-142 15219941-7 2004 All these alterations were found to be prerequisite for the subsequent release of proapopototic mitochondrial proteins, including cytochrome c and Samc, in parthenolide-treated cells. parthenolide 156-168 solute carrier family 25 member 26 Homo sapiens 147-151 15219941-9 2004 Therefore, the proapoptotic Bcl-2 family members are important mediators relaying the cell death signaling elicited by parthenolide from caspase 8 to downstream effector caspases such as caspase 3, and eventually to cell death. parthenolide 119-131 BCL2 apoptosis regulator Homo sapiens 28-33 15219941-9 2004 Therefore, the proapoptotic Bcl-2 family members are important mediators relaying the cell death signaling elicited by parthenolide from caspase 8 to downstream effector caspases such as caspase 3, and eventually to cell death. parthenolide 119-131 caspase 8 Homo sapiens 137-146 15219941-9 2004 Therefore, the proapoptotic Bcl-2 family members are important mediators relaying the cell death signaling elicited by parthenolide from caspase 8 to downstream effector caspases such as caspase 3, and eventually to cell death. parthenolide 119-131 caspase 3 Homo sapiens 187-196 15286701-8 2004 Parthenolide through JNK increased the TRAIL-mediated degradation of the antiapoptotic protein X-linked inhibitor of apoptosis (XIAP). parthenolide 0-12 TNF superfamily member 10 Homo sapiens 39-44 15286701-8 2004 Parthenolide through JNK increased the TRAIL-mediated degradation of the antiapoptotic protein X-linked inhibitor of apoptosis (XIAP). parthenolide 0-12 X-linked inhibitor of apoptosis Homo sapiens 95-126 15286701-8 2004 Parthenolide through JNK increased the TRAIL-mediated degradation of the antiapoptotic protein X-linked inhibitor of apoptosis (XIAP). parthenolide 0-12 X-linked inhibitor of apoptosis Homo sapiens 128-132 15286701-10 2004 These results identify a new antitumor activity of parthenolide, which can be exploited to reverse resistance of cancer cells to TRAIL, particularly those with elevated XIAP levels. parthenolide 51-63 TNF superfamily member 10 Homo sapiens 129-134 15286701-10 2004 These results identify a new antitumor activity of parthenolide, which can be exploited to reverse resistance of cancer cells to TRAIL, particularly those with elevated XIAP levels. parthenolide 51-63 X-linked inhibitor of apoptosis Homo sapiens 169-173 15183076-0 2004 Role of cysteine residues of p65/NF-kappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. parthenolide 90-102 RELA proto-oncogene, NF-kB subunit Homo sapiens 29-32 15183076-0 2004 Role of cysteine residues of p65/NF-kappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. parthenolide 90-102 nuclear factor kappa B subunit 1 Homo sapiens 33-42 12552998-0 2002 Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappaB activation, on drug-resistant mouse leukemia L1210 cells. parthenolide 73-85 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 103-111 15015572-5 2004 A series of assays were also performed in which we utilized parthenolide, a specific inhibitor of NF-kappaB, to analyze the possible role that the NF-kappaB/IkappaB signaling pathway has in mediating paclitaxel-induced apoptosis. parthenolide 60-72 nuclear factor kappa B subunit 1 Homo sapiens 98-107 15015572-8 2004 Parthenolide was found to inhibit paclitaxel-induced activation of the NF-kappaB/IkappaB signal pathway as well as apoptotic cell death. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 71-80 14501955-15 2003 Treatment with parthenolide also abolished formation of nitrotyrosine and expression of PARP-1 in thoracic aortas. parthenolide 15-27 poly (ADP-ribose) polymerase 1 Rattus norvegicus 88-94 12885939-6 2003 The key role of NF-kappaB in mediating the biological effects of TNF-alpha and TRAIL was demonstrated by the ability of unrelated pharmacological inhibitors of the NF-kappaB pathway (parthenolide and MG-132) to abrogate TNF-alpha- and TRAIL-induced monocytic maturation. parthenolide 183-195 tumor necrosis factor Homo sapiens 65-74 12885939-6 2003 The key role of NF-kappaB in mediating the biological effects of TNF-alpha and TRAIL was demonstrated by the ability of unrelated pharmacological inhibitors of the NF-kappaB pathway (parthenolide and MG-132) to abrogate TNF-alpha- and TRAIL-induced monocytic maturation. parthenolide 183-195 TNF superfamily member 10 Homo sapiens 79-84 12885939-6 2003 The key role of NF-kappaB in mediating the biological effects of TNF-alpha and TRAIL was demonstrated by the ability of unrelated pharmacological inhibitors of the NF-kappaB pathway (parthenolide and MG-132) to abrogate TNF-alpha- and TRAIL-induced monocytic maturation. parthenolide 183-195 tumor necrosis factor Homo sapiens 220-229 12885939-6 2003 The key role of NF-kappaB in mediating the biological effects of TNF-alpha and TRAIL was demonstrated by the ability of unrelated pharmacological inhibitors of the NF-kappaB pathway (parthenolide and MG-132) to abrogate TNF-alpha- and TRAIL-induced monocytic maturation. parthenolide 183-195 TNF superfamily member 10 Homo sapiens 235-240 15139112-3 2003 RESULT: Parthenolide inhibited protein levels of c-fos, c-myc in a time-dependent manner but didn"t affect the protein levels of p15, p16, p18, p19. parthenolide 8-20 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 49-54 15139112-3 2003 RESULT: Parthenolide inhibited protein levels of c-fos, c-myc in a time-dependent manner but didn"t affect the protein levels of p15, p16, p18, p19. parthenolide 8-20 MYC proto-oncogene, bHLH transcription factor Rattus norvegicus 56-61 15139112-6 2003 CONCLUSION: Parthenolide may inhibit proliferation of VSMC by inhibiting the expressions of c-fos, c-myc, but not the expressions of p15, p16, p18, p19. parthenolide 12-24 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 92-97 15139112-6 2003 CONCLUSION: Parthenolide may inhibit proliferation of VSMC by inhibiting the expressions of c-fos, c-myc, but not the expressions of p15, p16, p18, p19. parthenolide 12-24 MYC proto-oncogene, bHLH transcription factor Rattus norvegicus 99-104 15151944-6 2004 Importantly, we found that co-treatment with the NF-kappa B inhibitor, parthenolide, or overexpression of I kappa B superrepressor restored tamoxifen sensitivity to our refractory Akt MCF-7 cells. parthenolide 71-83 AKT serine/threonine kinase 1 Homo sapiens 180-183 15153562-11 2004 Treatment with two different NF-kappaB inhibitors, pirrolidin-dithiocarbamate and parthenolide, diminished monocyte infiltration and gene overexpression. parthenolide 82-94 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 29-38 14726605-5 2003 However, experiments with known inhibitors of activation of these transcription factors: pyrrolidine dithiocarbamate (PDTC), parthenolide and curcumin, indicate that NFkappaB and AP-1 cannot be solely responsible for the cytokine induced expression of stromelysin-1 gene in mouse astrocytes. parthenolide 125-137 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 166-174 14726605-5 2003 However, experiments with known inhibitors of activation of these transcription factors: pyrrolidine dithiocarbamate (PDTC), parthenolide and curcumin, indicate that NFkappaB and AP-1 cannot be solely responsible for the cytokine induced expression of stromelysin-1 gene in mouse astrocytes. parthenolide 125-137 jun proto-oncogene Mus musculus 179-183 12851492-0 2003 Cell cycle effects and caspase-dependent and independent death of HL-60 and Jurkat cells treated with the inhibitor of NF-kappaB parthenolide. parthenolide 129-141 nuclear factor kappa B subunit 1 Homo sapiens 119-128 12667793-10 2003 ICAM-1 mRNA upregulation was inhibited upon incubation with several chemicals, namely, the ERK1/2 inhibitors PD98059 and AG1288 (by 98 and 67%, respectively), of the p38/MAPK pathway SB203580 (by 50%), of the JNK pathway dimethylaminopurine (by 83%), and of the NF-kappaB parthenolide (by 96%). parthenolide 272-284 intercellular adhesion molecule 1 Homo sapiens 0-6 12667793-10 2003 ICAM-1 mRNA upregulation was inhibited upon incubation with several chemicals, namely, the ERK1/2 inhibitors PD98059 and AG1288 (by 98 and 67%, respectively), of the p38/MAPK pathway SB203580 (by 50%), of the JNK pathway dimethylaminopurine (by 83%), and of the NF-kappaB parthenolide (by 96%). parthenolide 272-284 mitogen-activated protein kinase 3 Homo sapiens 91-97 12667793-10 2003 ICAM-1 mRNA upregulation was inhibited upon incubation with several chemicals, namely, the ERK1/2 inhibitors PD98059 and AG1288 (by 98 and 67%, respectively), of the p38/MAPK pathway SB203580 (by 50%), of the JNK pathway dimethylaminopurine (by 83%), and of the NF-kappaB parthenolide (by 96%). parthenolide 272-284 mitogen-activated protein kinase 1 Homo sapiens 166-169 12504894-14 2003 The MGO-BSA-induced NFkappaB activation was prevented in the presence of PD98059, NAC, and parthenolide, a selective inhibitor of NFkappaB. parthenolide 91-103 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 20-28 12504894-14 2003 The MGO-BSA-induced NFkappaB activation was prevented in the presence of PD98059, NAC, and parthenolide, a selective inhibitor of NFkappaB. parthenolide 91-103 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 130-138 12504894-15 2003 Furthermore, the NFkappaB inhibitor parthenolide suppressed MGO-BSA-induced TNFalpha secretion. parthenolide 36-48 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 17-25 12504894-15 2003 Furthermore, the NFkappaB inhibitor parthenolide suppressed MGO-BSA-induced TNFalpha secretion. parthenolide 36-48 tumor necrosis factor Mus musculus 76-84 12552998-7 2002 Pretreatment of the intact Y8 cells with the caspase-3 inhibitor, Ac-DEVD-CHO, resulted in a marked decrease in the apoptosis caused by the LC plus PA combination. parthenolide 148-150 caspase 3 Mus musculus 45-54 12552998-8 2002 Cell-free extracts prepared from the LC plus PA combination-treated cells had activated caspase activities in the caspase cascade: caspase-3 >> caspase-8 > caspase-6 and caspase-10. parthenolide 45-47 caspase 6 Mus musculus 88-95 12552998-8 2002 Cell-free extracts prepared from the LC plus PA combination-treated cells had activated caspase activities in the caspase cascade: caspase-3 >> caspase-8 > caspase-6 and caspase-10. parthenolide 45-47 caspase 6 Mus musculus 114-121 12552998-8 2002 Cell-free extracts prepared from the LC plus PA combination-treated cells had activated caspase activities in the caspase cascade: caspase-3 >> caspase-8 > caspase-6 and caspase-10. parthenolide 45-47 caspase 3 Mus musculus 131-140 12552998-8 2002 Cell-free extracts prepared from the LC plus PA combination-treated cells had activated caspase activities in the caspase cascade: caspase-3 >> caspase-8 > caspase-6 and caspase-10. parthenolide 45-47 caspase 8 Mus musculus 150-159 12552998-8 2002 Cell-free extracts prepared from the LC plus PA combination-treated cells had activated caspase activities in the caspase cascade: caspase-3 >> caspase-8 > caspase-6 and caspase-10. parthenolide 45-47 caspase 6 Mus musculus 165-174 12170268-0 2002 The sesquiterpene lactone parthenolide inhibits LPS- but not TNF-alpha-induced maturation of human monocyte-derived dendritic cells by inhibition of the p38 mitogen-activated protein kinase pathway. parthenolide 26-38 mitogen-activated protein kinase 14 Homo sapiens 153-156 12151389-8 2002 Furthermore, stable overexpression of GADD153 sensitized the cells to apoptosis induced by parthenolide, and this susceptibility could be reversed by transfection with an antisense to GADD153. parthenolide 91-103 DNA damage inducible transcript 3 Homo sapiens 38-45 12151389-8 2002 Furthermore, stable overexpression of GADD153 sensitized the cells to apoptosis induced by parthenolide, and this susceptibility could be reversed by transfection with an antisense to GADD153. parthenolide 91-103 DNA damage inducible transcript 3 Homo sapiens 184-191 12368222-6 2002 In cultured mesangial cells and monocytes, gliotoxin and parthenolide inhibited NF-kappa B activation and expression of inflammatory genes induced by lipopolysaccharide and cytokines, by blocking the phosphorylation/degradation of the I kappa B(alpha) subunit. parthenolide 57-69 NFKB inhibitor alpha Rattus norvegicus 235-251 12570770-8 2003 Our ethnopharmacological research led to the identification of sesquiterpene lactones (SLs) like parthenolide as potent and relatively specific inhibitors of the transcription factor NF-kappaB, an important mediator of the inflammatory process. parthenolide 97-109 nuclear factor kappa B subunit 1 Homo sapiens 183-192 12417429-0 2002 Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells. parthenolide 80-92 nitric oxide synthase 2 Rattus norvegicus 59-63 12417429-3 2002 Here, we investigated the effect of parthenolide on inducible NO synthase (iNOS) synthesis and NO release using primary rat microglia. parthenolide 36-48 nitric oxide synthase 2 Rattus norvegicus 52-73 12417429-3 2002 Here, we investigated the effect of parthenolide on inducible NO synthase (iNOS) synthesis and NO release using primary rat microglia. parthenolide 36-48 nitric oxide synthase 2 Rattus norvegicus 75-79 12417429-4 2002 We found parthenolide to be an inhibitor of iNOS/NO synthesis. parthenolide 9-21 nitric oxide synthase 2 Rattus norvegicus 44-48 12417429-5 2002 Investigating the molecular mechanisms by which parthenolide prevents iNOS/NO synthesis, we found that parthenolide inhibits the activation of p42/44 mitogen-activated protein kinase (MAPK), but not IkBalpha (IkappaBalpha) degradation or nuclear factor-kappaB (NF-kappaB) p65 activation. parthenolide 48-60 nitric oxide synthase 2 Rattus norvegicus 70-74 12417429-5 2002 Investigating the molecular mechanisms by which parthenolide prevents iNOS/NO synthesis, we found that parthenolide inhibits the activation of p42/44 mitogen-activated protein kinase (MAPK), but not IkBalpha (IkappaBalpha) degradation or nuclear factor-kappaB (NF-kappaB) p65 activation. parthenolide 48-60 synaptotagmin 1 Rattus norvegicus 272-275 12417429-5 2002 Investigating the molecular mechanisms by which parthenolide prevents iNOS/NO synthesis, we found that parthenolide inhibits the activation of p42/44 mitogen-activated protein kinase (MAPK), but not IkBalpha (IkappaBalpha) degradation or nuclear factor-kappaB (NF-kappaB) p65 activation. parthenolide 103-115 nitric oxide synthase 2 Rattus norvegicus 70-74 12417429-5 2002 Investigating the molecular mechanisms by which parthenolide prevents iNOS/NO synthesis, we found that parthenolide inhibits the activation of p42/44 mitogen-activated protein kinase (MAPK), but not IkBalpha (IkappaBalpha) degradation or nuclear factor-kappaB (NF-kappaB) p65 activation. parthenolide 103-115 synaptotagmin 1 Rattus norvegicus 272-275 12138118-10 2002 Parthenolide-mediated overexpression of GADD153 resulted in enhanced 4HPR-induced apoptosis. parthenolide 0-12 DNA damage inducible transcript 3 Homo sapiens 40-47 12170268-2 2002 OBJECTIVE: In this study we examined the effect of the anti-inflammatory sesquiterpene lactone parthenolide (PTL) on DC maturation induced by LPS or TNF-alpha. parthenolide 109-112 tumor necrosis factor Homo sapiens 149-158 12067985-8 2002 Parthenolide, a potent and specific inhibitor of NFkappaB, inhibits the anchorage-dependent proliferation of antiestrogen-resistant but not antiestrogen-responsive cells. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 49-57 12056916-1 2002 p34, a specific p-nitrophenyl phosphatase (pNPPase) was identified and purified from the murine cell line EL4 in a screen for the intracellular molecular targets of the antiinflammatory natural product parthenolide. parthenolide 202-214 alpha- and gamma-adaptin binding protein Mus musculus 0-3 12056916-1 2002 p34, a specific p-nitrophenyl phosphatase (pNPPase) was identified and purified from the murine cell line EL4 in a screen for the intracellular molecular targets of the antiinflammatory natural product parthenolide. parthenolide 202-214 epilepsy 4 Mus musculus 106-109 11598079-9 2001 In the complete absence of activated NF-kappaB, when Mono Mac 6 cells were pretreated with the more potent NF-kappaB inhibitors MG-132 and parthenolide a C. pneumoniae-mediated rescue of cells from induced apoptosis could not be achieved. parthenolide 139-151 nuclear factor kappa B subunit 1 Homo sapiens 107-116 11961112-13 2002 Treatment with parthenolide also abolished nitrotyrosine formation, PARS expression, and apoptosis and reduced iNOS mRNA content in thoracic aortas. parthenolide 15-27 nitric oxide synthase 2 Rattus norvegicus 111-115 11944890-3 2002 Parthenolide blocked by 90.6 +/- 7.4% the IL-4-induced expression of the endothelial vascular cell adhesion molecule (VCAM)-1, a hallmark of extravasation of very late antigen-4-positive leukocytes. parthenolide 0-12 interleukin 4 Homo sapiens 42-46 11944890-3 2002 Parthenolide blocked by 90.6 +/- 7.4% the IL-4-induced expression of the endothelial vascular cell adhesion molecule (VCAM)-1, a hallmark of extravasation of very late antigen-4-positive leukocytes. parthenolide 0-12 vascular cell adhesion molecule 1 Homo sapiens 85-125 11944890-4 2002 The noncytotoxic concentrations of 10 microM parthenolide left a section of the IL-4 receptor signal transduction intact. parthenolide 45-57 interleukin 4 Homo sapiens 80-84 11944890-6 2002 But parthenolide inhibited the Stat6 DNA-binding activity in IL-4-stimulated endothelial cells and inhibited the IL-4-driven activation of a luciferase reporter gene under the control of Stat6-responsive elements (IC(50) 5.11 +/- 0.67 microM). parthenolide 4-16 signal transducer and activator of transcription 6 Homo sapiens 31-36 11944890-6 2002 But parthenolide inhibited the Stat6 DNA-binding activity in IL-4-stimulated endothelial cells and inhibited the IL-4-driven activation of a luciferase reporter gene under the control of Stat6-responsive elements (IC(50) 5.11 +/- 0.67 microM). parthenolide 4-16 interleukin 4 Homo sapiens 61-65 11944890-6 2002 But parthenolide inhibited the Stat6 DNA-binding activity in IL-4-stimulated endothelial cells and inhibited the IL-4-driven activation of a luciferase reporter gene under the control of Stat6-responsive elements (IC(50) 5.11 +/- 0.67 microM). parthenolide 4-16 interleukin 4 Homo sapiens 113-117 11944890-6 2002 But parthenolide inhibited the Stat6 DNA-binding activity in IL-4-stimulated endothelial cells and inhibited the IL-4-driven activation of a luciferase reporter gene under the control of Stat6-responsive elements (IC(50) 5.11 +/- 0.67 microM). parthenolide 4-16 signal transducer and activator of transcription 6 Homo sapiens 187-192 11921057-8 2002 IkappaBalpha degradation, NF-kappaB activation, and iNOS expression were attenuated by parthenolide (3mg/kg), the active constituent of feverfew, an anti-inflammatory drug used for migraine treatment. parthenolide 87-99 NFKB inhibitor alpha Homo sapiens 0-12 11921057-8 2002 IkappaBalpha degradation, NF-kappaB activation, and iNOS expression were attenuated by parthenolide (3mg/kg), the active constituent of feverfew, an anti-inflammatory drug used for migraine treatment. parthenolide 87-99 nuclear factor kappa B subunit 1 Homo sapiens 26-35 11921057-8 2002 IkappaBalpha degradation, NF-kappaB activation, and iNOS expression were attenuated by parthenolide (3mg/kg), the active constituent of feverfew, an anti-inflammatory drug used for migraine treatment. parthenolide 87-99 nitric oxide synthase 2 Homo sapiens 52-56 11877332-0 2002 Enhancement of 1 alpha,25-dihydroxyvitamin D(3)-induced differentiation of human leukaemia HL-60 cells into monocytes by parthenolide via inhibition of NF-kappa B activity. parthenolide 121-133 nuclear factor kappa B subunit 1 Homo sapiens 152-162 11877332-3 2002 In this report parthenolide (PT), a sesquiterpene lactone of herbal remedies such as feverfew (Tanacetum parthenium) with NF-kappa B inhibitory activity, markedly increased the degree of human leukaemia HL-60 cell differentiation when simultaneously combined with 5 nM 1 alpha,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)). parthenolide 15-27 nuclear factor kappa B subunit 1 Homo sapiens 122-132 11877332-3 2002 In this report parthenolide (PT), a sesquiterpene lactone of herbal remedies such as feverfew (Tanacetum parthenium) with NF-kappa B inhibitory activity, markedly increased the degree of human leukaemia HL-60 cell differentiation when simultaneously combined with 5 nM 1 alpha,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)). parthenolide 29-31 nuclear factor kappa B subunit 1 Homo sapiens 122-132 11911251-4 2001 In these studies, the effects of leflunomide and parthenolide (drugs reported to alter the activation of NFkappaB in a variety of cell types) were studied for their cell cycle and apoptotic effects in WT and Y8 cells as single agents and in combination with roscovitine. parthenolide 49-61 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 105-113 11571584-6 2001 The Ad.CFTR-dependent increase of ICAM-1 mRNA was abolished by inhibitors of NF-kB, such as N-acetyl-L-cysteine, pyrrolidine dithiocarbamate, parthenolide and the synthetic peptide SN50. parthenolide 142-154 CF transmembrane conductance regulator Homo sapiens 7-11 11500489-6 2001 Moreover, based on experiments using the SL parthenolide, an alternative mode of action has been proposed by other authors in which SLs inhibit IkappaB-alpha degradation. parthenolide 44-56 NFKB inhibitor alpha Homo sapiens 144-157 11500489-9 2001 In addition, we provide evidence that parthenolide uses a similar mechanism to other SLs in inhibiting NF-kappaB. parthenolide 38-50 nuclear factor kappa B subunit 1 Homo sapiens 103-112 11500489-10 2001 Contrary to previous reports, we show that parthenolide, like other SLs, inhibits NF-kappaB most probably by alkylating p65 at Cys(38). parthenolide 43-55 nuclear factor kappa B subunit 1 Homo sapiens 82-91 11500489-10 2001 Contrary to previous reports, we show that parthenolide, like other SLs, inhibits NF-kappaB most probably by alkylating p65 at Cys(38). parthenolide 43-55 RELA proto-oncogene, NF-kB subunit Homo sapiens 120-123 11588049-9 2001 Treatment of cells with a specific NFkappaB inhibitor, parthenolide, led to loss of NFkappaB activity and down-regulation of antiapoptotic c-IAP2. parthenolide 55-67 nuclear factor kappa B subunit 1 Homo sapiens 35-43 11588049-9 2001 Treatment of cells with a specific NFkappaB inhibitor, parthenolide, led to loss of NFkappaB activity and down-regulation of antiapoptotic c-IAP2. parthenolide 55-67 nuclear factor kappa B subunit 1 Homo sapiens 84-92 11588049-9 2001 Treatment of cells with a specific NFkappaB inhibitor, parthenolide, led to loss of NFkappaB activity and down-regulation of antiapoptotic c-IAP2. parthenolide 55-67 baculoviral IAP repeat containing 3 Homo sapiens 139-145 11571584-6 2001 The Ad.CFTR-dependent increase of ICAM-1 mRNA was abolished by inhibitors of NF-kB, such as N-acetyl-L-cysteine, pyrrolidine dithiocarbamate, parthenolide and the synthetic peptide SN50. parthenolide 142-154 intercellular adhesion molecule 1 Homo sapiens 34-40 11410248-4 2001 The effect of parthenolide on IL-12 p40 promoter activation was analyzed by transfecting RAW264.7 monocytic cells with p40 promoter/luciferase constructs. parthenolide 14-26 interleukin 12b Mus musculus 30-39 11410248-4 2001 The effect of parthenolide on IL-12 p40 promoter activation was analyzed by transfecting RAW264.7 monocytic cells with p40 promoter/luciferase constructs. parthenolide 14-26 interleukin 12b Mus musculus 36-39 11428868-6 2001 This induction was completely blocked by simultaneous administration of the two drugs or by incubation with inhibitors for activation of NF-kappaB such as BAY11-7085, CAPE, and parthenolide. parthenolide 177-189 nuclear factor kappa B subunit 1 Homo sapiens 137-146 11446741-0 2001 Feverfew extracts and the sesquiterpene lactone parthenolide inhibit intercellular adhesion molecule-1 expression in human synovial fibroblasts. parthenolide 48-60 intercellular adhesion molecule 1 Homo sapiens 69-102 11446741-3 2001 Pretreatment of synovial fibroblasts with either feverfew extracts or purified parthenolide could inhibit the expression of intercellular adhesion molecule-1 (ICAM-1) induced by the cytokines IL-1 (up to 95% suppression), TNF-alpha (up to 93% suppression), and, less strongly, interferon-gamma (up to 39% suppression). parthenolide 79-91 intercellular adhesion molecule 1 Homo sapiens 124-157 10623619-0 2000 Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. parthenolide 0-12 signal transducer and activator of transcription 3 Homo sapiens 88-93 11006954-4 2000 The induction of ICAM-1 by cytokines such as interleukin 1beta or tumour necrosis factor TNF as well as by lipopolysaccharide or T3 can be suppressed by the two anti-inflammatory compounds dexamethasone and parthenolide. parthenolide 207-219 intercellular adhesion molecule 1 Homo sapiens 17-23 11006954-4 2000 The induction of ICAM-1 by cytokines such as interleukin 1beta or tumour necrosis factor TNF as well as by lipopolysaccharide or T3 can be suppressed by the two anti-inflammatory compounds dexamethasone and parthenolide. parthenolide 207-219 interleukin 1 beta Homo sapiens 45-62 11006954-4 2000 The induction of ICAM-1 by cytokines such as interleukin 1beta or tumour necrosis factor TNF as well as by lipopolysaccharide or T3 can be suppressed by the two anti-inflammatory compounds dexamethasone and parthenolide. parthenolide 207-219 tumor necrosis factor Homo sapiens 89-92 11360202-6 2001 We also show that parthenolide, a NF-kappaB inhibitor, sensitizes breast cancer cells to tunicamycin. parthenolide 18-30 nuclear factor kappa B subunit 1 Homo sapiens 34-43 11301852-1 2001 A sesquiterpene lactone, costunolide (CTN), was identified from Magnolia grandiflora together with parthenolide (PTN) by its strong inhibition of LPS-induced NF-kappa B activation. parthenolide 99-111 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 158-168 11301852-1 2001 A sesquiterpene lactone, costunolide (CTN), was identified from Magnolia grandiflora together with parthenolide (PTN) by its strong inhibition of LPS-induced NF-kappa B activation. parthenolide 113-116 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 158-168 11301852-2 2001 CTN, which showed more potent inhibition than PTN in the NF-kappa B activation, strongly suppressed nitric oxide (NO) production in LPS-stimulated RAW 264.7 cells. parthenolide 46-49 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 57-67 10962577-9 2000 Parthenolide, an active ingredient of herbal remedies such as feverfew (tanacetum parthenium), mimicked the effects of IkappaBalpha by inhibiting NF-kappaB DNA binding activity and Mn-SOD expression, and increasing paclitaxel-induced apoptosis of breast cancer cells. parthenolide 0-12 NFKB inhibitor alpha Homo sapiens 119-131 10874135-0 2000 Inhibition by parthenolide of phorbol ester-induced transcriptional activation of inducible nitric oxide synthase gene in a human monocyte cell line THP-1. parthenolide 14-26 nitric oxide synthase 2 Homo sapiens 82-113 10874135-0 2000 Inhibition by parthenolide of phorbol ester-induced transcriptional activation of inducible nitric oxide synthase gene in a human monocyte cell line THP-1. parthenolide 14-26 GLI family zinc finger 2 Homo sapiens 149-154 10874135-4 2000 In this study, we demonstrate that parthenolide, the predominant sesquiterpene lactone in European feverfew (Tanacetum parthenium), exerts potent inhibitory effects on the promoter activity of the iNOS gene in THP-1 cells. parthenolide 35-47 nitric oxide synthase 2 Homo sapiens 197-201 10874135-4 2000 In this study, we demonstrate that parthenolide, the predominant sesquiterpene lactone in European feverfew (Tanacetum parthenium), exerts potent inhibitory effects on the promoter activity of the iNOS gene in THP-1 cells. parthenolide 35-47 GLI family zinc finger 2 Homo sapiens 210-215 10874135-5 2000 Parthenolide effectively suppressed iNOS promoter activity in a dose-dependent manner at concentrations higher than 2. parthenolide 0-12 nitric oxide synthase 2 Homo sapiens 36-40 10874135-7 2000 A tumor-promoting phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), significantly increased the iNOS promoter-dependent reporter gene activity, and the TPA-induced increase in iNOS promoter activity was effectively suppressed by parthenolide, with an IC(50) of approximately 2 microM. parthenolide 238-250 nitric oxide synthase 2 Homo sapiens 105-109 10874135-7 2000 A tumor-promoting phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), significantly increased the iNOS promoter-dependent reporter gene activity, and the TPA-induced increase in iNOS promoter activity was effectively suppressed by parthenolide, with an IC(50) of approximately 2 microM. parthenolide 238-250 nitric oxide synthase 2 Homo sapiens 185-189 10858246-8 2000 Treatment of C. pneumoniae-infected HUVEC with parthenolide, a specific inhibitor of NF-kappaB activation, suppressed MCP-1 mRNA expression. parthenolide 47-59 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 85-94 10858246-8 2000 Treatment of C. pneumoniae-infected HUVEC with parthenolide, a specific inhibitor of NF-kappaB activation, suppressed MCP-1 mRNA expression. parthenolide 47-59 chemokine (C-C motif) ligand 2 Mus musculus 118-123 10704251-3 2000 Because activation of NF-kappaB is involved in the regulation of the chemokine interleukin 8 (IL-8), we hypothesized that the sesquiterpene lactones, isohelenin and parthenolide, would inhibit IL-8 gene expression in cultured human respiratory epithelium. parthenolide 165-177 nuclear factor kappa B subunit 1 Homo sapiens 22-31 10704251-3 2000 Because activation of NF-kappaB is involved in the regulation of the chemokine interleukin 8 (IL-8), we hypothesized that the sesquiterpene lactones, isohelenin and parthenolide, would inhibit IL-8 gene expression in cultured human respiratory epithelium. parthenolide 165-177 C-X-C motif chemokine ligand 8 Homo sapiens 79-92 10704251-3 2000 Because activation of NF-kappaB is involved in the regulation of the chemokine interleukin 8 (IL-8), we hypothesized that the sesquiterpene lactones, isohelenin and parthenolide, would inhibit IL-8 gene expression in cultured human respiratory epithelium. parthenolide 165-177 C-X-C motif chemokine ligand 8 Homo sapiens 94-98 10704251-3 2000 Because activation of NF-kappaB is involved in the regulation of the chemokine interleukin 8 (IL-8), we hypothesized that the sesquiterpene lactones, isohelenin and parthenolide, would inhibit IL-8 gene expression in cultured human respiratory epithelium. parthenolide 165-177 C-X-C motif chemokine ligand 8 Homo sapiens 193-197 10704251-5 2000 Pretreatment with either isohelenin or parthenolide inhibited TNF-alpha-mediated IL-8 gene expression in a concentration-dependent manner. parthenolide 39-51 tumor necrosis factor Homo sapiens 62-71 10704251-5 2000 Pretreatment with either isohelenin or parthenolide inhibited TNF-alpha-mediated IL-8 gene expression in a concentration-dependent manner. parthenolide 39-51 C-X-C motif chemokine ligand 8 Homo sapiens 81-85 10704251-7 2000 In addition, pretreatment with isohelenin or parthenolide inhibited TNF-alpha-mediated degradation of the NF-kappaB inhibitory protein, I-kappaBalpha. parthenolide 45-57 tumor necrosis factor Homo sapiens 68-77 10704251-7 2000 In addition, pretreatment with isohelenin or parthenolide inhibited TNF-alpha-mediated degradation of the NF-kappaB inhibitory protein, I-kappaBalpha. parthenolide 45-57 nuclear factor kappa B subunit 1 Homo sapiens 106-115 10704251-7 2000 In addition, pretreatment with isohelenin or parthenolide inhibited TNF-alpha-mediated degradation of the NF-kappaB inhibitory protein, I-kappaBalpha. parthenolide 45-57 NFKB inhibitor alpha Homo sapiens 136-149 10623619-0 2000 Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. parthenolide 0-12 interleukin 6 Homo sapiens 123-127 10623619-3 2000 Parthenolide, a sesquiterpene lactone found in many medical plants, is an inhibitor of IL-1-type cytokine signaling that blocks the activation of NF-kappaB. parthenolide 0-12 interleukin 1 alpha Homo sapiens 87-91 10623619-4 2000 Here we show that parthenolide is also an effective inhibitor of IL-6-type cytokines. parthenolide 18-30 interleukin 6 Homo sapiens 65-69 10553091-0 1999 The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. parthenolide 43-55 nuclear factor kappa B subunit 1 Homo sapiens 65-75 10553091-3 1999 This study shows that the sesquiterpene lactone parthenolide inhibits a common step in NF-kappa B activation by preventing the TNF-alpha-induced induction of I kappa B kinase (IKK) and IKK beta, without affecting the activation of p38 and c-Jun N-terminal kinase. parthenolide 48-60 nuclear factor kappa B subunit 1 Homo sapiens 87-97 10553091-3 1999 This study shows that the sesquiterpene lactone parthenolide inhibits a common step in NF-kappa B activation by preventing the TNF-alpha-induced induction of I kappa B kinase (IKK) and IKK beta, without affecting the activation of p38 and c-Jun N-terminal kinase. parthenolide 48-60 tumor necrosis factor Homo sapiens 127-136 10553091-3 1999 This study shows that the sesquiterpene lactone parthenolide inhibits a common step in NF-kappa B activation by preventing the TNF-alpha-induced induction of I kappa B kinase (IKK) and IKK beta, without affecting the activation of p38 and c-Jun N-terminal kinase. parthenolide 48-60 inhibitor of nuclear factor kappa B kinase subunit beta Homo sapiens 185-193 10553091-3 1999 This study shows that the sesquiterpene lactone parthenolide inhibits a common step in NF-kappa B activation by preventing the TNF-alpha-induced induction of I kappa B kinase (IKK) and IKK beta, without affecting the activation of p38 and c-Jun N-terminal kinase. parthenolide 48-60 mitogen-activated protein kinase 14 Homo sapiens 231-234 10553091-4 1999 Parthenolide impairs NF-kappa B-dependent transcription triggered by expression of TNFR-associated factor-2, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEKK1), and NF-kappa B-inducing kinase. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 21-31 10553091-4 1999 Parthenolide impairs NF-kappa B-dependent transcription triggered by expression of TNFR-associated factor-2, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEKK1), and NF-kappa B-inducing kinase. parthenolide 0-12 mitogen-activated protein kinase kinase kinase 1 Homo sapiens 188-193 10553091-4 1999 Parthenolide impairs NF-kappa B-dependent transcription triggered by expression of TNFR-associated factor-2, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEKK1), and NF-kappa B-inducing kinase. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 200-210 10462483-5 1999 In the current studies we determined if the sesquiterpene lactones, parthenolide and isohelenin, modulate iNOS gene expression in cultured rat aortic smooth muscle cells (RASMC) treated with lipopolysaccharide and interferon-gamma. parthenolide 68-80 nitric oxide synthase 2 Rattus norvegicus 106-110 10462483-5 1999 In the current studies we determined if the sesquiterpene lactones, parthenolide and isohelenin, modulate iNOS gene expression in cultured rat aortic smooth muscle cells (RASMC) treated with lipopolysaccharide and interferon-gamma. parthenolide 68-80 interferon gamma Rattus norvegicus 214-230 10462483-6 1999 Treatment with parthenolide or isohelenin inhibited NO production and iNOS mRNA expression in a concentration-dependent manner. parthenolide 15-27 nitric oxide synthase 2 Rattus norvegicus 70-74 10462483-7 1999 Transient transfection studies with an iNOS promoter-luciferase reporter plasmid demonstrated that parthenolide and isohelenin also inhibited activation of the iNOS promoter. parthenolide 99-111 nitric oxide synthase 2 Rattus norvegicus 39-43 10462483-7 1999 Transient transfection studies with an iNOS promoter-luciferase reporter plasmid demonstrated that parthenolide and isohelenin also inhibited activation of the iNOS promoter. parthenolide 99-111 nitric oxide synthase 2 Rattus norvegicus 160-164 34821219-3 2021 In this research, we disclosed the capability of ACT001, a derivative of parthenolide analogues, to activate AMPK by increasing the intracellular reactive oxygen species (ROS) level and AMP/ATP ratio to reverse DA-resistance through dual pathways in prolactinoma cells. parthenolide 73-85 protein kinase AMP-activated catalytic subunit alpha 2 Rattus norvegicus 109-113 9214741-0 1997 Activity of Parthenolide at 5HT2A receptors. parthenolide 12-24 5-hydroxytryptamine receptor 2A Rattus norvegicus 28-33 9214741-1 1997 Parthenolide displaces [3H]ketanserin from 5HT2A receptors from rat and rabbit brain and cloned 5HT2A receptors. parthenolide 0-12 5-hydroxytryptamine receptor 2A Rattus norvegicus 43-48 32952998-3 2019 A novel parthenolide derivative with good bioavailability and pharmacological properties was identified through a screening cascade based on in vitro anti-leukaemic activity and calculated "drug-likeness" properties, in vitro and in vivo pharmacokinetics studies and hERG liability testing. parthenolide 8-20 ETS transcription factor ERG Homo sapiens 267-271 10696826-5 1999 Our results demonstrate a repressive effect of dexamethasone and parthenolide on the expression of the protein ICAM-1 stimulated by T3. parthenolide 65-77 intercellular adhesion molecule 1 Homo sapiens 111-117 34847663-0 2021 Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer. parthenolide 0-12 pyruvate kinase M1/2 Homo sapiens 28-32 34847663-2 2021 In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate 29e showed good activity on PKM2 (AC50 = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC50 = 0.66 muM) and SW480 (IC50 = 0.22 muM) cells. parthenolide 39-51 pyruvate kinase M1/2 Homo sapiens 167-171 34847663-2 2021 In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate 29e showed good activity on PKM2 (AC50 = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC50 = 0.66 muM) and SW480 (IC50 = 0.22 muM) cells. parthenolide 53-56 pyruvate kinase M1/2 Homo sapiens 167-171 34229108-1 2021 Melampomagnolide B (MMB, 3) is a parthenolide (PTL, 1) based sesquiterpene lactone that has been used as a template for the synthesis of a plethora of lead anticancer agents owing to its reactive C-10 primary hydroxyl group. parthenolide 33-45 homeobox C10 Homo sapiens 196-200 34229108-1 2021 Melampomagnolide B (MMB, 3) is a parthenolide (PTL, 1) based sesquiterpene lactone that has been used as a template for the synthesis of a plethora of lead anticancer agents owing to its reactive C-10 primary hydroxyl group. parthenolide 47-50 homeobox C10 Homo sapiens 196-200 35525305-0 2022 Parthenolide reverses the epithelial to mesenchymal transition process in breast cancer by targeting TGFbeta1: In vitro and in silico studies. parthenolide 0-12 transforming growth factor beta 1 Homo sapiens 101-109 34250656-0 2021 Parthenolide, bioactive compound of Chrysanthemum parthenium L., ameliorates fibrogenesis and inflammation in hepatic fibrosis via regulating the crosstalk of TLR4 and STAT3 signaling pathway. parthenolide 0-12 toll-like receptor 4 Mus musculus 159-163 34250656-0 2021 Parthenolide, bioactive compound of Chrysanthemum parthenium L., ameliorates fibrogenesis and inflammation in hepatic fibrosis via regulating the crosstalk of TLR4 and STAT3 signaling pathway. parthenolide 0-12 signal transducer and activator of transcription 3 Mus musculus 168-173 34250656-1 2021 The current study focused on the regulatory effects of parthenolide (PNL), a bioactive component derived from Chrysanthemum parthenium L., against hepatic fibrosis via regulating the crosstalk of toll-like receptor 4 (TLR4) and signal transducer and activator of transcription 3 (STAT3) in activated hepatic stellate cells (HSCs). parthenolide 55-67 toll-like receptor 4 Mus musculus 218-222 34250656-1 2021 The current study focused on the regulatory effects of parthenolide (PNL), a bioactive component derived from Chrysanthemum parthenium L., against hepatic fibrosis via regulating the crosstalk of toll-like receptor 4 (TLR4) and signal transducer and activator of transcription 3 (STAT3) in activated hepatic stellate cells (HSCs). parthenolide 55-67 signal transducer and activator of transcription 3 Mus musculus 280-285 34071580-3 2021 The cross-talk between NF-kB activation and PXR suppression was evaluated by NF-kB blockage (10 microM parthenolide). parthenolide 103-115 nuclear receptor subfamily 1 group I member 2 Homo sapiens 44-47 34569224-8 2021 The activity of PGP-I was further identified to be highly related to the phosphorylation of STAT3, which could be impeded by the natural product parthenolide. parthenolide 145-157 pyroglutamyl-peptidase I Mus musculus 16-21 34569224-8 2021 The activity of PGP-I was further identified to be highly related to the phosphorylation of STAT3, which could be impeded by the natural product parthenolide. parthenolide 145-157 signal transducer and activator of transcription 3 Mus musculus 92-97 34575860-12 2021 Pharmacological inhibition of NF-kappaB by parthenolide diminished CsA- and Tac-mediated proinflammatory effects. parthenolide 43-55 nuclear factor kappa B subunit 1 Homo sapiens 30-39 34101920-7 2021 In addition, parthenolide inhibited the NF-kB pathway suppressing IkB phosphorylation and p65 nuclear translocation. parthenolide 13-25 RELA proto-oncogene, NF-kB subunit Homo sapiens 90-93 34405014-0 2021 Suppression Of Aberrant Activation Of NF-kappaB Pathway In Drug-resistant Leukemia Stem Cells Contributes To Parthenolide-potentiated Reversal Of Drug Resistance In Leukemia. parthenolide 109-121 nuclear factor kappa B subunit 1 Homo sapiens 38-47 34405014-6 2021 Also, parthenolide (PTL), which is a specific NF-kappaB inhibitor, effectively eliminated drug-resistant LSCs and enhanced the sensitivity of K562/ADM cells to doxorubicin-induced apoptosis by down-regulating NF-kappaB pathway-mediated P-gp expression. parthenolide 6-18 nuclear factor kappa B subunit 1 Homo sapiens 46-55 34405014-6 2021 Also, parthenolide (PTL), which is a specific NF-kappaB inhibitor, effectively eliminated drug-resistant LSCs and enhanced the sensitivity of K562/ADM cells to doxorubicin-induced apoptosis by down-regulating NF-kappaB pathway-mediated P-gp expression. parthenolide 6-18 nuclear factor kappa B subunit 1 Homo sapiens 209-218 34405014-6 2021 Also, parthenolide (PTL), which is a specific NF-kappaB inhibitor, effectively eliminated drug-resistant LSCs and enhanced the sensitivity of K562/ADM cells to doxorubicin-induced apoptosis by down-regulating NF-kappaB pathway-mediated P-gp expression. parthenolide 6-18 ATP binding cassette subfamily B member 1 Homo sapiens 236-240 34405014-6 2021 Also, parthenolide (PTL), which is a specific NF-kappaB inhibitor, effectively eliminated drug-resistant LSCs and enhanced the sensitivity of K562/ADM cells to doxorubicin-induced apoptosis by down-regulating NF-kappaB pathway-mediated P-gp expression. parthenolide 20-23 nuclear factor kappa B subunit 1 Homo sapiens 46-55 34405014-6 2021 Also, parthenolide (PTL), which is a specific NF-kappaB inhibitor, effectively eliminated drug-resistant LSCs and enhanced the sensitivity of K562/ADM cells to doxorubicin-induced apoptosis by down-regulating NF-kappaB pathway-mediated P-gp expression. parthenolide 20-23 nuclear factor kappa B subunit 1 Homo sapiens 209-218 34405014-6 2021 Also, parthenolide (PTL), which is a specific NF-kappaB inhibitor, effectively eliminated drug-resistant LSCs and enhanced the sensitivity of K562/ADM cells to doxorubicin-induced apoptosis by down-regulating NF-kappaB pathway-mediated P-gp expression. parthenolide 20-23 ATP binding cassette subfamily B member 1 Homo sapiens 236-240 35525305-3 2022 The present study assessed the efficacy of parthenolide (PTL Tanacetum parthenium) on EMT and its underlying mechanisms in both lowly metastatic, estrogen-receptor positive, MCF-7 cells and highly metastatic, triple-negative MDA-MB-231 cells. parthenolide 43-55 pancreatic lipase Homo sapiens 57-60 33367934-7 2021 Western blot analysis was used to investigate the metastasis and epithelial-mesenchymal transition (EMT) induced by parthenolide on the expression levels of MMP2, MMP9, E-cadherin, N-cadherin, vimentin and snail. parthenolide 116-128 matrix metallopeptidase 2 Homo sapiens 157-161 35248947-3 2022 In this study, we found that epoxymicheliolide (EMCL), a derivative of parthenolide, has a high affinity to ERK1/2, but the treatment and mechanism of osteoporosis using EMCL have not been explored. parthenolide 71-83 mitogen-activated protein kinase 3 Mus musculus 108-114 35119950-0 2022 Effect of parthenolide, an NLRP3 inflammasome inhibitor, on insulin resistance in high-fat diet-obese mice. parthenolide 10-22 NLR family, pyrin domain containing 3 Mus musculus 27-32 34004586-0 2021 Design, synthesis and in vivo anticancer activity of novel parthenolide and micheliolide derivatives as NF-kappaB and STAT3 inhibitors. parthenolide 59-71 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 104-113 34004586-0 2021 Design, synthesis and in vivo anticancer activity of novel parthenolide and micheliolide derivatives as NF-kappaB and STAT3 inhibitors. parthenolide 59-71 signal transducer and activator of transcription 3 Mus musculus 118-123 34030041-0 2021 USP47 maintains the stemness of colorectal cancer cells and is inhibited by parthenolide. parthenolide 76-88 ubiquitin specific peptidase 47 Homo sapiens 0-5 34030041-7 2021 Furthermore, we identified Parthenolide (PTL), a natural sesquiterpene lactone, as a novel USP47 inhibitor. parthenolide 27-39 ubiquitin specific peptidase 47 Homo sapiens 91-96 34030041-7 2021 Furthermore, we identified Parthenolide (PTL), a natural sesquiterpene lactone, as a novel USP47 inhibitor. parthenolide 41-44 ubiquitin specific peptidase 47 Homo sapiens 91-96 34026767-0 2021 Retraction: Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway. parthenolide 12-24 AKT serine/threonine kinase 1 Homo sapiens 111-114 33704264-0 2021 Retracted: Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells In Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway. parthenolide 11-23 mechanistic target of rapamycin kinase Homo sapiens 198-227 33704264-0 2021 Retracted: Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells In Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway. parthenolide 11-23 mechanistic target of rapamycin kinase Homo sapiens 229-233 33704264-0 2021 Retracted: Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells In Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway. parthenolide 11-23 AKT serine/threonine kinase 1 Homo sapiens 240-243 33704264-3 2021 Chao Li, Yuqiu Zhou, Yongcong Cai, Chunyan Shui, Wei Liu, Xu Wang, Jian Jiang, Dingfen Zeng, Chunhan Gui, Ronghao Sun: Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells In Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway. parthenolide 119-131 mechanistic target of rapamycin kinase Homo sapiens 306-335 33704264-3 2021 Chao Li, Yuqiu Zhou, Yongcong Cai, Chunyan Shui, Wei Liu, Xu Wang, Jian Jiang, Dingfen Zeng, Chunhan Gui, Ronghao Sun: Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells In Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway. parthenolide 119-131 mechanistic target of rapamycin kinase Homo sapiens 337-341 33704264-3 2021 Chao Li, Yuqiu Zhou, Yongcong Cai, Chunyan Shui, Wei Liu, Xu Wang, Jian Jiang, Dingfen Zeng, Chunhan Gui, Ronghao Sun: Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells In Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway. parthenolide 119-131 AKT serine/threonine kinase 1 Homo sapiens 348-351 31135208-6 2021 Costunolide (1) and parthenolide (2) decreased WT1 protein levels and total cell numbers in K562 and Molt-4 cells. parthenolide 20-32 WT1 transcription factor Homo sapiens 47-50 33614623-0 2020 Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway. parthenolide 0-12 AKT serine/threonine kinase 1 Homo sapiens 99-102 35366876-11 2022 PRM verified that the apoptosis-related proteins HMOX1 and GCLM were up-regulated and IL1B was down-regulated in BCPAP cells treated with parthenolide. parthenolide 138-150 heme oxygenase 1 Homo sapiens 49-54 35366876-11 2022 PRM verified that the apoptosis-related proteins HMOX1 and GCLM were up-regulated and IL1B was down-regulated in BCPAP cells treated with parthenolide. parthenolide 138-150 glutamate-cysteine ligase modifier subunit Homo sapiens 59-63 35366876-11 2022 PRM verified that the apoptosis-related proteins HMOX1 and GCLM were up-regulated and IL1B was down-regulated in BCPAP cells treated with parthenolide. parthenolide 138-150 interleukin 1 beta Homo sapiens 86-90 33430602-11 2021 Higher tubulin detyrosination was also found in 2 unrelated MYBPC3 mouse models and its inhibition with parthenolide normalized contraction and relaxation time of isolated cardiomyocytes. parthenolide 104-116 myosin binding protein C, cardiac Mus musculus 60-66 33367934-7 2021 Western blot analysis was used to investigate the metastasis and epithelial-mesenchymal transition (EMT) induced by parthenolide on the expression levels of MMP2, MMP9, E-cadherin, N-cadherin, vimentin and snail. parthenolide 116-128 matrix metallopeptidase 9 Homo sapiens 163-167 33367934-7 2021 Western blot analysis was used to investigate the metastasis and epithelial-mesenchymal transition (EMT) induced by parthenolide on the expression levels of MMP2, MMP9, E-cadherin, N-cadherin, vimentin and snail. parthenolide 116-128 cadherin 1 Homo sapiens 169-179 33367934-7 2021 Western blot analysis was used to investigate the metastasis and epithelial-mesenchymal transition (EMT) induced by parthenolide on the expression levels of MMP2, MMP9, E-cadherin, N-cadherin, vimentin and snail. parthenolide 116-128 cadherin 2 Homo sapiens 181-191 33367934-7 2021 Western blot analysis was used to investigate the metastasis and epithelial-mesenchymal transition (EMT) induced by parthenolide on the expression levels of MMP2, MMP9, E-cadherin, N-cadherin, vimentin and snail. parthenolide 116-128 vimentin Homo sapiens 193-201 33367934-7 2021 Western blot analysis was used to investigate the metastasis and epithelial-mesenchymal transition (EMT) induced by parthenolide on the expression levels of MMP2, MMP9, E-cadherin, N-cadherin, vimentin and snail. parthenolide 116-128 snail family transcriptional repressor 1 Homo sapiens 206-211 33367934-10 2021 MMP-2/-9 expression (P<0.05) was inhibited by parthenolide. parthenolide 46-58 matrix metallopeptidase 2 Homo sapiens 0-8 33367934-11 2021 The protein levels of E-cadherin were increased (P<0.05) and N-cadherin, vimentin and snail were decreased (P<0.05) by parthenolide treatment. parthenolide 119-131 cadherin 1 Homo sapiens 22-32 33367934-11 2021 The protein levels of E-cadherin were increased (P<0.05) and N-cadherin, vimentin and snail were decreased (P<0.05) by parthenolide treatment. parthenolide 119-131 cadherin 2 Homo sapiens 61-71 33367934-11 2021 The protein levels of E-cadherin were increased (P<0.05) and N-cadherin, vimentin and snail were decreased (P<0.05) by parthenolide treatment. parthenolide 119-131 vimentin Homo sapiens 73-81 33367934-11 2021 The protein levels of E-cadherin were increased (P<0.05) and N-cadherin, vimentin and snail were decreased (P<0.05) by parthenolide treatment. parthenolide 119-131 snail family transcriptional repressor 1 Homo sapiens 86-91 33367934-12 2021 In addition, Parthenolide inhibited the expression of cancer stem cell markers and the PI3K/AKT pathway. parthenolide 13-25 AKT serine/threonine kinase 1 Homo sapiens 92-95 33391492-0 2021 Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling. parthenolide 43-55 AE binding protein 1 Homo sapiens 96-101 33391492-0 2021 Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling. parthenolide 43-55 AKT serine/threonine kinase 1 Homo sapiens 107-110 33391492-3 2021 Here, we identify ACT001, a parthenolide derivative, targeting GSCs through regulation of adipocyte enhancer binding protein 1 (AEBP1) signaling. parthenolide 28-40 AE binding protein 1 Homo sapiens 90-126 33391492-3 2021 Here, we identify ACT001, a parthenolide derivative, targeting GSCs through regulation of adipocyte enhancer binding protein 1 (AEBP1) signaling. parthenolide 28-40 AE binding protein 1 Homo sapiens 128-133 33083018-0 2020 Parthenolide promotes the repair of spinal cord injury by modulating M1/M2 polarization via the NF-kappaB and STAT 1/3 signaling pathway. parthenolide 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 96-105 33258341-5 2020 Mechanistically, PTL treatment resulted in downregulation of NF-kappaB activity and Bcl-2 expression, and upregulation of Caspase-8 activity. parthenolide 17-20 nuclear factor kappa B subunit 1 Homo sapiens 61-70 33258341-5 2020 Mechanistically, PTL treatment resulted in downregulation of NF-kappaB activity and Bcl-2 expression, and upregulation of Caspase-8 activity. parthenolide 17-20 BCL2 apoptosis regulator Homo sapiens 84-89 33258341-5 2020 Mechanistically, PTL treatment resulted in downregulation of NF-kappaB activity and Bcl-2 expression, and upregulation of Caspase-8 activity. parthenolide 17-20 caspase 8 Homo sapiens 122-131 33292235-0 2020 Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptor. parthenolide 0-12 epidermal growth factor receptor Mus musculus 76-108 33292235-6 2020 In silico molecular docking was used to evaluate the binding of parthenolide to EGFR. parthenolide 64-76 epidermal growth factor receptor Mus musculus 80-84 33292235-10 2020 RESULTS: In this study, parthenolide could induce apoptosis and growth inhibition in the EGFR mutated lung cancer cells. parthenolide 24-36 epidermal growth factor receptor Mus musculus 89-93 33292235-11 2020 Parthenolide also reduces the phosphorylation of EGFR as well as its downstream signaling pathways MAPK/ERK and PI3K/Akt. parthenolide 0-12 epidermal growth factor receptor Mus musculus 49-53 33292235-11 2020 Parthenolide also reduces the phosphorylation of EGFR as well as its downstream signaling pathways MAPK/ERK and PI3K/Akt. parthenolide 0-12 mitogen-activated protein kinase 1 Homo sapiens 99-103 33292235-11 2020 Parthenolide also reduces the phosphorylation of EGFR as well as its downstream signaling pathways MAPK/ERK and PI3K/Akt. parthenolide 0-12 mitogen-activated protein kinase 1 Mus musculus 104-107 33292235-11 2020 Parthenolide also reduces the phosphorylation of EGFR as well as its downstream signaling pathways MAPK/ERK and PI3K/Akt. parthenolide 0-12 thymoma viral proto-oncogene 1 Mus musculus 117-120 33292235-12 2020 Molecular docking analysis of EGFR binding site with parthenolide show that the anti-cancer effect of parthenolide against NSCLC is mediated by a strong binding to EGFR. parthenolide 53-65 epidermal growth factor receptor Mus musculus 30-34 33292235-12 2020 Molecular docking analysis of EGFR binding site with parthenolide show that the anti-cancer effect of parthenolide against NSCLC is mediated by a strong binding to EGFR. parthenolide 102-114 epidermal growth factor receptor Mus musculus 30-34 33292235-12 2020 Molecular docking analysis of EGFR binding site with parthenolide show that the anti-cancer effect of parthenolide against NSCLC is mediated by a strong binding to EGFR. parthenolide 102-114 epidermal growth factor receptor Mus musculus 164-168 33292235-13 2020 Network pharmacology analysis show parthenolide suppresses NSCLC via inhibition of EGFR expression. parthenolide 35-47 epidermal growth factor receptor Mus musculus 83-87 33292235-14 2020 In addition, parthenolide inhibits the growth of H1975 xenografts in nude mice, which is associated with the inhibition of the EGFR signaling pathway. parthenolide 13-25 epidermal growth factor receptor Mus musculus 127-131 33292235-15 2020 CONCLUSIONS: Taken together, these results demonstrate effective inhibition of parthenolide in NSCLC cell growth by targeting EGFR through downregulation of ERK and AKT expression, which could be promisingly used for patients carrying the EGFR mutation. parthenolide 79-91 epidermal growth factor receptor Homo sapiens 126-130 33292235-15 2020 CONCLUSIONS: Taken together, these results demonstrate effective inhibition of parthenolide in NSCLC cell growth by targeting EGFR through downregulation of ERK and AKT expression, which could be promisingly used for patients carrying the EGFR mutation. parthenolide 79-91 mitogen-activated protein kinase 1 Homo sapiens 157-160 33292235-15 2020 CONCLUSIONS: Taken together, these results demonstrate effective inhibition of parthenolide in NSCLC cell growth by targeting EGFR through downregulation of ERK and AKT expression, which could be promisingly used for patients carrying the EGFR mutation. parthenolide 79-91 AKT serine/threonine kinase 1 Homo sapiens 165-168 33292235-15 2020 CONCLUSIONS: Taken together, these results demonstrate effective inhibition of parthenolide in NSCLC cell growth by targeting EGFR through downregulation of ERK and AKT expression, which could be promisingly used for patients carrying the EGFR mutation. parthenolide 79-91 epidermal growth factor receptor Homo sapiens 239-243 33083018-0 2020 Parthenolide promotes the repair of spinal cord injury by modulating M1/M2 polarization via the NF-kappaB and STAT 1/3 signaling pathway. parthenolide 0-12 signal transducer and activator of transcription 1 Mus musculus 110-118 32472655-7 2020 Parthenolide is the principal sesquiterpene lactones and the main biologically active constituent Tanacetum parthenium (commonly known as feverfew) which has could significantly reduce IL-1, IL-2, IL-6, IL-8, and TNF-alpha production pathways established in several human cell line models in vitro and in vivo studies. parthenolide 0-12 interleukin 6 Homo sapiens 197-201 32887995-11 2020 The drugs parthenolide and dimethyl fumarate have both been shown to effectively inhibit NFkappaB, reducing tumor aggressiveness and reversing endocrine therapy resistance. parthenolide 10-22 nuclear factor kappa B subunit 1 Homo sapiens 89-97 32751648-0 2020 Parthenolide Has Negative Effects on In Vitro Enhanced Osteogenic Phenotypes by Inflammatory Cytokine TNF-alpha via Inhibiting JNK Signaling. parthenolide 0-12 tumor necrosis factor Homo sapiens 102-111 32738997-0 2020 Synthesis and biological evaluation of parthenolide derivatives with reduced toxicity as potential inhibitors of the NLRP3 inflammasome. parthenolide 39-51 NLR family, pyrin domain containing 3 Mus musculus 117-122 32738997-1 2020 Parthenolide (PTL) can target NLRP3 inflammasome to treat inflammation and its related disease, but its cytotoxicity limits further development as an anti-inflammatory drug. parthenolide 0-12 NLR family, pyrin domain containing 3 Mus musculus 30-35 32738997-1 2020 Parthenolide (PTL) can target NLRP3 inflammasome to treat inflammation and its related disease, but its cytotoxicity limits further development as an anti-inflammatory drug. parthenolide 14-17 NLR family, pyrin domain containing 3 Mus musculus 30-35 32705224-0 2020 Parthenolide inhibits human lung cancer cell growth by modulating the IGF-1R/PI3K/Akt signaling pathway. parthenolide 0-12 insulin like growth factor 1 receptor Homo sapiens 70-76 32705224-0 2020 Parthenolide inhibits human lung cancer cell growth by modulating the IGF-1R/PI3K/Akt signaling pathway. parthenolide 0-12 AKT serine/threonine kinase 1 Homo sapiens 82-85 32823992-2 2020 Parthenolide (PN) has been shown to inhibit NF-kappaB signaling and other pro-survival signaling pathways, induce apoptosis and reduce a subpopulation of cancer stem-like cells in several cancers. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 44-53 32823992-2 2020 Parthenolide (PN) has been shown to inhibit NF-kappaB signaling and other pro-survival signaling pathways, induce apoptosis and reduce a subpopulation of cancer stem-like cells in several cancers. parthenolide 14-16 nuclear factor kappa B subunit 1 Homo sapiens 44-53 32903383-10 2020 Importantly, Tisp40 overexpression significantly increased TECs pyroptosis via p-p65 activation, however, the effects of Tisp40 overexpression were partially blocked by parthenolide (PTL). parthenolide 169-181 cAMP responsive element binding protein 3-like 4 Mus musculus 121-127 32903383-10 2020 Importantly, Tisp40 overexpression significantly increased TECs pyroptosis via p-p65 activation, however, the effects of Tisp40 overexpression were partially blocked by parthenolide (PTL). parthenolide 183-186 cAMP responsive element binding protein 3-like 4 Mus musculus 13-19 32903383-10 2020 Importantly, Tisp40 overexpression significantly increased TECs pyroptosis via p-p65 activation, however, the effects of Tisp40 overexpression were partially blocked by parthenolide (PTL). parthenolide 183-186 cAMP responsive element binding protein 3-like 4 Mus musculus 121-127 32783891-9 2021 Meanwhile, at the transcription level, the adverse effects of CdCl2 exposure may be reversed via genetic modification with siRNA (siPTGS2) or by using phytochemical inhibitors (parthenolide, PN) of COX-2. parthenolide 177-189 prostaglandin-endoperoxide synthase 2 Homo sapiens 198-203 32686017-9 2020 Moreover, Parthenolide treatment led to the obvious alternation of Caspase3 protein level. parthenolide 10-22 caspase 3 Homo sapiens 67-75 32751648-0 2020 Parthenolide Has Negative Effects on In Vitro Enhanced Osteogenic Phenotypes by Inflammatory Cytokine TNF-alpha via Inhibiting JNK Signaling. parthenolide 0-12 mitogen-activated protein kinase 8 Homo sapiens 127-130 32751648-3 2020 Parthenolide (PTL) is an abundant sesquiterpene lactone, found in Mexican Indian Asteraceae family plants, with reported anti-inflammatory activity, through the inhibition of a common step in the NF-kappaB activation pathway. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 196-205 32751648-3 2020 Parthenolide (PTL) is an abundant sesquiterpene lactone, found in Mexican Indian Asteraceae family plants, with reported anti-inflammatory activity, through the inhibition of a common step in the NF-kappaB activation pathway. parthenolide 14-17 nuclear factor kappa B subunit 1 Homo sapiens 196-205 32708381-8 2020 In addition, the effect that ivalin and parthenolide has on desmin, an important cytoskeletal intermediate filament in myocytes, was evaluated using the C2C12 myoblasts. parthenolide 40-52 desmin Mus musculus 60-66 32572732-0 2020 Parthenolide ameliorates tweak-induced podocytes injury. parthenolide 0-12 tumor necrosis factor (ligand) superfamily, member 12 Mus musculus 25-30 31030314-3 2020 They exhibited better cytostatic effects than etoposide (GI50 = 0.56-36.62 muM), parthenolide (GI50 = 3.58-25.97 muM) and VK3 (GI50 = 3.41-22.59 muM) against several of the cancer cell lines. parthenolide 81-93 latexin Homo sapiens 113-116 32742599-8 2020 Moreover, molecular analysis revealed significant down-regulation of CD44, NF-kappaB (REL-A), BMI-1, and C-MYC upon combinatorial administration of parthenolide and ATO in comparison with relevant controls. parthenolide 148-160 CD44 molecule (Indian blood group) Homo sapiens 69-73 32742599-8 2020 Moreover, molecular analysis revealed significant down-regulation of CD44, NF-kappaB (REL-A), BMI-1, and C-MYC upon combinatorial administration of parthenolide and ATO in comparison with relevant controls. parthenolide 148-160 RELA proto-oncogene, NF-kB subunit Homo sapiens 86-91 32742599-8 2020 Moreover, molecular analysis revealed significant down-regulation of CD44, NF-kappaB (REL-A), BMI-1, and C-MYC upon combinatorial administration of parthenolide and ATO in comparison with relevant controls. parthenolide 148-160 BMI1 proto-oncogene, polycomb ring finger Homo sapiens 94-99 32742599-8 2020 Moreover, molecular analysis revealed significant down-regulation of CD44, NF-kappaB (REL-A), BMI-1, and C-MYC upon combinatorial administration of parthenolide and ATO in comparison with relevant controls. parthenolide 148-160 MYC proto-oncogene, bHLH transcription factor Homo sapiens 105-110 32686017-8 2020 Our data indicated that the treatment of cells with Parthenolide led to up-regulation of Bax and downregulation of Bcl2 at mRNA level. parthenolide 52-64 BCL2 associated X, apoptosis regulator Homo sapiens 89-92 32686017-8 2020 Our data indicated that the treatment of cells with Parthenolide led to up-regulation of Bax and downregulation of Bcl2 at mRNA level. parthenolide 52-64 BCL2 apoptosis regulator Homo sapiens 115-119 32373209-11 2020 PTL treatment downregulated the level of proinflammatory cytokines, including IL-1beta, TNF-alpha, IL-6, and IL-17A and upregulated the immunosuppressive cytokine IL-10 in colon tissue. parthenolide 0-3 interleukin 1 alpha Mus musculus 78-86 32373209-11 2020 PTL treatment downregulated the level of proinflammatory cytokines, including IL-1beta, TNF-alpha, IL-6, and IL-17A and upregulated the immunosuppressive cytokine IL-10 in colon tissue. parthenolide 0-3 tumor necrosis factor Mus musculus 88-97 32373209-11 2020 PTL treatment downregulated the level of proinflammatory cytokines, including IL-1beta, TNF-alpha, IL-6, and IL-17A and upregulated the immunosuppressive cytokine IL-10 in colon tissue. parthenolide 0-3 interleukin 6 Mus musculus 99-103 32373209-11 2020 PTL treatment downregulated the level of proinflammatory cytokines, including IL-1beta, TNF-alpha, IL-6, and IL-17A and upregulated the immunosuppressive cytokine IL-10 in colon tissue. parthenolide 0-3 interleukin 17A Mus musculus 109-115 32373209-11 2020 PTL treatment downregulated the level of proinflammatory cytokines, including IL-1beta, TNF-alpha, IL-6, and IL-17A and upregulated the immunosuppressive cytokine IL-10 in colon tissue. parthenolide 0-3 interleukin 10 Mus musculus 163-168 31030314-3 2020 They exhibited better cytostatic effects than etoposide (GI50 = 0.56-36.62 muM), parthenolide (GI50 = 3.58-25.97 muM) and VK3 (GI50 = 3.41-22.59 muM) against several of the cancer cell lines. parthenolide 81-93 latexin Homo sapiens 113-116 32299536-0 2020 NF-kappaB Inhibitor Parthenolide Promotes Renal Tubules Albumin Uptake in Type 2 Diabetic Nephropathy. parthenolide 20-32 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 0-9 32299536-11 2020 PTN significantly reduced the renal expression of NF-kappaB p65 and ameliorated the decline of p-AKT (s473) compared with the db/db group (P<0.05). parthenolide 0-3 thymoma viral proto-oncogene 1 Mus musculus 97-100 32299536-18 2020 PTN could reduce inflammation and remodel the impaired insulin signaling pathway, which promoted the expression of cubilin and albumin uptake. parthenolide 0-3 cubilin (intrinsic factor-cobalamin receptor) Mus musculus 115-122 32029476-5 2020 Consistent with the role of USP7 in stimulating Wnt signaling and carcinogenesis, PTL treatment inhibited the activity of Wnt signaling partly by destabilizing beta-catenin. parthenolide 82-85 catenin beta 1 Homo sapiens 160-172 31497910-11 2020 Furthermore, PN significantly suppressed the expressions of active caspase-3 and Bax in ipsilateral hemispheres of the brain at Day 3 after ICH, as well as increased the surviving neurons. parthenolide 13-15 caspase 3 Rattus norvegicus 67-76 31313842-6 2020 We also show that parthenolide, a naturally occurring small molecule, induces the expression of miR-29b-1-5p which could suppress NRF2 activation via AKT inhibition. parthenolide 18-30 microRNA 29b-1 Homo sapiens 96-105 31313842-6 2020 We also show that parthenolide, a naturally occurring small molecule, induces the expression of miR-29b-1-5p which could suppress NRF2 activation via AKT inhibition. parthenolide 18-30 NFE2 like bZIP transcription factor 2 Homo sapiens 130-134 31313842-6 2020 We also show that parthenolide, a naturally occurring small molecule, induces the expression of miR-29b-1-5p which could suppress NRF2 activation via AKT inhibition. parthenolide 18-30 AKT serine/threonine kinase 1 Homo sapiens 150-153 32029476-0 2020 Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth. parthenolide 0-12 ubiquitin specific peptidase 7 Homo sapiens 22-52 32029476-0 2020 Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth. parthenolide 0-12 ubiquitin specific peptidase 7 Homo sapiens 54-58 32029476-3 2020 Here, we report that sesquiterpene lactone parthenolide (PTL) inhibits USP7 activity, assessed with deubiquitinating enzyme activity assays, including fluorogenic Ub-AMC/Ub-Rho110, Ub-VME/PA labeling, and Di-Ub hydrolysis assays. parthenolide 57-60 ubiquitin specific peptidase 7 Homo sapiens 71-75 31977207-1 2020 Herein we detail the discovery of a series of parthenolide dimers as activators of PKM2 and evaluation of their anti-GBM activities. parthenolide 46-58 pyruvate kinase M1/2 Homo sapiens 83-87 32015157-7 2020 The anti-inflammatory natural product parthenolide was synthetically lethal to ARID1A-depleted SCC cells due to its inhibition of both HDAC1 and oncogenic signaling. parthenolide 38-50 AT-rich interaction domain 1A Homo sapiens 79-85 32015157-7 2020 The anti-inflammatory natural product parthenolide was synthetically lethal to ARID1A-depleted SCC cells due to its inhibition of both HDAC1 and oncogenic signaling. parthenolide 38-50 histone deacetylase 1 Homo sapiens 135-140 32015157-8 2020 These findings support the clinical application of parthenolide to treat patients with SCC with low ARID1A expression. parthenolide 51-63 AT-rich interaction domain 1A Homo sapiens 100-106 32015157-9 2020 SIGNIFICANCE: This study reveals novel inactivation mechanisms and tumor-suppressive roles of ARID1A in SCC and proposes parthenolide as an effective treatment for patients with SCC with low ARID1A expression. parthenolide 121-133 AT-rich interaction domain 1A Homo sapiens 94-100 32015157-9 2020 SIGNIFICANCE: This study reveals novel inactivation mechanisms and tumor-suppressive roles of ARID1A in SCC and proposes parthenolide as an effective treatment for patients with SCC with low ARID1A expression. parthenolide 121-133 AT-rich interaction domain 1A Homo sapiens 191-197 32250214-7 2020 Parthenolide, apocynin, proanthocyanidins and boswellic acid present different mechanisms of actions - among others, through NF-kappaB or NADPH oxidase inhibition, therefore showing a wide range of applications in various inflammatory diseases. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 125-134 31497910-11 2020 Furthermore, PN significantly suppressed the expressions of active caspase-3 and Bax in ipsilateral hemispheres of the brain at Day 3 after ICH, as well as increased the surviving neurons. parthenolide 13-15 BCL2 associated X, apoptosis regulator Rattus norvegicus 81-84 31497910-12 2020 Finally, the ICH-induced activation of TLR4/NF-kappaB pathway was suppressed by PN treatment. parthenolide 80-82 toll-like receptor 4 Rattus norvegicus 39-43 30929064-6 2019 Pre-exposure of osteoblasts to PTN prior to the addition of conditioned medium from Mat-Ly-Lu cells suppressed their ability to support the formation of osteoclasts by inhibition of RANKL/OPG ratio. parthenolide 31-34 TNF superfamily member 11 Rattus norvegicus 182-187 30484368-6 2019 The half-maximal inhibitory concentration (IC50) of PTL on the activity of UGT1A1 was determined to be 64.4 muM. parthenolide 52-55 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 75-81 30484368-6 2019 The half-maximal inhibitory concentration (IC50) of PTL on the activity of UGT1A1 was determined to be 64.4 muM. parthenolide 52-55 latexin Homo sapiens 108-111 30484368-7 2019 Inhibition kinetics determination showed that PTL exerted noncompetitive inhibition toward UGT1A1, and the inhibition kinetic constant (Ki) was determined to be 12.1 muM. parthenolide 46-49 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 91-97 30484368-7 2019 Inhibition kinetics determination showed that PTL exerted noncompetitive inhibition toward UGT1A1, and the inhibition kinetic constant (Ki) was determined to be 12.1 muM. parthenolide 46-49 latexin Homo sapiens 166-169 30484368-8 2019 In silico docking method has been employed to show that hydrogen bonds between PTL and the activity cavity of UGT1A1 contributed to the stronger inhibition of PTL on the activity of UGT1A1 than MCL. parthenolide 79-82 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 110-116 30484368-8 2019 In silico docking method has been employed to show that hydrogen bonds between PTL and the activity cavity of UGT1A1 contributed to the stronger inhibition of PTL on the activity of UGT1A1 than MCL. parthenolide 79-82 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 182-188 30484368-9 2019 In conclusion, PTL can more easily induce drug-drug interaction (DDI) with clinical drugs mainly undergoing UGT1A1-catalyzed glucuronidation. parthenolide 15-18 UDP glucuronosyltransferase family 1 member A1 Homo sapiens 108-114 31608008-7 2019 Similar results were observed in human tubular cells (HK-2) subjected to high-glucose (HG) conditions and treated with TAK-242 or parthenolide (inhibitor of NF-kappaB) by Western blot, Enzyme-linked immunosorbent assay (ELISA), and flow cytometry. parthenolide 130-142 nuclear factor kappa B subunit 1 Homo sapiens 157-166 31637187-7 2019 In addition, PTL induced the apoptosis of C918 cells, and decreased the expressions of Cyclin D1, B-cell lymphoma-2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-XL). parthenolide 13-16 cyclin D1 Homo sapiens 87-96 31637187-7 2019 In addition, PTL induced the apoptosis of C918 cells, and decreased the expressions of Cyclin D1, B-cell lymphoma-2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-XL). parthenolide 13-16 BCL2 apoptosis regulator Homo sapiens 98-115 31637187-7 2019 In addition, PTL induced the apoptosis of C918 cells, and decreased the expressions of Cyclin D1, B-cell lymphoma-2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-XL). parthenolide 13-16 BCL2 apoptosis regulator Homo sapiens 117-122 31637187-7 2019 In addition, PTL induced the apoptosis of C918 cells, and decreased the expressions of Cyclin D1, B-cell lymphoma-2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-XL). parthenolide 13-16 BCL2 like 1 Homo sapiens 157-163 31637187-8 2019 Also, PTL increased Cyclin inhibition protein 1 (P21), Bcl-2-associated X protein (Bax), Cysteinyl aspartate specific proteinas-3 (Caspase-3) and Caspase-9 expression. parthenolide 6-9 H3 histone pseudogene 16 Homo sapiens 49-52 31637187-8 2019 Also, PTL increased Cyclin inhibition protein 1 (P21), Bcl-2-associated X protein (Bax), Cysteinyl aspartate specific proteinas-3 (Caspase-3) and Caspase-9 expression. parthenolide 6-9 BCL2 associated X, apoptosis regulator Homo sapiens 55-81 31637187-8 2019 Also, PTL increased Cyclin inhibition protein 1 (P21), Bcl-2-associated X protein (Bax), Cysteinyl aspartate specific proteinas-3 (Caspase-3) and Caspase-9 expression. parthenolide 6-9 BCL2 associated X, apoptosis regulator Homo sapiens 83-86 31637187-8 2019 Also, PTL increased Cyclin inhibition protein 1 (P21), Bcl-2-associated X protein (Bax), Cysteinyl aspartate specific proteinas-3 (Caspase-3) and Caspase-9 expression. parthenolide 6-9 caspase 3 Homo sapiens 89-140 31637187-8 2019 Also, PTL increased Cyclin inhibition protein 1 (P21), Bcl-2-associated X protein (Bax), Cysteinyl aspartate specific proteinas-3 (Caspase-3) and Caspase-9 expression. parthenolide 6-9 caspase 9 Homo sapiens 146-155 31144365-0 2019 Parthenolide regulates oxidative stress-induced mitophagy and suppresses apoptosis through p53 signaling pathway in C2C12 myoblasts. parthenolide 0-12 transformation related protein 53, pseudogene Mus musculus 91-94 30929064-6 2019 Pre-exposure of osteoblasts to PTN prior to the addition of conditioned medium from Mat-Ly-Lu cells suppressed their ability to support the formation of osteoclasts by inhibition of RANKL/OPG ratio. parthenolide 31-34 TNF receptor superfamily member 11B Rattus norvegicus 188-191 31365959-5 2019 Results: Different concentrations of parthenolide could up-regulate the mRNA of StAR in primary endometriotic stromal cells (F=5.722, P<0.05); the mRNA of StAR in the group of 20 mumol/L was significantly higher than that of the control group [2.6+-0.3 versus 1.0, P<0.01]. parthenolide 37-49 steroidogenic acute regulatory protein Homo sapiens 80-84 31080076-3 2019 We find that parthenolide, as well as other related exocyclic methylene lactone-containing sesquiterpenes, covalently modify cysteine 427 of focal adhesion kinase 1 (FAK1), leading to impairment of FAK1-dependent signaling pathways and breast cancer cell proliferation, survival, and motility. parthenolide 13-25 protein tyrosine kinase 2 Homo sapiens 141-164 31365959-5 2019 Results: Different concentrations of parthenolide could up-regulate the mRNA of StAR in primary endometriotic stromal cells (F=5.722, P<0.05); the mRNA of StAR in the group of 20 mumol/L was significantly higher than that of the control group [2.6+-0.3 versus 1.0, P<0.01]. parthenolide 37-49 steroidogenic acute regulatory protein Homo sapiens 158-162 31365959-6 2019 Different concentrations of parthenolide could down-regulate the mRNA of ERalpha (F=6.921, P<0.01); the mRNA of ERalpha in the group of 20 mumol/L and 10 mumol/L were significantly lower than those of the control group [0.2+-0.3 versus 0.3+-0.3 versus 1.0, all P<0.05]. parthenolide 28-40 estrogen receptor 1 Homo sapiens 73-80 31365959-6 2019 Different concentrations of parthenolide could down-regulate the mRNA of ERalpha (F=6.921, P<0.01); the mRNA of ERalpha in the group of 20 mumol/L and 10 mumol/L were significantly lower than those of the control group [0.2+-0.3 versus 0.3+-0.3 versus 1.0, all P<0.05]. parthenolide 28-40 estrogen receptor 1 Homo sapiens 115-122 31365959-7 2019 Different concentrations of parthenolide could down-regulate the ratios of ERalpha/ERbeta mRNA levels (F=4.209, P<0.05). parthenolide 28-40 estrogen receptor 1 Homo sapiens 75-82 31365959-7 2019 Different concentrations of parthenolide could down-regulate the ratios of ERalpha/ERbeta mRNA levels (F=4.209, P<0.05). parthenolide 28-40 estrogen receptor 2 Homo sapiens 83-89 31365959-8 2019 Different concentrations of parthenolide could up-regulate the mRNA of VEGF and TNFR1 (F=10.964, P<0.01; F=7.286, P<0.01). parthenolide 28-40 vascular endothelial growth factor A Homo sapiens 71-75 31365959-8 2019 Different concentrations of parthenolide could up-regulate the mRNA of VEGF and TNFR1 (F=10.964, P<0.01; F=7.286, P<0.01). parthenolide 28-40 TNF receptor superfamily member 1A Homo sapiens 80-85 31080076-3 2019 We find that parthenolide, as well as other related exocyclic methylene lactone-containing sesquiterpenes, covalently modify cysteine 427 of focal adhesion kinase 1 (FAK1), leading to impairment of FAK1-dependent signaling pathways and breast cancer cell proliferation, survival, and motility. parthenolide 13-25 protein tyrosine kinase 2 Homo sapiens 166-170 31080076-3 2019 We find that parthenolide, as well as other related exocyclic methylene lactone-containing sesquiterpenes, covalently modify cysteine 427 of focal adhesion kinase 1 (FAK1), leading to impairment of FAK1-dependent signaling pathways and breast cancer cell proliferation, survival, and motility. parthenolide 13-25 protein tyrosine kinase 2 Homo sapiens 198-202 31163672-7 2019 In vitro, in leukemic cell lines Kasumi-1, KG-1a, and THP-1, proliferation was decreased by 40% (** p < 0.01) with 5 microM PLGA-antiCD44-PTL nanoparticles in comparison to the same concentration of free PTL (~10%). parthenolide 138-141 GLI family zinc finger 2 Homo sapiens 54-59 31322140-0 2019 Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells in Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway. parthenolide 0-12 mechanistic target of rapamycin kinase Homo sapiens 187-216 31322140-0 2019 Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells in Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway. parthenolide 0-12 mechanistic target of rapamycin kinase Homo sapiens 218-222 31322140-0 2019 Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells in Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway. parthenolide 0-12 AKT serine/threonine kinase 1 Homo sapiens 229-232 31235910-4 2019 Here, we report the crystal structures of human VASH1-SVBP alone, in complex with a tyrosine-derived covalent inhibitor and bound to the natural product parthenolide. parthenolide 153-165 vasohibin 1 Homo sapiens 48-53 31235910-4 2019 Here, we report the crystal structures of human VASH1-SVBP alone, in complex with a tyrosine-derived covalent inhibitor and bound to the natural product parthenolide. parthenolide 153-165 small vasohibin binding protein Homo sapiens 54-58 30739826-5 2019 Compound 7d exhibited the most potent activity against different breast cancer cells with IC50 values ranging from 0.20 muM to 0.27 muM, which demonstrated 11.6- to 18.6-fold improvement comparing to that of the parent compound parthenolide with IC50 values of 2.68-4.63 muM. parthenolide 228-240 latexin Homo sapiens 132-135 31018556-5 2019 Parthenolide, a pan-inflammation inhibitor, reversed the PAH-induced inhibition of GJIC, the decreased CX43 expression, and the induction of KC and TNF. parthenolide 0-12 gap junction protein, alpha 1 Mus musculus 103-107 31018556-5 2019 Parthenolide, a pan-inflammation inhibitor, reversed the PAH-induced inhibition of GJIC, the decreased CX43 expression, and the induction of KC and TNF. parthenolide 0-12 tumor necrosis factor Mus musculus 148-151 31164821-0 2019 Collateral Sensitivity of Parthenolide via NF-kappaB and HIF-alpha Inhibition and Epigenetic Changes in Drug-Resistant Cancer Cell Lines. parthenolide 26-38 nuclear factor kappa B subunit 1 Homo sapiens 43-52 30739826-5 2019 Compound 7d exhibited the most potent activity against different breast cancer cells with IC50 values ranging from 0.20 muM to 0.27 muM, which demonstrated 11.6- to 18.6-fold improvement comparing to that of the parent compound parthenolide with IC50 values of 2.68-4.63 muM. parthenolide 228-240 latexin Homo sapiens 132-135 30396951-0 2018 MicroRNA-107 Targets IKBKG and Sensitizes A549 Cells to Parthenolide. parthenolide 56-68 microRNA 107 Homo sapiens 0-12 30066289-7 2018 Typically, diabetic db/db mice were intraperitoneally treated with 1 mg/kg NF-kappaB inhibitor parthenolide (PTN) or saline as control every other day. parthenolide 95-107 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 75-84 30066289-7 2018 Typically, diabetic db/db mice were intraperitoneally treated with 1 mg/kg NF-kappaB inhibitor parthenolide (PTN) or saline as control every other day. parthenolide 109-112 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 75-84 30257366-0 2018 Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 - dependent apoptosis and inhibiting VEGF expression. parthenolide 0-12 tumor protein p53 Homo sapiens 85-88 30257366-0 2018 Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 - dependent apoptosis and inhibiting VEGF expression. parthenolide 0-12 vascular endothelial growth factor A Homo sapiens 126-130 30257366-9 2018 Caspase-3 activity and VEGF assays evidenced an apoptosis-inducing and VEGF- inhibiting effects of parthenolide. parthenolide 99-111 caspase 3 Homo sapiens 0-9 30257366-9 2018 Caspase-3 activity and VEGF assays evidenced an apoptosis-inducing and VEGF- inhibiting effects of parthenolide. parthenolide 99-111 vascular endothelial growth factor A Homo sapiens 23-27 30257366-9 2018 Caspase-3 activity and VEGF assays evidenced an apoptosis-inducing and VEGF- inhibiting effects of parthenolide. parthenolide 99-111 vascular endothelial growth factor A Homo sapiens 71-75 30257366-10 2018 The real time PCR assay demonstrated that parthenolide down-regulated the expression of Bcl-2 and up-regulated the expression of E2F1, P53, GADD45, BAX, BIM, and CASP 3,7,8,9, which indicates an activation of P53- dependent apoptosis pathway in response to parthenolide. parthenolide 42-54 BCL2 apoptosis regulator Homo sapiens 88-93 30257366-10 2018 The real time PCR assay demonstrated that parthenolide down-regulated the expression of Bcl-2 and up-regulated the expression of E2F1, P53, GADD45, BAX, BIM, and CASP 3,7,8,9, which indicates an activation of P53- dependent apoptosis pathway in response to parthenolide. parthenolide 42-54 E2F transcription factor 1 Homo sapiens 129-133 30257366-10 2018 The real time PCR assay demonstrated that parthenolide down-regulated the expression of Bcl-2 and up-regulated the expression of E2F1, P53, GADD45, BAX, BIM, and CASP 3,7,8,9, which indicates an activation of P53- dependent apoptosis pathway in response to parthenolide. parthenolide 42-54 tumor protein p53 Homo sapiens 135-138 30257366-10 2018 The real time PCR assay demonstrated that parthenolide down-regulated the expression of Bcl-2 and up-regulated the expression of E2F1, P53, GADD45, BAX, BIM, and CASP 3,7,8,9, which indicates an activation of P53- dependent apoptosis pathway in response to parthenolide. parthenolide 42-54 growth arrest and DNA damage inducible alpha Homo sapiens 140-146 30257366-10 2018 The real time PCR assay demonstrated that parthenolide down-regulated the expression of Bcl-2 and up-regulated the expression of E2F1, P53, GADD45, BAX, BIM, and CASP 3,7,8,9, which indicates an activation of P53- dependent apoptosis pathway in response to parthenolide. parthenolide 42-54 BCL2 associated X, apoptosis regulator Homo sapiens 148-151 30257366-10 2018 The real time PCR assay demonstrated that parthenolide down-regulated the expression of Bcl-2 and up-regulated the expression of E2F1, P53, GADD45, BAX, BIM, and CASP 3,7,8,9, which indicates an activation of P53- dependent apoptosis pathway in response to parthenolide. parthenolide 42-54 BCL2 like 11 Homo sapiens 153-156 30257366-10 2018 The real time PCR assay demonstrated that parthenolide down-regulated the expression of Bcl-2 and up-regulated the expression of E2F1, P53, GADD45, BAX, BIM, and CASP 3,7,8,9, which indicates an activation of P53- dependent apoptosis pathway in response to parthenolide. parthenolide 42-54 caspase 3 Homo sapiens 162-168 30257366-10 2018 The real time PCR assay demonstrated that parthenolide down-regulated the expression of Bcl-2 and up-regulated the expression of E2F1, P53, GADD45, BAX, BIM, and CASP 3,7,8,9, which indicates an activation of P53- dependent apoptosis pathway in response to parthenolide. parthenolide 42-54 tumor protein p53 Homo sapiens 209-212 30257366-13 2018 The anticancer effect of parthenolide is mediated by angiogenesis inhibition and activation of P53- dependent apoptosis. parthenolide 25-37 tumor protein p53 Homo sapiens 95-98 30396951-7 2018 Overexpression of miR-107 in A549 cells sensitized them to parthenolide along with a marked reduction of cyclin-dependent kinase 2. parthenolide 59-71 microRNA 107 Homo sapiens 18-25 30396951-8 2018 CONCLUSION: Our findings unveil an important biological function of miR-107 in regulating lung cancer cell proliferation and elevating an antiproliferative effect of parthenolide on lung cancer cells, suggesting that miR-107 could be beneficial benefit treatment for advanced NSCLC. parthenolide 166-178 microRNA 107 Homo sapiens 68-75 30396951-8 2018 CONCLUSION: Our findings unveil an important biological function of miR-107 in regulating lung cancer cell proliferation and elevating an antiproliferative effect of parthenolide on lung cancer cells, suggesting that miR-107 could be beneficial benefit treatment for advanced NSCLC. parthenolide 166-178 microRNA 107 Homo sapiens 217-224 29462785-0 2018 The plant sesquiterpene lactone parthenolide inhibits Wnt/beta-catenin signaling by blocking synthesis of the transcriptional regulators TCF4/LEF1. parthenolide 32-44 catenin beta 1 Homo sapiens 58-70 29936575-0 2018 Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. parthenolide 108-120 translocating chain-associating membrane protein 1 Mus musculus 71-76 29936575-2 2018 Here we examined the potential anti-cancer effect of the NF-kappaB inhibitor parthenolide (PTL) and its water soluble analogue dimethylaminoparthenolide (DMAPT) on tumour progression and metastasis in the TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model of prostate cancer. parthenolide 77-89 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 57-66 29936575-2 2018 Here we examined the potential anti-cancer effect of the NF-kappaB inhibitor parthenolide (PTL) and its water soluble analogue dimethylaminoparthenolide (DMAPT) on tumour progression and metastasis in the TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model of prostate cancer. parthenolide 91-94 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 57-66 30079458-5 2018 PTL and DMAPT caused an increase in reactive oxygen species (ROS) levels and inhibited NF-kappaB activation. parthenolide 0-3 nuclear factor kappa B subunit 1 Homo sapiens 87-96 29871641-0 2018 Parthenolide attenuated bleomycin-induced pulmonary fibrosis via the NF-kappaB/Snail signaling pathway. parthenolide 0-12 snail family zinc finger 1 Mus musculus 79-84 29871641-9 2018 We further demonstrated that PTL attenuated BLM-induced PF primarily via inhibition of the NF-kappaB/Snail signaling pathway. parthenolide 29-32 snail family zinc finger 1 Mus musculus 101-106 29871641-10 2018 CONCLUSION: These findings suggest that PTL inhibits EMT and attenuates BLM-induced PF via the NF-kappaB/Snail signaling pathway. parthenolide 40-43 snail family zinc finger 1 Mus musculus 105-110 29861832-9 2018 TAK242 and parthenolide were used as TLR4 and NF-kappaB blockers, respectively. parthenolide 11-23 toll-like receptor 4 Mus musculus 37-41 30121494-4 2018 Compound 7h was significantly more potent than parthenolide as an inhibitor of p65 phosphorylation in both hematological and solid tumor cell lines, indicating its ability to inhibit the NF-kappaB pathway. parthenolide 47-59 RELA proto-oncogene, NF-kB subunit Homo sapiens 79-82 29705182-7 2018 Genetic or pharmacological (especially parthenolide) inhibition of NF-kappaB activity down-regulated MGMT gene expression and substantially restored TMZ chemosensitivity in vitro and in vivo. parthenolide 39-51 nuclear factor kappa B subunit 1 Homo sapiens 67-76 29705182-7 2018 Genetic or pharmacological (especially parthenolide) inhibition of NF-kappaB activity down-regulated MGMT gene expression and substantially restored TMZ chemosensitivity in vitro and in vivo. parthenolide 39-51 O-6-methylguanine-DNA methyltransferase Homo sapiens 101-105 29705182-8 2018 Importantly, the TMZ sensitizing effect of siNF-kappaB(p65) or parthenolide were rescued by MGMT cDNA expression. parthenolide 63-75 O-6-methylguanine-DNA methyltransferase Homo sapiens 92-96 29705182-10 2018 A targeted combination strategy in which the response to TMZ is synergistically enhanced by the addition of parthenolide which may be useful, especially in chemoresistant gliomas with high MGMT expression. parthenolide 108-120 O-6-methylguanine-DNA methyltransferase Homo sapiens 189-193 29462785-0 2018 The plant sesquiterpene lactone parthenolide inhibits Wnt/beta-catenin signaling by blocking synthesis of the transcriptional regulators TCF4/LEF1. parthenolide 32-44 transcription factor 4 Homo sapiens 137-141 29462785-0 2018 The plant sesquiterpene lactone parthenolide inhibits Wnt/beta-catenin signaling by blocking synthesis of the transcriptional regulators TCF4/LEF1. parthenolide 32-44 lymphoid enhancer binding factor 1 Homo sapiens 142-146 29462785-4 2018 We found that PTL dose-dependently inhibits Wnt3a- and CHIR99021-induced transcriptional activity assessed with the T-cell factor (TCF)/lymphoid enhancer factor (LEF) firefly luciferase (TOPFlash) assay in HEK293 cells. parthenolide 14-17 Wnt family member 3A Homo sapiens 44-49 29462785-5 2018 Further investigations revealed that PTL decreases the levels of the transcription factors TCF4/LEF1 without affecting beta-catenin stability or subcellular distribution. parthenolide 37-40 transcription factor 4 Homo sapiens 91-95 29462785-5 2018 Further investigations revealed that PTL decreases the levels of the transcription factors TCF4/LEF1 without affecting beta-catenin stability or subcellular distribution. parthenolide 37-40 lymphoid enhancer binding factor 1 Homo sapiens 96-100 29216473-4 2018 Likewise, phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 in activated Jurkat cells was inhibited by these five compounds, with the most potent being parthenolide and estafiatin (IC50 = 13.8 and 15.4 muM, respectively). parthenolide 169-181 mitogen-activated protein kinase 3 Homo sapiens 29-76 29519321-0 2018 Parthenolide reduces metastasis by inhibition of vimentin expression and induces apoptosis by suppression elongation factor alpha - 1 expression. parthenolide 0-12 vimentin Homo sapiens 49-57 29519321-0 2018 Parthenolide reduces metastasis by inhibition of vimentin expression and induces apoptosis by suppression elongation factor alpha - 1 expression. parthenolide 0-12 adrenoceptor alpha 1D Homo sapiens 124-133 29519321-4 2018 PURPOSE: We examined the expression of vimentin and Elongation factor alpha - 1 as breast cancer biomarkers in MCF7 cells exposure to Parthenolide. parthenolide 134-146 vimentin Homo sapiens 39-47 29519321-4 2018 PURPOSE: We examined the expression of vimentin and Elongation factor alpha - 1 as breast cancer biomarkers in MCF7 cells exposure to Parthenolide. parthenolide 134-146 adrenoceptor alpha 1D Homo sapiens 70-79 29519321-6 2018 RESULT: Comparative proteome analyses are shown Elongation factor1-alpha and vimentin was suppressed in response to Parthenolide treatment. parthenolide 116-128 vimentin Homo sapiens 77-85 29467878-0 2018 Parthenolide facilitates apoptosis and reverses drug-resistance of human gastric carcinoma cells by inhibiting the STAT3 signaling pathway. parthenolide 0-12 signal transducer and activator of transcription 3 Homo sapiens 115-120 29467878-8 2018 The present study demonstrated that PN induces SGC-7901/DDP apoptosis, inhibits SGC-7901/DDP proliferation, migration and invasion, and enhances the drug sensitivity of the cells to DDP. parthenolide 36-38 translocase of inner mitochondrial membrane 8A Homo sapiens 56-59 29467878-8 2018 The present study demonstrated that PN induces SGC-7901/DDP apoptosis, inhibits SGC-7901/DDP proliferation, migration and invasion, and enhances the drug sensitivity of the cells to DDP. parthenolide 36-38 translocase of inner mitochondrial membrane 8A Homo sapiens 89-92 29467878-8 2018 The present study demonstrated that PN induces SGC-7901/DDP apoptosis, inhibits SGC-7901/DDP proliferation, migration and invasion, and enhances the drug sensitivity of the cells to DDP. parthenolide 36-38 translocase of inner mitochondrial membrane 8A Homo sapiens 89-92 29216473-0 2018 The natural sesquiterpene lactones arglabin, grosheimin, agracin, parthenolide, and estafiatin inhibit T cell receptor (TCR) activation. parthenolide 66-78 T cell receptor beta variable 20/OR9-2 (non-functional) Homo sapiens 103-118 29216473-0 2018 The natural sesquiterpene lactones arglabin, grosheimin, agracin, parthenolide, and estafiatin inhibit T cell receptor (TCR) activation. parthenolide 66-78 T cell receptor beta variable 20/OR9-2 (non-functional) Homo sapiens 120-123 29216473-4 2018 Likewise, phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 in activated Jurkat cells was inhibited by these five compounds, with the most potent being parthenolide and estafiatin (IC50 = 13.8 and 15.4 muM, respectively). parthenolide 169-181 latexin Homo sapiens 219-222 29216473-9 2018 These results suggest that arglabin, grosheimin, agracin, parthenolide, and estafiatin can selectively inhibit initial phases of TCR activation and may be natural compounds with previously undescribed immunotherapeutic properties. parthenolide 58-70 T cell receptor beta variable 20/OR9-2 (non-functional) Homo sapiens 129-132 28965856-3 2017 Here, we report that pretreatment of osteoblasts with the sesquiterpene lactone Parthenolide (PTN), a verified NFkappaB inhibitor, prior to exposure to conditioned medium from human and mouse breast cancer cell lines enhanced osteoblast differentiation and reduced osteoblast ability to stimulate osteoclastogenesis. parthenolide 80-92 nuclear factor kappa B subunit 1 Homo sapiens 111-119 29375984-8 2018 Further, Western blot assay showed that the parthenolide treatment reduced the expression of caspase-3 and caspase-9, which are considered core apoptotic proteins, and decreased the levels of phosphorylated nuclear factor-kappaB (NF-kappaB), ERK1/2 [a member of the mitogen-activated protein kinase (MAPK) family], and Akt proteins in HLE cells. parthenolide 44-56 caspase 3 Homo sapiens 93-102 29375984-8 2018 Further, Western blot assay showed that the parthenolide treatment reduced the expression of caspase-3 and caspase-9, which are considered core apoptotic proteins, and decreased the levels of phosphorylated nuclear factor-kappaB (NF-kappaB), ERK1/2 [a member of the mitogen-activated protein kinase (MAPK) family], and Akt proteins in HLE cells. parthenolide 44-56 caspase 9 Homo sapiens 107-116 29375984-8 2018 Further, Western blot assay showed that the parthenolide treatment reduced the expression of caspase-3 and caspase-9, which are considered core apoptotic proteins, and decreased the levels of phosphorylated nuclear factor-kappaB (NF-kappaB), ERK1/2 [a member of the mitogen-activated protein kinase (MAPK) family], and Akt proteins in HLE cells. parthenolide 44-56 mitogen-activated protein kinase 3 Homo sapiens 242-248 29375984-8 2018 Further, Western blot assay showed that the parthenolide treatment reduced the expression of caspase-3 and caspase-9, which are considered core apoptotic proteins, and decreased the levels of phosphorylated nuclear factor-kappaB (NF-kappaB), ERK1/2 [a member of the mitogen-activated protein kinase (MAPK) family], and Akt proteins in HLE cells. parthenolide 44-56 mitogen-activated protein kinase 3 Homo sapiens 300-304 29375984-8 2018 Further, Western blot assay showed that the parthenolide treatment reduced the expression of caspase-3 and caspase-9, which are considered core apoptotic proteins, and decreased the levels of phosphorylated nuclear factor-kappaB (NF-kappaB), ERK1/2 [a member of the mitogen-activated protein kinase (MAPK) family], and Akt proteins in HLE cells. parthenolide 44-56 AKT serine/threonine kinase 1 Homo sapiens 319-322 29375984-9 2018 CONCLUSION: Parthenolide may suppress H2O2-induced apoptosis in HLE cells by interfering with NF-kappaB, MAPKs, and Akt signaling. parthenolide 12-24 AKT serine/threonine kinase 1 Homo sapiens 116-119 30001535-7 2018 The expression of p65 protein decreased, the expression of caspases 8 and 9 increased, and the expression of c-Jun N-terminal kinase (JNK) and p38 protein was altered in infected cells after parthenolide treatment, resulting in lower cell survival. parthenolide 191-203 golgi reassembly stacking protein 1 Homo sapiens 18-21 30001535-7 2018 The expression of p65 protein decreased, the expression of caspases 8 and 9 increased, and the expression of c-Jun N-terminal kinase (JNK) and p38 protein was altered in infected cells after parthenolide treatment, resulting in lower cell survival. parthenolide 191-203 caspase 8 Homo sapiens 59-75 30001535-7 2018 The expression of p65 protein decreased, the expression of caspases 8 and 9 increased, and the expression of c-Jun N-terminal kinase (JNK) and p38 protein was altered in infected cells after parthenolide treatment, resulting in lower cell survival. parthenolide 191-203 mitogen-activated protein kinase 8 Homo sapiens 109-132 30001535-7 2018 The expression of p65 protein decreased, the expression of caspases 8 and 9 increased, and the expression of c-Jun N-terminal kinase (JNK) and p38 protein was altered in infected cells after parthenolide treatment, resulting in lower cell survival. parthenolide 191-203 mitogen-activated protein kinase 8 Homo sapiens 134-137 30001535-7 2018 The expression of p65 protein decreased, the expression of caspases 8 and 9 increased, and the expression of c-Jun N-terminal kinase (JNK) and p38 protein was altered in infected cells after parthenolide treatment, resulting in lower cell survival. parthenolide 191-203 mitogen-activated protein kinase 14 Homo sapiens 143-146 29354292-0 2017 Parthenolide prevents resistance of MDA-MB231 cells to doxorubicin and mitoxantrone: the role of Nrf2. parthenolide 0-12 NFE2 like bZIP transcription factor 2 Homo sapiens 97-101 28965856-3 2017 Here, we report that pretreatment of osteoblasts with the sesquiterpene lactone Parthenolide (PTN), a verified NFkappaB inhibitor, prior to exposure to conditioned medium from human and mouse breast cancer cell lines enhanced osteoblast differentiation and reduced osteoblast ability to stimulate osteoclastogenesis. parthenolide 94-97 nuclear factor kappa B subunit 1 Homo sapiens 111-119 28965856-6 2017 Mechanistic studies revealed that NFkappaB inhibition by PTN in osteoblasts and osteoclasts was accompanied by a significant increase in beta-catenin activation and expression. parthenolide 57-60 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 34-42 28965856-6 2017 Mechanistic studies revealed that NFkappaB inhibition by PTN in osteoblasts and osteoclasts was accompanied by a significant increase in beta-catenin activation and expression. parthenolide 57-60 catenin (cadherin associated protein), beta 1 Mus musculus 137-149 28782644-2 2017 Our lab and others have demonstrated that the natural product parthenolide can inhibit NF-kappaB activity and sensitize PC-3 prostate cancers cells to X-rays in vitro; however, parthenolide has poor bioavailability in vivo and therefore has little clinical utility in this regard. parthenolide 62-74 nuclear factor kappa B subunit 1 Homo sapiens 87-96 32454618-12 2017 Conclusion: As a result, the n-hexane extract was found more active than the positive control parthenolide in iNOS test (IC50: 0.627+-0.16 mug/mL) and cytotoxic experiments against PC3 and MPANC-96 cell lines (IC50: 2.85+-0.51 mug/mL and 5.35+-1.24 mug/mL, respectively). parthenolide 94-106 inositol-3-phosphate synthase 1 Homo sapiens 110-114 32454618-12 2017 Conclusion: As a result, the n-hexane extract was found more active than the positive control parthenolide in iNOS test (IC50: 0.627+-0.16 mug/mL) and cytotoxic experiments against PC3 and MPANC-96 cell lines (IC50: 2.85+-0.51 mug/mL and 5.35+-1.24 mug/mL, respectively). parthenolide 94-106 chromobox 8 Homo sapiens 181-184 28935249-0 2017 Osteopontin plays a unique role in resistance of CD34+/CD123+ human leukemia cell lines KG1a to parthenolide. parthenolide 96-108 secreted phosphoprotein 1 Homo sapiens 0-11 28935249-1 2017 OBJECTIVES: To determine if parthenolide (PTL) is cytotoxic for leukemia-like KG1a cells and if it involves in certain molecular-mediated resistance, especially osteopontin (OPN). parthenolide 28-40 secreted phosphoprotein 1 Homo sapiens 174-177 28935249-10 2017 The sub-population cells of CD34+ and CD123+ from KG1a cells are enriched by PTL treatment. parthenolide 77-80 CD34 molecule Homo sapiens 28-32 28935249-11 2017 CONCLUSION: Parthenolide in spite of the reduction in gene expression of AKT, mTOR or beta-catenin, stimulates the OPN expression in KG1a cells. parthenolide 12-24 AKT serine/threonine kinase 1 Homo sapiens 73-76 28935249-11 2017 CONCLUSION: Parthenolide in spite of the reduction in gene expression of AKT, mTOR or beta-catenin, stimulates the OPN expression in KG1a cells. parthenolide 12-24 mechanistic target of rapamycin kinase Homo sapiens 78-82 28935249-11 2017 CONCLUSION: Parthenolide in spite of the reduction in gene expression of AKT, mTOR or beta-catenin, stimulates the OPN expression in KG1a cells. parthenolide 12-24 catenin beta 1 Homo sapiens 86-98 28935249-11 2017 CONCLUSION: Parthenolide in spite of the reduction in gene expression of AKT, mTOR or beta-catenin, stimulates the OPN expression in KG1a cells. parthenolide 12-24 secreted phosphoprotein 1 Homo sapiens 115-118 28782644-3 2017 We show here that treatment of PC-3 and DU145 human prostate cancer cells with dimethylaminoparthenolide (DMAPT), a parthenolide derivative with increased bioavailability, inhibits constitutive and radiation-induced NF-kappaB binding activity and slows prostate cancer cell growth. parthenolide 92-104 nuclear factor kappa B subunit 1 Homo sapiens 216-225 30023543-4 2017 To identify sites of modification of Hsp72 by parthenolide, we used high-resolution tandem mass spectrometry to detect 10 lysine, histidine, and cysteine residues of recombinant Hsp72 as modified in vitro by 10 and 100 muM parthenolide. parthenolide 223-235 heat shock protein family A (Hsp70) member 1A Homo sapiens 178-183 30023543-0 2017 Hsp72 Is an Intracellular Target of the alpha,beta-Unsaturated Sesquiterpene Lactone, Parthenolide. parthenolide 86-98 heat shock protein family A (Hsp70) member 1A Homo sapiens 0-5 28902368-0 2017 Smad4 re-expression increases the sensitivity to parthenolide in colorectal cancer. parthenolide 49-61 SMAD family member 4 Mus musculus 0-5 30023543-5 2017 To further ascertain that modification of Hsp72 by parthenolide occurs inside cells and not simply as an in vitro artifact, an alkyne-labeled derivative of parthenolide was synthesized to enable enrichment and detection of protein targets of parthenolide using copper-catalyzed [3 + 2] azide-alkyne cycloaddition. parthenolide 51-63 heat shock protein family A (Hsp70) member 1A Homo sapiens 42-47 30023543-4 2017 To identify sites of modification of Hsp72 by parthenolide, we used high-resolution tandem mass spectrometry to detect 10 lysine, histidine, and cysteine residues of recombinant Hsp72 as modified in vitro by 10 and 100 muM parthenolide. parthenolide 46-58 heat shock protein family A (Hsp70) member 1A Homo sapiens 37-42 30023543-4 2017 To identify sites of modification of Hsp72 by parthenolide, we used high-resolution tandem mass spectrometry to detect 10 lysine, histidine, and cysteine residues of recombinant Hsp72 as modified in vitro by 10 and 100 muM parthenolide. parthenolide 46-58 heat shock protein family A (Hsp70) member 1A Homo sapiens 178-183 30023543-5 2017 To further ascertain that modification of Hsp72 by parthenolide occurs inside cells and not simply as an in vitro artifact, an alkyne-labeled derivative of parthenolide was synthesized to enable enrichment and detection of protein targets of parthenolide using copper-catalyzed [3 + 2] azide-alkyne cycloaddition. parthenolide 156-168 heat shock protein family A (Hsp70) member 1A Homo sapiens 42-47 30023543-5 2017 To further ascertain that modification of Hsp72 by parthenolide occurs inside cells and not simply as an in vitro artifact, an alkyne-labeled derivative of parthenolide was synthesized to enable enrichment and detection of protein targets of parthenolide using copper-catalyzed [3 + 2] azide-alkyne cycloaddition. parthenolide 156-168 heat shock protein family A (Hsp70) member 1A Homo sapiens 42-47 30023543-6 2017 The alkyne-labeled parthenolide derivative displays an half maximal inhibitory concentration (IC50) in undifferentiated acute monocytic leukemia cells (THP-1) of 13.1 +- 1.1 muM, whereas parthenolide has an IC50 of 4.7 +- 1.1 muM. parthenolide 19-31 GLI family zinc finger 2 Homo sapiens 152-177 28314243-0 2017 Parthenolide attenuates cerebral ischemia/reperfusion injury via Akt/GSK-3beta pathway in PC12 cells. parthenolide 0-12 AKT serine/threonine kinase 1 Rattus norvegicus 65-68 28829282-0 2017 Parthenolide Promotes Differentiation of Osteoblasts Through the Wnt/beta-Catenin Signaling Pathway in Inflammatory Environments. parthenolide 0-12 catenin beta 1 Homo sapiens 69-81 28829282-4 2017 We have previously shown the anti-inflammatory and antiosteoclastogenic activities of parthenolide (PTL) in human periodontal ligament-derived cells by inhibiting nuclear factor kappa B (NF-kappaB) signaling, indicating its potential for periodontitis treatment. parthenolide 86-98 nuclear factor kappa B subunit 1 Homo sapiens 163-185 28829282-4 2017 We have previously shown the anti-inflammatory and antiosteoclastogenic activities of parthenolide (PTL) in human periodontal ligament-derived cells by inhibiting nuclear factor kappa B (NF-kappaB) signaling, indicating its potential for periodontitis treatment. parthenolide 86-98 nuclear factor kappa B subunit 1 Homo sapiens 187-196 28829282-4 2017 We have previously shown the anti-inflammatory and antiosteoclastogenic activities of parthenolide (PTL) in human periodontal ligament-derived cells by inhibiting nuclear factor kappa B (NF-kappaB) signaling, indicating its potential for periodontitis treatment. parthenolide 100-103 nuclear factor kappa B subunit 1 Homo sapiens 163-185 28829282-4 2017 We have previously shown the anti-inflammatory and antiosteoclastogenic activities of parthenolide (PTL) in human periodontal ligament-derived cells by inhibiting nuclear factor kappa B (NF-kappaB) signaling, indicating its potential for periodontitis treatment. parthenolide 100-103 nuclear factor kappa B subunit 1 Homo sapiens 187-196 28829282-6 2017 The results showed that PTL significantly stimulated alkaline phosphatase activity, mineralization nodule formation, and osteogenesis-related gene/protein expression of osteoblasts under the stimulation of tumor necrosis factor-alpha (TNF-alpha). parthenolide 24-27 tumor necrosis factor Homo sapiens 206-233 28829282-6 2017 The results showed that PTL significantly stimulated alkaline phosphatase activity, mineralization nodule formation, and osteogenesis-related gene/protein expression of osteoblasts under the stimulation of tumor necrosis factor-alpha (TNF-alpha). parthenolide 24-27 tumor necrosis factor Homo sapiens 235-244 28829282-7 2017 In addition, PTL inhibited the NF-kappaB/p50 pathway and resisted the inhibition of Wnt/beta-catenin signaling induced by TNF-alpha. parthenolide 13-16 nuclear factor kappa B subunit 1 Homo sapiens 31-40 28829282-7 2017 In addition, PTL inhibited the NF-kappaB/p50 pathway and resisted the inhibition of Wnt/beta-catenin signaling induced by TNF-alpha. parthenolide 13-16 nuclear factor kappa B subunit 1 Homo sapiens 41-44 28829282-7 2017 In addition, PTL inhibited the NF-kappaB/p50 pathway and resisted the inhibition of Wnt/beta-catenin signaling induced by TNF-alpha. parthenolide 13-16 catenin beta 1 Homo sapiens 88-100 28829282-7 2017 In addition, PTL inhibited the NF-kappaB/p50 pathway and resisted the inhibition of Wnt/beta-catenin signaling induced by TNF-alpha. parthenolide 13-16 tumor necrosis factor Homo sapiens 122-131 28555525-8 2017 Increased hepatic TNF-alpha, NF-kappaB and CYP2E1 at the both gene expression and protein levels were found associated with necroinflammatory changes in histopathological observations and were abrogated almost completely after parthenolide treatment. parthenolide 227-239 tumor necrosis factor Rattus norvegicus 18-27 28555525-8 2017 Increased hepatic TNF-alpha, NF-kappaB and CYP2E1 at the both gene expression and protein levels were found associated with necroinflammatory changes in histopathological observations and were abrogated almost completely after parthenolide treatment. parthenolide 227-239 cytochrome P450, family 2, subfamily e, polypeptide 1 Rattus norvegicus 43-49 29050271-4 2017 We showed that PTL inhibited the proliferation and migration by reverse EMT via the ERK2/NF-kappaB/Snail pathway in vivo and in vitro. parthenolide 15-18 mitogen-activated protein kinase 1 Homo sapiens 84-88 29050271-4 2017 We showed that PTL inhibited the proliferation and migration by reverse EMT via the ERK2/NF-kappaB/Snail pathway in vivo and in vitro. parthenolide 15-18 nuclear factor kappa B subunit 1 Homo sapiens 89-98 29050271-4 2017 We showed that PTL inhibited the proliferation and migration by reverse EMT via the ERK2/NF-kappaB/Snail pathway in vivo and in vitro. parthenolide 15-18 snail family transcriptional repressor 1 Homo sapiens 99-104 28314243-0 2017 Parthenolide attenuates cerebral ischemia/reperfusion injury via Akt/GSK-3beta pathway in PC12 cells. parthenolide 0-12 glycogen synthase kinase 3 beta Rattus norvegicus 69-78 28423582-0 2017 Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway. parthenolide 0-12 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 75-80 27997959-8 2017 The results suggested that parthenolide may regulate the activity of Th17 and Th1 cells, mainly by decreasing IL-17, TNF-alpha, and interferon gamma production. parthenolide 27-39 interleukin 17A Mus musculus 110-115 27997959-8 2017 The results suggested that parthenolide may regulate the activity of Th17 and Th1 cells, mainly by decreasing IL-17, TNF-alpha, and interferon gamma production. parthenolide 27-39 tumor necrosis factor Mus musculus 117-126 27997959-9 2017 This modulation may be related to the lower levels of IL-12p40 and IL-6 after treatment with parthenolide. parthenolide 93-105 interleukin 12b Mus musculus 54-62 27997959-9 2017 This modulation may be related to the lower levels of IL-12p40 and IL-6 after treatment with parthenolide. parthenolide 93-105 interleukin 6 Mus musculus 67-71 28284336-2 2017 Here we show that PAR treatment inhibits the initiation of experimental autoimmune neuritis (EAN), suppresses the production of TNF-alpha, IFN-gamma, IL-1beta and IL-17, and decreases Th1 and Th17 cells at early time point. parthenolide 18-21 tumor necrosis factor Homo sapiens 128-137 28284336-2 2017 Here we show that PAR treatment inhibits the initiation of experimental autoimmune neuritis (EAN), suppresses the production of TNF-alpha, IFN-gamma, IL-1beta and IL-17, and decreases Th1 and Th17 cells at early time point. parthenolide 18-21 interferon gamma Homo sapiens 139-148 28284336-2 2017 Here we show that PAR treatment inhibits the initiation of experimental autoimmune neuritis (EAN), suppresses the production of TNF-alpha, IFN-gamma, IL-1beta and IL-17, and decreases Th1 and Th17 cells at early time point. parthenolide 18-21 interleukin 1 beta Homo sapiens 150-158 28284336-2 2017 Here we show that PAR treatment inhibits the initiation of experimental autoimmune neuritis (EAN), suppresses the production of TNF-alpha, IFN-gamma, IL-1beta and IL-17, and decreases Th1 and Th17 cells at early time point. parthenolide 18-21 interleukin 17A Homo sapiens 163-168 28284336-2 2017 Here we show that PAR treatment inhibits the initiation of experimental autoimmune neuritis (EAN), suppresses the production of TNF-alpha, IFN-gamma, IL-1beta and IL-17, and decreases Th1 and Th17 cells at early time point. parthenolide 18-21 negative elongation factor complex member C/D Homo sapiens 184-187 28423582-0 2017 Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway. parthenolide 0-12 mitogen-activated protein kinase 1 Homo sapiens 86-89 28423582-4 2017 The effect of parthenolide on NSCLC cells and its potential as B-Raf inhibitor were studied in this study. parthenolide 14-26 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 63-68 28423582-7 2017 In terms of the involved mechanism, parthenolide suppressed GLC-82 cell response via targeting on B-Raf and inhibiting MAPK/Erk pathway signaling. parthenolide 36-48 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 98-103 28423582-7 2017 In terms of the involved mechanism, parthenolide suppressed GLC-82 cell response via targeting on B-Raf and inhibiting MAPK/Erk pathway signaling. parthenolide 36-48 mitogen-activated protein kinase 1 Homo sapiens 124-127 28423582-8 2017 The effect of parthenolide on B-Raf and MAPK/Erk pathway was further confirmed by RNA interference of B-Raf. parthenolide 14-26 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 30-35 28423582-8 2017 The effect of parthenolide on B-Raf and MAPK/Erk pathway was further confirmed by RNA interference of B-Raf. parthenolide 14-26 mitogen-activated protein kinase 1 Homo sapiens 45-48 28423582-8 2017 The effect of parthenolide on B-Raf and MAPK/Erk pathway was further confirmed by RNA interference of B-Raf. parthenolide 14-26 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 102-107 28423582-10 2017 In addition, STAT3 activity inhibition by parthenolide contributed to its effect on GLC-82 cells, which is independent of PI3K pathway signaling and GSK3. parthenolide 42-54 signal transducer and activator of transcription 3 Homo sapiens 13-18 28423582-11 2017 All above provide an insight to understand the action of parthenolide as a potential B-Raf inhibitor in treatment of NSCLC. parthenolide 57-69 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 85-90 28522946-10 2017 PT also inhibited the expression of antiapoptotic proteins (Bcl-2 and Bcl-xL) and activated apoptosis terminal factor (caspase-3) in a dose-dependent manner. parthenolide 0-2 BCL2 apoptosis regulator Homo sapiens 60-65 28522946-10 2017 PT also inhibited the expression of antiapoptotic proteins (Bcl-2 and Bcl-xL) and activated apoptosis terminal factor (caspase-3) in a dose-dependent manner. parthenolide 0-2 BCL2 like 1 Homo sapiens 70-76 28522946-10 2017 PT also inhibited the expression of antiapoptotic proteins (Bcl-2 and Bcl-xL) and activated apoptosis terminal factor (caspase-3) in a dose-dependent manner. parthenolide 0-2 caspase 3 Homo sapiens 119-128 28361855-2 2017 AIM: To analyze the response of U937 cells to parthenolide (PTL) through the involvement of expression of OPN protein, RelB, AKT1, mTOR, PTEN and beta-catenin genes. parthenolide 46-58 secreted phosphoprotein 1 Homo sapiens 106-109 28108625-0 2017 Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-kappaB Activation. parthenolide 9-21 nuclear factor kappa B subunit 1 Homo sapiens 91-100 28108625-2 2017 Parthenolide, a strong NF-kappaB inhibitor, has recently been demonstrated to be a promising therapeutic agent, promoting apoptosis of cancer cells. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 23-32 28108625-4 2017 The results demonstrate that the combination of balsalazide and parthenolide markedly suppress proliferation, nuclear translocation of NF-kappaB, IkappaB-alpha phosphorylation, NF-kappaB DNA binding, and expression of NF-kappaB targets. parthenolide 64-76 nuclear factor kappa B subunit 1 Homo sapiens 135-144 28108625-4 2017 The results demonstrate that the combination of balsalazide and parthenolide markedly suppress proliferation, nuclear translocation of NF-kappaB, IkappaB-alpha phosphorylation, NF-kappaB DNA binding, and expression of NF-kappaB targets. parthenolide 64-76 NFKB inhibitor alpha Homo sapiens 146-159 28108625-4 2017 The results demonstrate that the combination of balsalazide and parthenolide markedly suppress proliferation, nuclear translocation of NF-kappaB, IkappaB-alpha phosphorylation, NF-kappaB DNA binding, and expression of NF-kappaB targets. parthenolide 64-76 nuclear factor kappa B subunit 1 Homo sapiens 177-186 28108625-4 2017 The results demonstrate that the combination of balsalazide and parthenolide markedly suppress proliferation, nuclear translocation of NF-kappaB, IkappaB-alpha phosphorylation, NF-kappaB DNA binding, and expression of NF-kappaB targets. parthenolide 64-76 nuclear factor kappa B subunit 1 Homo sapiens 177-186 28108625-8 2017 These results demonstrate that parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-kappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation. parthenolide 31-43 nuclear factor kappa B subunit 1 Homo sapiens 118-127 27553015-8 2017 Moreover, TNF-alpha and IL-6 levels were significantly decreased in cortex and hippocampus of parthenolide-treated rats. parthenolide 94-106 tumor necrosis factor Rattus norvegicus 10-19 27553015-8 2017 Moreover, TNF-alpha and IL-6 levels were significantly decreased in cortex and hippocampus of parthenolide-treated rats. parthenolide 94-106 interleukin 6 Rattus norvegicus 24-28 28176967-6 2017 Parthenolide treatment concentration-dependently increased the percentage of autophagic cells and significantly increased the expression levels of p62/SQSTM1, Beclin 1, and LC3II in Panc-1 cells. parthenolide 0-12 sequestosome 1 Homo sapiens 147-150 28176967-6 2017 Parthenolide treatment concentration-dependently increased the percentage of autophagic cells and significantly increased the expression levels of p62/SQSTM1, Beclin 1, and LC3II in Panc-1 cells. parthenolide 0-12 sequestosome 1 Homo sapiens 151-157 28176967-6 2017 Parthenolide treatment concentration-dependently increased the percentage of autophagic cells and significantly increased the expression levels of p62/SQSTM1, Beclin 1, and LC3II in Panc-1 cells. parthenolide 0-12 beclin 1 Homo sapiens 159-167 28361855-2 2017 AIM: To analyze the response of U937 cells to parthenolide (PTL) through the involvement of expression of OPN protein, RelB, AKT1, mTOR, PTEN and beta-catenin genes. parthenolide 46-58 mechanistic target of rapamycin kinase Homo sapiens 131-135 28361855-2 2017 AIM: To analyze the response of U937 cells to parthenolide (PTL) through the involvement of expression of OPN protein, RelB, AKT1, mTOR, PTEN and beta-catenin genes. parthenolide 46-58 phosphatase and tensin homolog Homo sapiens 137-141 28361855-2 2017 AIM: To analyze the response of U937 cells to parthenolide (PTL) through the involvement of expression of OPN protein, RelB, AKT1, mTOR, PTEN and beta-catenin genes. parthenolide 46-58 catenin beta 1 Homo sapiens 146-158 28361855-2 2017 AIM: To analyze the response of U937 cells to parthenolide (PTL) through the involvement of expression of OPN protein, RelB, AKT1, mTOR, PTEN and beta-catenin genes. parthenolide 60-63 secreted phosphoprotein 1 Homo sapiens 106-109 28361855-2 2017 AIM: To analyze the response of U937 cells to parthenolide (PTL) through the involvement of expression of OPN protein, RelB, AKT1, mTOR, PTEN and beta-catenin genes. parthenolide 60-63 mechanistic target of rapamycin kinase Homo sapiens 131-135 28361855-2 2017 AIM: To analyze the response of U937 cells to parthenolide (PTL) through the involvement of expression of OPN protein, RelB, AKT1, mTOR, PTEN and beta-catenin genes. parthenolide 60-63 phosphatase and tensin homolog Homo sapiens 137-141 27717727-8 2017 Improvement of most of the histologic parameters was similar in Groups III and V. Interleukin-4 levels were significantly reduced in the parthenolide group when compared to the placebo group. parthenolide 137-149 interleukin 4 Mus musculus 82-95 28361855-2 2017 AIM: To analyze the response of U937 cells to parthenolide (PTL) through the involvement of expression of OPN protein, RelB, AKT1, mTOR, PTEN and beta-catenin genes. parthenolide 60-63 catenin beta 1 Homo sapiens 146-158 28361855-4 2017 Western blot analysis using antibodies against OPN was performed with lysates of PTL-treated cells. parthenolide 81-84 secreted phosphoprotein 1 Homo sapiens 47-50 27536701-0 2016 Parthenolide Induces Apoptosis in Committed Progenitor AML Cell line U937 via Reduction in Osteopontin. parthenolide 0-12 secreted phosphoprotein 1 Homo sapiens 91-102 27757770-6 2016 Further, LPS-stimulated phosphorylation of NF-kappaB, the key regulatory transcription factor in ALI, was inhibited by parthenolide treatment in lung epithelial BEAS-2B cells and alveolar macrophage MH-S cells. parthenolide 119-131 nuclear factor kappa B subunit 1 Homo sapiens 43-52 27573247-5 2016 Next, using proteomic, genomic, and metabolomic methods, we determined that treatment with parthenolide leads to induction of compensatory mechanisms that include up-regulated NADPH production via the pentose phosphate pathway as well as activation of the Nrf2-mediated oxidative stress response pathway. parthenolide 91-103 NFE2 like bZIP transcription factor 2 Homo sapiens 256-260 27270078-5 2016 Meanwhile, parthenolide treatment recover the liver function which indicated by decreased the serum alanine transaminase and alkaline phosphatase activities and promoted the expression of Ki67 in the livers of these mice. parthenolide 11-23 antigen identified by monoclonal antibody Ki 67 Mus musculus 188-192 27270078-6 2016 In addition, parthenolide administration suppressed the Concanavalin A-induced immune reaction, as indicated by the number of F4/80, CD49b and CD4 cells present in the liver. parthenolide 13-25 adhesion G protein-coupled receptor E1 Mus musculus 126-131 27270078-6 2016 In addition, parthenolide administration suppressed the Concanavalin A-induced immune reaction, as indicated by the number of F4/80, CD49b and CD4 cells present in the liver. parthenolide 13-25 integrin alpha 2 Mus musculus 133-138 27270078-7 2016 Furthermore, parthenolide also significantly reduced the expression of pro-inflammatory cytokines such as IFN-gamma, TNF-alpha, IL-17A, IL-1beta and IL-6 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells in vitro. parthenolide 13-25 interferon gamma Mus musculus 106-115 27270078-7 2016 Furthermore, parthenolide also significantly reduced the expression of pro-inflammatory cytokines such as IFN-gamma, TNF-alpha, IL-17A, IL-1beta and IL-6 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells in vitro. parthenolide 13-25 tumor necrosis factor Mus musculus 117-126 27270078-7 2016 Furthermore, parthenolide also significantly reduced the expression of pro-inflammatory cytokines such as IFN-gamma, TNF-alpha, IL-17A, IL-1beta and IL-6 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells in vitro. parthenolide 13-25 interleukin 1 beta Mus musculus 136-144 27270078-7 2016 Furthermore, parthenolide also significantly reduced the expression of pro-inflammatory cytokines such as IFN-gamma, TNF-alpha, IL-17A, IL-1beta and IL-6 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells in vitro. parthenolide 13-25 interleukin 6 Mus musculus 149-153 27270078-8 2016 Moreover, parthenolide exposure decreased the phosphorylation of STAT3 and p38, and promoted the phosphorylation of p53 in RAW264.7 cells in vitro. parthenolide 10-22 signal transducer and activator of transcription 3 Mus musculus 65-70 27270078-8 2016 Moreover, parthenolide exposure decreased the phosphorylation of STAT3 and p38, and promoted the phosphorylation of p53 in RAW264.7 cells in vitro. parthenolide 10-22 mitogen-activated protein kinase 14 Mus musculus 75-78 27270078-8 2016 Moreover, parthenolide exposure decreased the phosphorylation of STAT3 and p38, and promoted the phosphorylation of p53 in RAW264.7 cells in vitro. parthenolide 10-22 transformation related protein 53, pseudogene Mus musculus 116-119 27270078-10 2016 The possible molecular mechanism involves the anti-inflammatory effects of parthenolide may by suppressing the STAT3/p38 signals and enhanced the p53 signals. parthenolide 75-87 signal transducer and activator of transcription 3 Mus musculus 111-116 27270078-10 2016 The possible molecular mechanism involves the anti-inflammatory effects of parthenolide may by suppressing the STAT3/p38 signals and enhanced the p53 signals. parthenolide 75-87 mitogen-activated protein kinase 14 Mus musculus 117-120 27270078-10 2016 The possible molecular mechanism involves the anti-inflammatory effects of parthenolide may by suppressing the STAT3/p38 signals and enhanced the p53 signals. parthenolide 75-87 transformation related protein 53, pseudogene Mus musculus 146-149 27353740-0 2016 Pharmacological targeting of glucose-6-phosphate dehydrogenase in human erythrocytes by Bay 11-7082, parthenolide and dimethyl fumarate. parthenolide 101-113 glucose-6-phosphate dehydrogenase Homo sapiens 29-62 27002142-0 2016 Targeting Thioredoxin Reductase by Parthenolide Contributes to Inducing Apoptosis of HeLa Cells. parthenolide 35-47 peroxiredoxin 5 Homo sapiens 10-31 27002142-3 2016 We reported here that PTL interacts with both cytosolic thioredoxin reductase (TrxR1) and mitochondrial thioredoxin reductase (TrxR2), two ubiquitous selenocysteine-containing antioxidant enzymes, to elicit reactive oxygen species-mediated apoptosis in HeLa cells. parthenolide 22-25 thioredoxin Homo sapiens 56-67 27002142-3 2016 We reported here that PTL interacts with both cytosolic thioredoxin reductase (TrxR1) and mitochondrial thioredoxin reductase (TrxR2), two ubiquitous selenocysteine-containing antioxidant enzymes, to elicit reactive oxygen species-mediated apoptosis in HeLa cells. parthenolide 22-25 thioredoxin reductase 1 Homo sapiens 79-84 27002142-3 2016 We reported here that PTL interacts with both cytosolic thioredoxin reductase (TrxR1) and mitochondrial thioredoxin reductase (TrxR2), two ubiquitous selenocysteine-containing antioxidant enzymes, to elicit reactive oxygen species-mediated apoptosis in HeLa cells. parthenolide 22-25 thioredoxin Homo sapiens 104-115 27002142-3 2016 We reported here that PTL interacts with both cytosolic thioredoxin reductase (TrxR1) and mitochondrial thioredoxin reductase (TrxR2), two ubiquitous selenocysteine-containing antioxidant enzymes, to elicit reactive oxygen species-mediated apoptosis in HeLa cells. parthenolide 22-25 thioredoxin reductase 2 Homo sapiens 127-132 27099069-0 2016 Parthenolide induces apoptosis and autophagy through the suppression of PI3K/Akt signaling pathway in cervical cancer. parthenolide 0-12 AKT serine/threonine kinase 1 Homo sapiens 77-80 27099069-3 2016 Parthenolide (6 microM) induces mitochondrial-mediated apoptosis and autophagy by activation of caspase-3, upregulation of Bax, Beclin-1, ATG5, ATG3 and down-regulation of Bcl-2 and mTOR. parthenolide 0-12 caspase 3 Homo sapiens 96-105 27099069-3 2016 Parthenolide (6 microM) induces mitochondrial-mediated apoptosis and autophagy by activation of caspase-3, upregulation of Bax, Beclin-1, ATG5, ATG3 and down-regulation of Bcl-2 and mTOR. parthenolide 0-12 BCL2 associated X, apoptosis regulator Homo sapiens 123-126 27099069-3 2016 Parthenolide (6 microM) induces mitochondrial-mediated apoptosis and autophagy by activation of caspase-3, upregulation of Bax, Beclin-1, ATG5, ATG3 and down-regulation of Bcl-2 and mTOR. parthenolide 0-12 beclin 1 Homo sapiens 128-136 27099069-3 2016 Parthenolide (6 microM) induces mitochondrial-mediated apoptosis and autophagy by activation of caspase-3, upregulation of Bax, Beclin-1, ATG5, ATG3 and down-regulation of Bcl-2 and mTOR. parthenolide 0-12 autophagy related 5 Homo sapiens 138-142 27099069-3 2016 Parthenolide (6 microM) induces mitochondrial-mediated apoptosis and autophagy by activation of caspase-3, upregulation of Bax, Beclin-1, ATG5, ATG3 and down-regulation of Bcl-2 and mTOR. parthenolide 0-12 autophagy related 3 Homo sapiens 144-148 27099069-3 2016 Parthenolide (6 microM) induces mitochondrial-mediated apoptosis and autophagy by activation of caspase-3, upregulation of Bax, Beclin-1, ATG5, ATG3 and down-regulation of Bcl-2 and mTOR. parthenolide 0-12 BCL2 apoptosis regulator Homo sapiens 172-177 27099069-3 2016 Parthenolide (6 microM) induces mitochondrial-mediated apoptosis and autophagy by activation of caspase-3, upregulation of Bax, Beclin-1, ATG5, ATG3 and down-regulation of Bcl-2 and mTOR. parthenolide 0-12 mechanistic target of rapamycin kinase Homo sapiens 182-186 27099069-4 2016 Parthenolide also inhibits PI3K and Akt expression through activation of PTEN expression. parthenolide 0-12 AKT serine/threonine kinase 1 Homo sapiens 36-39 27099069-4 2016 Parthenolide also inhibits PI3K and Akt expression through activation of PTEN expression. parthenolide 0-12 phosphatase and tensin homolog Homo sapiens 73-77 27099069-6 2016 CONCLUSION: Parthenolide induces apoptosis and autophagy-mediated growth inhibition in HeLa cells by suppressing the PI3K/Akt signaling pathway and mitochondrial membrane depolarization and ROS generation. parthenolide 12-24 AKT serine/threonine kinase 1 Homo sapiens 122-125 27353019-5 2016 The inhibitor of canonical NFkappaB activation parthenolide inhibited the CCL19 and the early RANTES responses, but not the CCL21 or late RANTES responses. parthenolide 47-59 C-C motif chemokine ligand 19 Rattus norvegicus 74-79 27353019-5 2016 The inhibitor of canonical NFkappaB activation parthenolide inhibited the CCL19 and the early RANTES responses, but not the CCL21 or late RANTES responses. parthenolide 47-59 C-C motif chemokine ligand 5 Rattus norvegicus 94-100 27077810-9 2016 Prolonging the treatment with PN or DMAPT we observed between 12 and 24 h that the levels of both superoxide anion and hROS increased in concomitance with the downregulation of manganese superoxide dismutase and catalase. parthenolide 30-32 catalase Homo sapiens 212-220 26521947-11 2015 The presence of HDAC1 inhibitor, butyrate or parthenolide, significantly enforced irradiation-induced glioma cell apoptosis. parthenolide 45-57 histone deacetylase 1 Homo sapiens 16-21 26824319-0 2016 Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations. parthenolide 0-12 melanocyte inducing transcription factor Homo sapiens 21-25 26824319-0 2016 Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations. parthenolide 0-12 melanocyte inducing transcription factor Homo sapiens 77-81 26824319-4 2016 Our results obtained in patient-derived melanoma cell populations indicate that parthenolide efficiently decreases the MITF-M level. parthenolide 80-92 melanocyte inducing transcription factor Homo sapiens 119-123 26824319-5 2016 This is neither dependent on p65/NF-kappaB signaling nor RAF/MEK/ERK pathway activity as inhibition of MEK by GSK1120212 (trametinib) and induction of ERK1/2 activity by parthenolide itself do not interfere with parthenolide-triggered depletion of MITF-M in both wild-type BRAF and BRAF(V600E) melanoma populations. parthenolide 170-182 mitogen-activated protein kinase 3 Homo sapiens 151-157 26824319-7 2016 As parthenolide reduces MITF-M transcript level and HDAC1 protein level, parthenolide-activated depletion of MITF-M protein may be considered as a result of transcriptional regulation, however, the influence of parthenolide on other elements of a dynamic control over MITF-M cannot be ruled out. parthenolide 3-15 melanocyte inducing transcription factor Homo sapiens 24-28 26824319-7 2016 As parthenolide reduces MITF-M transcript level and HDAC1 protein level, parthenolide-activated depletion of MITF-M protein may be considered as a result of transcriptional regulation, however, the influence of parthenolide on other elements of a dynamic control over MITF-M cannot be ruled out. parthenolide 73-85 melanocyte inducing transcription factor Homo sapiens 24-28 26824319-7 2016 As parthenolide reduces MITF-M transcript level and HDAC1 protein level, parthenolide-activated depletion of MITF-M protein may be considered as a result of transcriptional regulation, however, the influence of parthenolide on other elements of a dynamic control over MITF-M cannot be ruled out. parthenolide 73-85 melanocyte inducing transcription factor Homo sapiens 109-113 26824319-7 2016 As parthenolide reduces MITF-M transcript level and HDAC1 protein level, parthenolide-activated depletion of MITF-M protein may be considered as a result of transcriptional regulation, however, the influence of parthenolide on other elements of a dynamic control over MITF-M cannot be ruled out. parthenolide 73-85 melanocyte inducing transcription factor Homo sapiens 109-113 26824319-7 2016 As parthenolide reduces MITF-M transcript level and HDAC1 protein level, parthenolide-activated depletion of MITF-M protein may be considered as a result of transcriptional regulation, however, the influence of parthenolide on other elements of a dynamic control over MITF-M cannot be ruled out. parthenolide 73-85 melanocyte inducing transcription factor Homo sapiens 24-28 26824319-7 2016 As parthenolide reduces MITF-M transcript level and HDAC1 protein level, parthenolide-activated depletion of MITF-M protein may be considered as a result of transcriptional regulation, however, the influence of parthenolide on other elements of a dynamic control over MITF-M cannot be ruled out. parthenolide 73-85 melanocyte inducing transcription factor Homo sapiens 109-113 26824319-7 2016 As parthenolide reduces MITF-M transcript level and HDAC1 protein level, parthenolide-activated depletion of MITF-M protein may be considered as a result of transcriptional regulation, however, the influence of parthenolide on other elements of a dynamic control over MITF-M cannot be ruled out. parthenolide 73-85 melanocyte inducing transcription factor Homo sapiens 109-113 26824319-9 2016 The mode of the response to parthenolide is bound to the molecular characteristics of melanoma cells, particularly to the basal MITF-M expression level but other cell-autonomous differences such as NF-kappaB activity and MCL-1 level might also contribute. parthenolide 28-40 melanocyte inducing transcription factor Homo sapiens 128-132 26824319-9 2016 The mode of the response to parthenolide is bound to the molecular characteristics of melanoma cells, particularly to the basal MITF-M expression level but other cell-autonomous differences such as NF-kappaB activity and MCL-1 level might also contribute. parthenolide 28-40 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 221-226 26824319-10 2016 Our data suggest that parthenolide can be developed as a drug used in combination therapy against melanoma when simultaneous inhibition of MITF-M, NF-kappaB and HDAC1 is needed. parthenolide 22-34 melanocyte inducing transcription factor Homo sapiens 139-143 26824319-10 2016 Our data suggest that parthenolide can be developed as a drug used in combination therapy against melanoma when simultaneous inhibition of MITF-M, NF-kappaB and HDAC1 is needed. parthenolide 22-34 histone deacetylase 1 Homo sapiens 161-166 26821066-6 2016 CJ also provoked a slight activation of NF-kappaB, and consistent with this notion a combined treatment of CJ and the NF-kappaB inhibitor parthenolide (Pt) led to a remarkable synergistic cell death in T-ALL cells. parthenolide 138-150 nuclear factor kappa B subunit 1 Homo sapiens 40-49 26821066-6 2016 CJ also provoked a slight activation of NF-kappaB, and consistent with this notion a combined treatment of CJ and the NF-kappaB inhibitor parthenolide (Pt) led to a remarkable synergistic cell death in T-ALL cells. parthenolide 138-150 nuclear factor kappa B subunit 1 Homo sapiens 118-127 26821066-6 2016 CJ also provoked a slight activation of NF-kappaB, and consistent with this notion a combined treatment of CJ and the NF-kappaB inhibitor parthenolide (Pt) led to a remarkable synergistic cell death in T-ALL cells. parthenolide 152-154 nuclear factor kappa B subunit 1 Homo sapiens 40-49 26821066-6 2016 CJ also provoked a slight activation of NF-kappaB, and consistent with this notion a combined treatment of CJ and the NF-kappaB inhibitor parthenolide (Pt) led to a remarkable synergistic cell death in T-ALL cells. parthenolide 152-154 nuclear factor kappa B subunit 1 Homo sapiens 118-127 26821066-7 2016 Altogether, our data support the concept that inhibition of the SERCA pump may be a novel strategy for the treatment of T-ALL with HD-domain-mutant Notch1 receptors and that additional treatment with the NF-kappaB inhibitor parthenolide may have further therapeutic benefits. parthenolide 224-236 nuclear factor kappa B subunit 1 Homo sapiens 204-213 27800490-12 2016 Pretreatment with anti-TLR4 attenuated Resistin-enhanced IL-1beta, but not TNF-alpha, expression and pretreatment with parthenolide or QNZ demolished Resistin-enhanced TNF-alpha expression in HACECs. parthenolide 119-131 resistin Mus musculus 150-158 27800490-13 2016 Pretreatment with parthenolide, but not QNZ, blocked Resistin-enhanced IL-1beta expression in HCAECs. parthenolide 18-30 resistin Mus musculus 53-61 27800490-13 2016 Pretreatment with parthenolide, but not QNZ, blocked Resistin-enhanced IL-1beta expression in HCAECs. parthenolide 18-30 interleukin 1 beta Mus musculus 71-79 27855364-9 2016 Instead, parthenolide increased the autophagy and mitophagy, as characterized by increased PINK1 and Parkin translocation to mitochondria and enhanced autophagy proteins. parthenolide 9-21 PTEN induced kinase 1 Homo sapiens 91-96 26378023-7 2015 Administration of the p65 inhibitor parthenolide significantly improved hematology and myelogram indices while prolonging the life span of erythroleukemia mice. parthenolide 36-48 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 22-25 26206887-7 2015 Notch siRNA prevented the activation of nuclear factor kappa B (NFkappaB), and NFkappaB activation contributed to Notch1-mediated inflammatory responses as the NFkappaB inhibitor, parthenolide, prevented lyso-Gb3-induced chemokine upregulation. parthenolide 180-192 nuclear factor kappa B subunit 1 Homo sapiens 64-72 26206887-7 2015 Notch siRNA prevented the activation of nuclear factor kappa B (NFkappaB), and NFkappaB activation contributed to Notch1-mediated inflammatory responses as the NFkappaB inhibitor, parthenolide, prevented lyso-Gb3-induced chemokine upregulation. parthenolide 180-192 nuclear factor kappa B subunit 1 Homo sapiens 79-87 26206887-7 2015 Notch siRNA prevented the activation of nuclear factor kappa B (NFkappaB), and NFkappaB activation contributed to Notch1-mediated inflammatory responses as the NFkappaB inhibitor, parthenolide, prevented lyso-Gb3-induced chemokine upregulation. parthenolide 180-192 notch receptor 1 Homo sapiens 114-120 26206887-7 2015 Notch siRNA prevented the activation of nuclear factor kappa B (NFkappaB), and NFkappaB activation contributed to Notch1-mediated inflammatory responses as the NFkappaB inhibitor, parthenolide, prevented lyso-Gb3-induced chemokine upregulation. parthenolide 180-192 nuclear factor kappa B subunit 1 Homo sapiens 79-87 26206887-7 2015 Notch siRNA prevented the activation of nuclear factor kappa B (NFkappaB), and NFkappaB activation contributed to Notch1-mediated inflammatory responses as the NFkappaB inhibitor, parthenolide, prevented lyso-Gb3-induced chemokine upregulation. parthenolide 180-192 alpha 1,4-galactosyltransferase (P blood group) Homo sapiens 209-212 26109312-9 2015 Remarkably, HDAC4 silencing and the administration of the HDAC inhibitor parthenolide during obstructive cholestasis in vivo promote genomic reprogramming, leading to regression of the fibrotic phenotype in liver-specific Phb1 knockout mice. parthenolide 73-85 prohibitin 1 Homo sapiens 222-226 26206887-7 2015 Notch siRNA prevented the activation of nuclear factor kappa B (NFkappaB), and NFkappaB activation contributed to Notch1-mediated inflammatory responses as the NFkappaB inhibitor, parthenolide, prevented lyso-Gb3-induced chemokine upregulation. parthenolide 180-192 nuclear factor kappa B subunit 1 Homo sapiens 40-62 25847297-9 2015 Tat-induced effects were prevented by the NF-kappaB inhibitor parthenolide, indicating that Tat triggered senescence via NF-kappaB activation leading to oxidative stress. parthenolide 62-74 tyrosine aminotransferase Homo sapiens 0-3 29552235-7 2015 In addition, PTL-loaded PSMA-b-PS micelles exhibited a dose-dependent cytotoxicity towards AML cells and were capable of reducing cell viability by 75% at 10 muM PTL, while unloaded micelles were nontoxic. parthenolide 13-16 folate hydrolase 1 Homo sapiens 24-28 29552235-7 2015 In addition, PTL-loaded PSMA-b-PS micelles exhibited a dose-dependent cytotoxicity towards AML cells and were capable of reducing cell viability by 75% at 10 muM PTL, while unloaded micelles were nontoxic. parthenolide 162-165 folate hydrolase 1 Homo sapiens 24-28 29552235-11 2015 The physical properties, stability, and efficacy of PTL-loaded PSMA-b-PS micelles support further development of a leukemia therapeutic with greater bioavailability and the potential to eliminate LSCs. parthenolide 52-55 folate hydrolase 1 Homo sapiens 63-67 25971793-3 2015 However, the effect of parthenolide on the Akt/mTOR and NF-kappaB pathway activation-induced productions of inflammatory mediators in keratinocytes has not been studied. parthenolide 23-35 nuclear factor kappa B subunit 1 Homo sapiens 56-65 25971793-4 2015 Using human keratinocytes, we investigated the effect of parthenolide on the inflammatory mediator production in relation to the Toll-like receptor-4-mediated-Akt/mTOR and NF-kappaB pathways, which regulate the transcription genes involved in immune and inflammatory responses. parthenolide 57-69 toll like receptor 4 Homo sapiens 129-149 25971793-4 2015 Using human keratinocytes, we investigated the effect of parthenolide on the inflammatory mediator production in relation to the Toll-like receptor-4-mediated-Akt/mTOR and NF-kappaB pathways, which regulate the transcription genes involved in immune and inflammatory responses. parthenolide 57-69 AKT serine/threonine kinase 1 Homo sapiens 159-162 25971793-4 2015 Using human keratinocytes, we investigated the effect of parthenolide on the inflammatory mediator production in relation to the Toll-like receptor-4-mediated-Akt/mTOR and NF-kappaB pathways, which regulate the transcription genes involved in immune and inflammatory responses. parthenolide 57-69 mechanistic target of rapamycin kinase Homo sapiens 163-167 25971793-4 2015 Using human keratinocytes, we investigated the effect of parthenolide on the inflammatory mediator production in relation to the Toll-like receptor-4-mediated-Akt/mTOR and NF-kappaB pathways, which regulate the transcription genes involved in immune and inflammatory responses. parthenolide 57-69 nuclear factor kappa B subunit 1 Homo sapiens 172-181 25971793-5 2015 Parthenolide, Akt inhibitor, Bay 11-7085, and N-acetylcysteine each attenuated the lipopolysaccharide-induced production of IL-1beta and PGE2, increase in the levels of cyclooxygenase, formation of reactive oxygen species, increase in the levels of Toll-like receptor-4, and activation of the Akt/mTOR and NF-kappaB in keratinocytes. parthenolide 0-12 interleukin 1 beta Homo sapiens 124-132 25971793-6 2015 The results show that parthenolide appears to attenuate the lipopolysaccharide-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor-4-mediated activation of the Akt, mTOR, and NF-kappaB pathways. parthenolide 22-34 toll like receptor 4 Homo sapiens 163-183 25971793-6 2015 The results show that parthenolide appears to attenuate the lipopolysaccharide-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor-4-mediated activation of the Akt, mTOR, and NF-kappaB pathways. parthenolide 22-34 AKT serine/threonine kinase 1 Homo sapiens 211-214 25971793-6 2015 The results show that parthenolide appears to attenuate the lipopolysaccharide-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor-4-mediated activation of the Akt, mTOR, and NF-kappaB pathways. parthenolide 22-34 mechanistic target of rapamycin kinase Homo sapiens 216-220 25971793-6 2015 The results show that parthenolide appears to attenuate the lipopolysaccharide-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor-4-mediated activation of the Akt, mTOR, and NF-kappaB pathways. parthenolide 22-34 nuclear factor kappa B subunit 1 Homo sapiens 226-235 25980581-6 2015 Compared with the control, ING5 transfectants displayed drug resistance to triciribine, paclitaxel, cisplatin, SAHA, MG132 and parthenolide, which was positively related to their apoptotic induction and the overexpression of chemoresistance-related genes (MDR1, GRP78, GRP94, IRE, CD147, FBXW7, TOP1, TOP2, MLH1, MRP1, BRCP1 and GST-pi). parthenolide 127-139 inhibitor of growth family member 5 Homo sapiens 27-31 25980581-6 2015 Compared with the control, ING5 transfectants displayed drug resistance to triciribine, paclitaxel, cisplatin, SAHA, MG132 and parthenolide, which was positively related to their apoptotic induction and the overexpression of chemoresistance-related genes (MDR1, GRP78, GRP94, IRE, CD147, FBXW7, TOP1, TOP2, MLH1, MRP1, BRCP1 and GST-pi). parthenolide 127-139 ATP binding cassette subfamily B member 1 Homo sapiens 256-260 25980581-6 2015 Compared with the control, ING5 transfectants displayed drug resistance to triciribine, paclitaxel, cisplatin, SAHA, MG132 and parthenolide, which was positively related to their apoptotic induction and the overexpression of chemoresistance-related genes (MDR1, GRP78, GRP94, IRE, CD147, FBXW7, TOP1, TOP2, MLH1, MRP1, BRCP1 and GST-pi). parthenolide 127-139 heat shock protein family A (Hsp70) member 5 Homo sapiens 262-267 25980581-6 2015 Compared with the control, ING5 transfectants displayed drug resistance to triciribine, paclitaxel, cisplatin, SAHA, MG132 and parthenolide, which was positively related to their apoptotic induction and the overexpression of chemoresistance-related genes (MDR1, GRP78, GRP94, IRE, CD147, FBXW7, TOP1, TOP2, MLH1, MRP1, BRCP1 and GST-pi). parthenolide 127-139 heat shock protein 90 beta family member 1 Homo sapiens 269-274 25980581-6 2015 Compared with the control, ING5 transfectants displayed drug resistance to triciribine, paclitaxel, cisplatin, SAHA, MG132 and parthenolide, which was positively related to their apoptotic induction and the overexpression of chemoresistance-related genes (MDR1, GRP78, GRP94, IRE, CD147, FBXW7, TOP1, TOP2, MLH1, MRP1, BRCP1 and GST-pi). parthenolide 127-139 basigin (Ok blood group) Homo sapiens 281-286 25980581-6 2015 Compared with the control, ING5 transfectants displayed drug resistance to triciribine, paclitaxel, cisplatin, SAHA, MG132 and parthenolide, which was positively related to their apoptotic induction and the overexpression of chemoresistance-related genes (MDR1, GRP78, GRP94, IRE, CD147, FBXW7, TOP1, TOP2, MLH1, MRP1, BRCP1 and GST-pi). parthenolide 127-139 F-box and WD repeat domain containing 7 Homo sapiens 288-293 25980581-6 2015 Compared with the control, ING5 transfectants displayed drug resistance to triciribine, paclitaxel, cisplatin, SAHA, MG132 and parthenolide, which was positively related to their apoptotic induction and the overexpression of chemoresistance-related genes (MDR1, GRP78, GRP94, IRE, CD147, FBXW7, TOP1, TOP2, MLH1, MRP1, BRCP1 and GST-pi). parthenolide 127-139 mutL homolog 1 Homo sapiens 307-311 25980581-6 2015 Compared with the control, ING5 transfectants displayed drug resistance to triciribine, paclitaxel, cisplatin, SAHA, MG132 and parthenolide, which was positively related to their apoptotic induction and the overexpression of chemoresistance-related genes (MDR1, GRP78, GRP94, IRE, CD147, FBXW7, TOP1, TOP2, MLH1, MRP1, BRCP1 and GST-pi). parthenolide 127-139 CD9 molecule Homo sapiens 313-317 25847297-9 2015 Tat-induced effects were prevented by the NF-kappaB inhibitor parthenolide, indicating that Tat triggered senescence via NF-kappaB activation leading to oxidative stress. parthenolide 62-74 tyrosine aminotransferase Homo sapiens 92-95 25826425-4 2015 Parthenolide, but not wortmanin or the MAPK inhibitor PD98059, significantly decreased production of RANTES, indicating that this effect of TWEAK is mediated via NF-kappaB signaling. parthenolide 0-12 chemokine (C-C motif) ligand 5 Mus musculus 101-107 26024595-6 2015 In addition, treatment with parthenolide, which is capable of depleting HDAC1, and knockdown of HDAC1 using siRNA resulted in increased 5-HTT mRNA expression, confirming the role of HDAC1 in the down-regulation of 5-HTT in the tumor cells. parthenolide 28-40 histone deacetylase 1 Gallus gallus 72-77 26024595-6 2015 In addition, treatment with parthenolide, which is capable of depleting HDAC1, and knockdown of HDAC1 using siRNA resulted in increased 5-HTT mRNA expression, confirming the role of HDAC1 in the down-regulation of 5-HTT in the tumor cells. parthenolide 28-40 solute carrier family 6 member 4 Homo sapiens 136-141 26024595-6 2015 In addition, treatment with parthenolide, which is capable of depleting HDAC1, and knockdown of HDAC1 using siRNA resulted in increased 5-HTT mRNA expression, confirming the role of HDAC1 in the down-regulation of 5-HTT in the tumor cells. parthenolide 28-40 solute carrier family 6 member 4 Homo sapiens 214-219 25826425-4 2015 Parthenolide, but not wortmanin or the MAPK inhibitor PD98059, significantly decreased production of RANTES, indicating that this effect of TWEAK is mediated via NF-kappaB signaling. parthenolide 0-12 tumor necrosis factor (ligand) superfamily, member 12 Mus musculus 140-145 25968579-7 2015 Incubation with parthenolide abolished LIF-induced glucose uptake and STAT3 Tyr(705) P, whereas incubation with LY-294002 and wortmannin suppressed both basal and LIF-induced glucose uptake and Akt Ser(473) P, indicating that JAK and PI 3-kinase signaling is required for LIF-stimulated glucose uptake. parthenolide 16-28 leukemia inhibitory factor Mus musculus 39-42 25968579-7 2015 Incubation with parthenolide abolished LIF-induced glucose uptake and STAT3 Tyr(705) P, whereas incubation with LY-294002 and wortmannin suppressed both basal and LIF-induced glucose uptake and Akt Ser(473) P, indicating that JAK and PI 3-kinase signaling is required for LIF-stimulated glucose uptake. parthenolide 16-28 signal transducer and activator of transcription 3 Mus musculus 70-75 25978958-0 2015 Parthenolide prodrug LC-1 slows growth of intracranial glioma. parthenolide 0-12 microtubule-associated protein 1B Mus musculus 21-25 26160345-4 2015 Application of different inhibitors and activators showed that transcription factors NF-kappaB (inhibitors caffeic acid phenethyl ester and parthenolide, activator betulinic acid), AP-1 (inhibitor SR11302), and STAT-3 (inhibitors stattic and cucurbitacine) influenced PDT-induced death and survival of neurons and glial cells in different ways. parthenolide 140-152 nuclear factor kappa B subunit 1 Homo sapiens 85-94 25978958-1 2015 LC-1 (also known as DMAPT or dimethylamino-parthenolide), a prodrug of parthenolide, was tested for anti-proliferative activity against glioma. parthenolide 43-55 microtubule-associated protein 1B Mus musculus 0-4 25502339-0 2015 Parthenolide enhances sensitivity of colorectal cancer cells to TRAIL by inducing death receptor 5 and promotes TRAIL-induced apoptosis. parthenolide 0-12 TNF superfamily member 10 Homo sapiens 64-69 25370819-6 2015 However, when the cells were treated with SAHA/PN combination, SAHA suppressed PN effect on Akt/mTOR/Nrf2 pathway, while PN reduced the prosurvival autophagic activity of SAHA. parthenolide 47-49 AKT serine/threonine kinase 1 Homo sapiens 92-95 25370819-6 2015 However, when the cells were treated with SAHA/PN combination, SAHA suppressed PN effect on Akt/mTOR/Nrf2 pathway, while PN reduced the prosurvival autophagic activity of SAHA. parthenolide 47-49 mechanistic target of rapamycin kinase Homo sapiens 96-100 25370819-6 2015 However, when the cells were treated with SAHA/PN combination, SAHA suppressed PN effect on Akt/mTOR/Nrf2 pathway, while PN reduced the prosurvival autophagic activity of SAHA. parthenolide 47-49 NFE2 like bZIP transcription factor 2 Homo sapiens 101-105 25370819-7 2015 In addition SAHA/PN combination induced GSH depletion, fall in Deltapsim, release of cytochrome c, activation of caspase 3 and apoptosis. parthenolide 17-19 cytochrome c, somatic Homo sapiens 85-97 25370819-7 2015 In addition SAHA/PN combination induced GSH depletion, fall in Deltapsim, release of cytochrome c, activation of caspase 3 and apoptosis. parthenolide 17-19 caspase 3 Homo sapiens 113-122 25971793-0 2015 Sesquiterpene lactone parthenolide attenuates production of inflammatory mediators by suppressing the Toll-like receptor-4-mediated activation of the Akt, mTOR, and NF-kappaB pathways. parthenolide 22-34 toll like receptor 4 Homo sapiens 102-122 25971793-0 2015 Sesquiterpene lactone parthenolide attenuates production of inflammatory mediators by suppressing the Toll-like receptor-4-mediated activation of the Akt, mTOR, and NF-kappaB pathways. parthenolide 22-34 AKT serine/threonine kinase 1 Homo sapiens 150-153 25971793-0 2015 Sesquiterpene lactone parthenolide attenuates production of inflammatory mediators by suppressing the Toll-like receptor-4-mediated activation of the Akt, mTOR, and NF-kappaB pathways. parthenolide 22-34 mechanistic target of rapamycin kinase Homo sapiens 155-159 25971793-0 2015 Sesquiterpene lactone parthenolide attenuates production of inflammatory mediators by suppressing the Toll-like receptor-4-mediated activation of the Akt, mTOR, and NF-kappaB pathways. parthenolide 22-34 nuclear factor kappa B subunit 1 Homo sapiens 165-174 25971793-3 2015 However, the effect of parthenolide on the Akt/mTOR and NF-kappaB pathway activation-induced productions of inflammatory mediators in keratinocytes has not been studied. parthenolide 23-35 AKT serine/threonine kinase 1 Homo sapiens 43-46 25971793-3 2015 However, the effect of parthenolide on the Akt/mTOR and NF-kappaB pathway activation-induced productions of inflammatory mediators in keratinocytes has not been studied. parthenolide 23-35 mechanistic target of rapamycin kinase Homo sapiens 47-51 25370819-5 2015 It is noteworthy that treatment with PN alone stimulated the survival pathway Akt/mTOR and the consequent nuclear translocation of Nrf2, while treatment with SAHA alone induced autophagic activity. parthenolide 37-39 AKT serine/threonine kinase 1 Homo sapiens 78-81 25370819-5 2015 It is noteworthy that treatment with PN alone stimulated the survival pathway Akt/mTOR and the consequent nuclear translocation of Nrf2, while treatment with SAHA alone induced autophagic activity. parthenolide 37-39 mechanistic target of rapamycin kinase Homo sapiens 82-86 25370819-5 2015 It is noteworthy that treatment with PN alone stimulated the survival pathway Akt/mTOR and the consequent nuclear translocation of Nrf2, while treatment with SAHA alone induced autophagic activity. parthenolide 37-39 NFE2 like bZIP transcription factor 2 Homo sapiens 131-135 26072071-0 2015 Inhibitory effects of parthenolide on the activity of NF-kappaB in multiple myeloma via targeting TRAF6. parthenolide 22-34 nuclear factor kappa B subunit 1 Homo sapiens 54-63 26072071-0 2015 Inhibitory effects of parthenolide on the activity of NF-kappaB in multiple myeloma via targeting TRAF6. parthenolide 22-34 TNF receptor associated factor 6 Homo sapiens 98-103 26072071-1 2015 This study examined the mechanism of the inhibitory effect of parthenolide (PTL) on the activity of NF-kappaB in multiple myeloma (MM). parthenolide 62-74 nuclear factor kappa B subunit 1 Homo sapiens 100-109 26072071-1 2015 This study examined the mechanism of the inhibitory effect of parthenolide (PTL) on the activity of NF-kappaB in multiple myeloma (MM). parthenolide 76-79 nuclear factor kappa B subunit 1 Homo sapiens 100-109 26072071-7 2015 Exposure of RPMI 8226 cells to PTL attenuated the level of ubiquitinated Nemo, increased the expression of IkappaB-alpha and reduced the level of p65 in nucleus, finally leading to the decrease of the activity of NF-kappaB. parthenolide 31-34 inhibitor of nuclear factor kappa B kinase regulatory subunit gamma Homo sapiens 73-77 26072071-7 2015 Exposure of RPMI 8226 cells to PTL attenuated the level of ubiquitinated Nemo, increased the expression of IkappaB-alpha and reduced the level of p65 in nucleus, finally leading to the decrease of the activity of NF-kappaB. parthenolide 31-34 NFKB inhibitor alpha Homo sapiens 107-120 26072071-7 2015 Exposure of RPMI 8226 cells to PTL attenuated the level of ubiquitinated Nemo, increased the expression of IkappaB-alpha and reduced the level of p65 in nucleus, finally leading to the decrease of the activity of NF-kappaB. parthenolide 31-34 RELA proto-oncogene, NF-kB subunit Homo sapiens 146-149 26072071-7 2015 Exposure of RPMI 8226 cells to PTL attenuated the level of ubiquitinated Nemo, increased the expression of IkappaB-alpha and reduced the level of p65 in nucleus, finally leading to the decrease of the activity of NF-kappaB. parthenolide 31-34 nuclear factor kappa B subunit 1 Homo sapiens 213-222 26072071-11 2015 Taken together, our findings suggest that PTL inhibits the activation of NF-kappaB signaling pathway via directly binding with TRAF6, thereby suppressing MM cell proliferation and inducing apoptosis. parthenolide 42-45 nuclear factor kappa B subunit 1 Homo sapiens 73-82 26072071-11 2015 Taken together, our findings suggest that PTL inhibits the activation of NF-kappaB signaling pathway via directly binding with TRAF6, thereby suppressing MM cell proliferation and inducing apoptosis. parthenolide 42-45 TNF receptor associated factor 6 Homo sapiens 127-132 25817195-6 2015 PTL treatment also induced the translocation of cytosolic Bim into the mitochondria and, more importantly, PTL-induced apoptosis was significantly attenuated, when the Bim expression was knockdown by siRNA transfection. parthenolide 0-3 BCL2 like 11 Homo sapiens 58-61 25817195-6 2015 PTL treatment also induced the translocation of cytosolic Bim into the mitochondria and, more importantly, PTL-induced apoptosis was significantly attenuated, when the Bim expression was knockdown by siRNA transfection. parthenolide 0-3 BCL2 like 11 Homo sapiens 168-171 25841439-0 2015 Parthenolide inhibits LPS-induced inflammatory cytokines through the toll-like receptor 4 signal pathway in THP-1 cells. parthenolide 0-12 toll like receptor 4 Homo sapiens 69-89 26137027-2 2015 Additionally, our previous study demonstrated that PT administration suppresses tumor growth in a xenograft model of colorectal cancer cells via regulation of the B-cell lymphoma-2 (Bcl-2) family. parthenolide 51-53 B cell leukemia/lymphoma 2 Mus musculus 163-180 26137027-2 2015 Additionally, our previous study demonstrated that PT administration suppresses tumor growth in a xenograft model of colorectal cancer cells via regulation of the B-cell lymphoma-2 (Bcl-2) family. parthenolide 51-53 B cell leukemia/lymphoma 2 Mus musculus 182-187 26137027-7 2015 Furthermore, PT administration appeared to enhance the process of carcinogenesis via the downregulation of the antiapoptotic proteins Bcl-2 and Bcl-extra large, mediated by inhibition of NF-kappaB activation. parthenolide 13-15 B cell leukemia/lymphoma 2 Mus musculus 134-139 25439190-7 2015 RESULTS: We established that PAR, as a prototype compound, suppressed lipopolysaccharide (LPS)- and tumour necrosis factor (TNF)-alpha-induced increases in matrix metalloproteinase (MMP)-1, MMP-3, inducible nitric oxide synthase (iNOS), and interleukin (IL)-1beta mRNA in chondrocytes. parthenolide 29-32 tumor necrosis factor Rattus norvegicus 100-134 25439190-7 2015 RESULTS: We established that PAR, as a prototype compound, suppressed lipopolysaccharide (LPS)- and tumour necrosis factor (TNF)-alpha-induced increases in matrix metalloproteinase (MMP)-1, MMP-3, inducible nitric oxide synthase (iNOS), and interleukin (IL)-1beta mRNA in chondrocytes. parthenolide 29-32 matrix metallopeptidase 1 Rattus norvegicus 156-188 25439190-7 2015 RESULTS: We established that PAR, as a prototype compound, suppressed lipopolysaccharide (LPS)- and tumour necrosis factor (TNF)-alpha-induced increases in matrix metalloproteinase (MMP)-1, MMP-3, inducible nitric oxide synthase (iNOS), and interleukin (IL)-1beta mRNA in chondrocytes. parthenolide 29-32 matrix metallopeptidase 3 Rattus norvegicus 190-195 25439190-7 2015 RESULTS: We established that PAR, as a prototype compound, suppressed lipopolysaccharide (LPS)- and tumour necrosis factor (TNF)-alpha-induced increases in matrix metalloproteinase (MMP)-1, MMP-3, inducible nitric oxide synthase (iNOS), and interleukin (IL)-1beta mRNA in chondrocytes. parthenolide 29-32 nitric oxide synthase 2 Rattus norvegicus 197-228 25439190-7 2015 RESULTS: We established that PAR, as a prototype compound, suppressed lipopolysaccharide (LPS)- and tumour necrosis factor (TNF)-alpha-induced increases in matrix metalloproteinase (MMP)-1, MMP-3, inducible nitric oxide synthase (iNOS), and interleukin (IL)-1beta mRNA in chondrocytes. parthenolide 29-32 nitric oxide synthase 2 Rattus norvegicus 230-234 25439190-7 2015 RESULTS: We established that PAR, as a prototype compound, suppressed lipopolysaccharide (LPS)- and tumour necrosis factor (TNF)-alpha-induced increases in matrix metalloproteinase (MMP)-1, MMP-3, inducible nitric oxide synthase (iNOS), and interleukin (IL)-1beta mRNA in chondrocytes. parthenolide 29-32 interleukin 1 beta Rattus norvegicus 241-263 25502339-0 2015 Parthenolide enhances sensitivity of colorectal cancer cells to TRAIL by inducing death receptor 5 and promotes TRAIL-induced apoptosis. parthenolide 0-12 TNF receptor superfamily member 10b Homo sapiens 82-98 25502339-0 2015 Parthenolide enhances sensitivity of colorectal cancer cells to TRAIL by inducing death receptor 5 and promotes TRAIL-induced apoptosis. parthenolide 0-12 TNF superfamily member 10 Homo sapiens 112-117 25102048-4 2014 The results revealed that the C1, C10 double bond configuration of parthenolide has little or no effect on the activity, and the C6 and C7 configurations of the lactone ring have a moderate impact on the activities against some cancer cell lines. parthenolide 67-79 homeobox C10 Homo sapiens 34-37 25611383-2 2015 We recently developed dimethylaminoparthenolide (DMAPT), a clinical grade water-soluble analog of parthenolide, as a potent inhibitor of NF-kappaB and demonstrated in vitro and in vivo anti-tumor activities in multiple cancers. parthenolide 35-47 nuclear factor kappa B subunit 1 Homo sapiens 137-146 25611383-9 2015 These results add KMT5C to the list NF-kappaB-independent epigenetic targets of parthenolide, which include previously described histone deacetylase 1 (HDAC-1) and DNA methyltransferase 1. parthenolide 80-92 lysine methyltransferase 5C Homo sapiens 18-23 25611383-9 2015 These results add KMT5C to the list NF-kappaB-independent epigenetic targets of parthenolide, which include previously described histone deacetylase 1 (HDAC-1) and DNA methyltransferase 1. parthenolide 80-92 nuclear factor kappa B subunit 1 Homo sapiens 36-45 25611383-9 2015 These results add KMT5C to the list NF-kappaB-independent epigenetic targets of parthenolide, which include previously described histone deacetylase 1 (HDAC-1) and DNA methyltransferase 1. parthenolide 80-92 histone deacetylase 1 Homo sapiens 129-150 25611383-9 2015 These results add KMT5C to the list NF-kappaB-independent epigenetic targets of parthenolide, which include previously described histone deacetylase 1 (HDAC-1) and DNA methyltransferase 1. parthenolide 80-92 histone deacetylase 1 Homo sapiens 152-159 25611383-9 2015 These results add KMT5C to the list NF-kappaB-independent epigenetic targets of parthenolide, which include previously described histone deacetylase 1 (HDAC-1) and DNA methyltransferase 1. parthenolide 80-92 DNA methyltransferase 1 Homo sapiens 164-187 25289524-1 2015 CONTEXT: Parthenolide (a sesquiterpene lactone), a bioactive compound of Tanacetum parthenium (L.) Schultz Bip. parthenolide 9-21 growth differentiation factor 10 Homo sapiens 107-110 25289524-8 2015 Parthenolide-treated cells showed up-regulation of p53, Bax, caspase-3, -6, and -3 genes and down-regulation of Bcl-2 gene (p <= 0.008). parthenolide 0-12 tumor protein p53 Homo sapiens 51-54 25289524-8 2015 Parthenolide-treated cells showed up-regulation of p53, Bax, caspase-3, -6, and -3 genes and down-regulation of Bcl-2 gene (p <= 0.008). parthenolide 0-12 BCL2 associated X, apoptosis regulator Homo sapiens 56-59 25289524-8 2015 Parthenolide-treated cells showed up-regulation of p53, Bax, caspase-3, -6, and -3 genes and down-regulation of Bcl-2 gene (p <= 0.008). parthenolide 0-12 caspase 3 Homo sapiens 61-82 25289524-8 2015 Parthenolide-treated cells showed up-regulation of p53, Bax, caspase-3, -6, and -3 genes and down-regulation of Bcl-2 gene (p <= 0.008). parthenolide 0-12 BCL2 apoptosis regulator Homo sapiens 112-117 25553117-0 2015 Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-kappaB/COX-2 pathway. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 112-121 25553117-0 2015 Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-kappaB/COX-2 pathway. parthenolide 0-12 prostaglandin-endoperoxide synthase 2 Homo sapiens 122-127 25553117-5 2015 The present study also demonstrated that in contrast to the classical chemotherapy drug 5-fluorouracil, which increased the proportion of side population cells and upregulated the expression of COX-2, parthenolide, a naturally occurring small molecule, preferentially targeted the side population cells of nasopharyngeal carcinoma cells and downregulated COX-2. parthenolide 201-213 prostaglandin-endoperoxide synthase 2 Homo sapiens 194-199 25553117-5 2015 The present study also demonstrated that in contrast to the classical chemotherapy drug 5-fluorouracil, which increased the proportion of side population cells and upregulated the expression of COX-2, parthenolide, a naturally occurring small molecule, preferentially targeted the side population cells of nasopharyngeal carcinoma cells and downregulated COX-2. parthenolide 201-213 prostaglandin-endoperoxide synthase 2 Homo sapiens 355-360 25553117-7 2015 These findings suggest that COX-2 inhibition is the mechanism by which parthenolide induces cell death in the cancer stem-like cells of nasopharyngeal carcinoma. parthenolide 71-83 prostaglandin-endoperoxide synthase 2 Homo sapiens 28-33 25553117-8 2015 In addition, parthenolide exhibited an inhibitory effect on nuclear factor-kappa B (NF-kappaB) nucler translocation by suppressing both the phosphorylation of IkappaB kinase complex and IkappaBalpha degradation. parthenolide 13-25 nuclear factor kappa B subunit 1 Homo sapiens 60-82 25553117-8 2015 In addition, parthenolide exhibited an inhibitory effect on nuclear factor-kappa B (NF-kappaB) nucler translocation by suppressing both the phosphorylation of IkappaB kinase complex and IkappaBalpha degradation. parthenolide 13-25 nuclear factor kappa B subunit 1 Homo sapiens 84-93 25553117-8 2015 In addition, parthenolide exhibited an inhibitory effect on nuclear factor-kappa B (NF-kappaB) nucler translocation by suppressing both the phosphorylation of IkappaB kinase complex and IkappaBalpha degradation. parthenolide 13-25 NFKB inhibitor alpha Homo sapiens 186-198 25553117-9 2015 Taken together, these results suggest that parthenolide may exert its cancer stem cell-targeted chemotherapy through the NF-kappaB/COX-2 pathway. parthenolide 43-55 nuclear factor kappa B subunit 1 Homo sapiens 121-130 25553117-9 2015 Taken together, these results suggest that parthenolide may exert its cancer stem cell-targeted chemotherapy through the NF-kappaB/COX-2 pathway. parthenolide 43-55 prostaglandin-endoperoxide synthase 2 Homo sapiens 131-136 24893328-12 2014 The effect of parthenolide and the outcomes obtained so far suggest that HMGB1 indirectly up-regulates AQP4 expression through diffusible factor(s) such as IL-1beta from microglia since HMGB1 by itself didnot affect NF-kappaB intracellular localization in astrocytes. parthenolide 14-26 high mobility group box 1 Rattus norvegicus 73-78 24893328-12 2014 The effect of parthenolide and the outcomes obtained so far suggest that HMGB1 indirectly up-regulates AQP4 expression through diffusible factor(s) such as IL-1beta from microglia since HMGB1 by itself didnot affect NF-kappaB intracellular localization in astrocytes. parthenolide 14-26 aquaporin 4 Rattus norvegicus 103-107 24893328-12 2014 The effect of parthenolide and the outcomes obtained so far suggest that HMGB1 indirectly up-regulates AQP4 expression through diffusible factor(s) such as IL-1beta from microglia since HMGB1 by itself didnot affect NF-kappaB intracellular localization in astrocytes. parthenolide 14-26 interleukin 1 beta Rattus norvegicus 156-164 27122844-2 2015 Parthenolide, a sesquiterpene lactone compound which could inhibit NF-kappa B, has been shown to ameliorate myocardial reperfusion injury but may also produce toxic effects in cardiomyocytes at high concentrations. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 67-77 27122844-7 2015 RESULTS: Parthenolide caused apoptosis at 30 mu M, as judged by TUNEL assay and Bax and cytochrome c translocation. parthenolide 9-21 BCL2 associated X, apoptosis regulator Homo sapiens 80-83 27122844-7 2015 RESULTS: Parthenolide caused apoptosis at 30 mu M, as judged by TUNEL assay and Bax and cytochrome c translocation. parthenolide 9-21 cytochrome c, somatic Homo sapiens 88-100 26089941-5 2015 Molecular docking in silico suggested that K100, having highly analogous structure as parthenolide (PTL), an anticancer compound, could bind PTL target proteins at similar positions and with comparable binding affinities. parthenolide 86-98 C1q-like 3 Mus musculus 43-47 26089941-5 2015 Molecular docking in silico suggested that K100, having highly analogous structure as parthenolide (PTL), an anticancer compound, could bind PTL target proteins at similar positions and with comparable binding affinities. parthenolide 86-98 pancreatic lipase Homo sapiens 100-103 26089941-5 2015 Molecular docking in silico suggested that K100, having highly analogous structure as parthenolide (PTL), an anticancer compound, could bind PTL target proteins at similar positions and with comparable binding affinities. parthenolide 86-98 pancreatic lipase Homo sapiens 141-144 25664142-6 2015 The IKK/NF-kappaB inhibitor parthenolide decreased AOPP-induced MCP-1 expression. parthenolide 28-40 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 8-17 25664142-6 2015 The IKK/NF-kappaB inhibitor parthenolide decreased AOPP-induced MCP-1 expression. parthenolide 28-40 peroxiredoxin 5 Mus musculus 51-55 25664142-6 2015 The IKK/NF-kappaB inhibitor parthenolide decreased AOPP-induced MCP-1 expression. parthenolide 28-40 chemokine (C-C motif) ligand 2 Mus musculus 64-69 24619908-0 2014 Inhibition of AMPK/autophagy potentiates parthenolide-induced apoptosis in human breast cancer cells. parthenolide 41-53 protein kinase AMP-activated catalytic subunit alpha 1 Homo sapiens 14-18 24619908-3 2014 Here, we showed that parthenolide increased reactive oxygen species (ROS), induced cell death, activated AMPK and autophagy, and led to M phase cell cycle arrest in breast cancer cells. parthenolide 21-33 protein kinase AMP-activated catalytic subunit alpha 1 Homo sapiens 105-109 24619908-8 2014 Therefore, our results show that parthenolide activates both apoptosis pathway and AMPK-autophagy survival pathway through the generation of ROS, and that suppression of AMPK or autophagy can potentially enhance the anti-cancer effect of parthenolide on breast cancer cells. parthenolide 33-45 protein kinase AMP-activated catalytic subunit alpha 1 Homo sapiens 83-87 24619908-4 2014 Removal of ROS inhibited all parthenolide-associated events, such as cell death, AMPK activation, autophagy induction, and cell cycle arrest. parthenolide 29-41 protein kinase AMP-activated catalytic subunit alpha 1 Homo sapiens 81-85 24619908-8 2014 Therefore, our results show that parthenolide activates both apoptosis pathway and AMPK-autophagy survival pathway through the generation of ROS, and that suppression of AMPK or autophagy can potentially enhance the anti-cancer effect of parthenolide on breast cancer cells. parthenolide 238-250 protein kinase AMP-activated catalytic subunit alpha 1 Homo sapiens 170-174 24619908-6 2014 These observations clearly showed that parthenolide-driven ROS activated AMPK-autophagy pathway. parthenolide 39-51 protein kinase AMP-activated catalytic subunit alpha 1 Homo sapiens 73-77 24619908-7 2014 Furthermore, inhibition of either AMPK or autophagy significantly potentiated parthenolide-induced apoptosis. parthenolide 78-90 protein kinase AMP-activated catalytic subunit alpha 1 Homo sapiens 34-38 24955779-5 2014 The highest loading and prolonged release of PTL was observed from predominantly hydrophobic PSMA-b-PS micelles (e.g., PSMA100-b-PS258), which exhibited the most ordered hydrophobic environment for more favorable core-drug interactions. parthenolide 45-48 folate hydrolase 1 Homo sapiens 93-97 25263356-4 2014 RESULTS: The medicated rat serum time- and concentration-dependently promoted the proliferation of MPC5, with the optimal serum concentration of 5% and incubation time of 24 h. AOPP significantly increased MCP-1 expression in the cell supernatant in a time-and concentration-dependent manner; pretreatment with SB203580 (a p38 inhibitor) or parthenolide (a NF-kappaB inhibitor) significantly decreased MCP-1 expression, and treatment with the medicated serum significantly decreased AOPP-induced MCP-1 expression. parthenolide 341-353 peroxiredoxin 5 Mus musculus 177-181 24909514-0 2014 RIP3 overexpression sensitizes human breast cancer cells to parthenolide in vitro via intracellular ROS accumulation. parthenolide 60-72 receptor interacting serine/threonine kinase 3 Homo sapiens 0-4 24909514-2 2014 The aim of this study was to determine whether overexpression of the RIP3 gene could sensitize human breast cancer cells to parthenolide in vitro. parthenolide 124-136 receptor interacting serine/threonine kinase 3 Homo sapiens 69-73 24909514-8 2014 Furthermore, overexpression of RIP3 decreased the IC50 values of parthenolide from 17.6 to 12.6 mumol/L in MCF-7 cells, and from 16.6 to 9.9 mumol/L in MDA-MB-231 cells. parthenolide 65-77 receptor interacting serine/threonine kinase 3 Homo sapiens 31-35 24909514-9 2014 Moreover, overexpression of RIP3 significantly increased parthenolide-induced apoptosis and ROS accumulation in MCF-7 and MDA-MB-231 cells. parthenolide 57-69 receptor interacting serine/threonine kinase 3 Homo sapiens 28-32 24909514-10 2014 Pretreatment with N-acetyl-cysteine abrogated the increased sensitivity of RIP3-transfected MCF-7 and MDA-MB-231 cells to parthenolide. parthenolide 122-134 receptor interacting serine/threonine kinase 3 Homo sapiens 75-79 24909514-11 2014 CONCLUSION: Overexpression of RIP3 sensitizes MCF-7 and MDA-MB-231 breast cancer cells to parthenolide in vitro via intracellular ROS accumulation. parthenolide 90-102 receptor interacting serine/threonine kinase 3 Homo sapiens 30-34 24440756-9 2014 In addition, RT-PCR analysis, alizarin red staining and immunoblot analysis showed that inhibition of osteoblast differentiation in presence of PD98059 and parthenolide (inhibitors of ERK and NFkappaB pathways respectively) was rescued in presence of V (IV) oxide. parthenolide 156-168 mitogen-activated protein kinase 1 Mus musculus 184-187 24440756-9 2014 In addition, RT-PCR analysis, alizarin red staining and immunoblot analysis showed that inhibition of osteoblast differentiation in presence of PD98059 and parthenolide (inhibitors of ERK and NFkappaB pathways respectively) was rescued in presence of V (IV) oxide. parthenolide 156-168 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 192-200 24801981-9 2014 NF-kB was observed to play a main role in DU145 and PC3 cells in which treatment with the NF-kB inhibitor parthenolide was able to counteract both the hypoxic pro-inflammatory shift and HIF1alpha activation but not in LNCaP cells. parthenolide 106-118 hypoxia inducible factor 1 subunit alpha Homo sapiens 186-195 24859613-4 2014 Since the effect on DCF signal was suppressed by apocynin and diphenyleneiodonium (DPI), two inhibitors of NADPH oxidase (NOX), we suggest that parthenolide rapidly stimulated NOX activity with production of superoxide anion (O2 -), which was converted by superoxide dismutase 1 (SOD1) into hydrogen peroxide (H2O2). parthenolide 144-156 superoxide dismutase 1 Homo sapiens 256-278 24859613-4 2014 Since the effect on DCF signal was suppressed by apocynin and diphenyleneiodonium (DPI), two inhibitors of NADPH oxidase (NOX), we suggest that parthenolide rapidly stimulated NOX activity with production of superoxide anion (O2 -), which was converted by superoxide dismutase 1 (SOD1) into hydrogen peroxide (H2O2). parthenolide 144-156 superoxide dismutase 1 Homo sapiens 280-284 24432684-0 2013 [Effect of parthenolide on serum expressions of interleukin-1beta and tumor necrosis factor-alpha in rabbits with knee osteoarthritis]. parthenolide 11-23 interleukin-1 beta Oryctolagus cuniculus 48-65 24387758-0 2014 Parthenolide induces apoptosis via TNFRSF10B and PMAIP1 pathways in human lung cancer cells. parthenolide 0-12 TNF receptor superfamily member 10b Homo sapiens 35-44 24387758-0 2014 Parthenolide induces apoptosis via TNFRSF10B and PMAIP1 pathways in human lung cancer cells. parthenolide 0-12 phorbol-12-myristate-13-acetate-induced protein 1 Homo sapiens 49-55 24387758-11 2014 Knockdown of ATF4 and DDIT3 abrogated PTL-induced apoptosis, which suggested that PTL induced apoptosis in NSCLC cells through activation of endoplasmic reticulum stress pathway. parthenolide 38-41 activating transcription factor 4 Homo sapiens 13-17 24387758-11 2014 Knockdown of ATF4 and DDIT3 abrogated PTL-induced apoptosis, which suggested that PTL induced apoptosis in NSCLC cells through activation of endoplasmic reticulum stress pathway. parthenolide 38-41 DNA damage inducible transcript 3 Homo sapiens 22-27 24387758-11 2014 Knockdown of ATF4 and DDIT3 abrogated PTL-induced apoptosis, which suggested that PTL induced apoptosis in NSCLC cells through activation of endoplasmic reticulum stress pathway. parthenolide 82-85 activating transcription factor 4 Homo sapiens 13-17 24387758-11 2014 Knockdown of ATF4 and DDIT3 abrogated PTL-induced apoptosis, which suggested that PTL induced apoptosis in NSCLC cells through activation of endoplasmic reticulum stress pathway. parthenolide 82-85 DNA damage inducible transcript 3 Homo sapiens 22-27 24387758-13 2014 CONCLUSION: We showed that parthenolide not only triggered extrinsic apoptosis by up-regulating TNFRSF10B and down-regulating CFLAR, but also induced intrinsic apoptosis through increasing the expression of PMAIP1 and decreasing the level of MCL1 in NSCLC cells. parthenolide 27-39 TNF receptor superfamily member 10b Homo sapiens 96-105 24387758-13 2014 CONCLUSION: We showed that parthenolide not only triggered extrinsic apoptosis by up-regulating TNFRSF10B and down-regulating CFLAR, but also induced intrinsic apoptosis through increasing the expression of PMAIP1 and decreasing the level of MCL1 in NSCLC cells. parthenolide 27-39 CASP8 and FADD like apoptosis regulator Homo sapiens 126-131 24387758-13 2014 CONCLUSION: We showed that parthenolide not only triggered extrinsic apoptosis by up-regulating TNFRSF10B and down-regulating CFLAR, but also induced intrinsic apoptosis through increasing the expression of PMAIP1 and decreasing the level of MCL1 in NSCLC cells. parthenolide 27-39 phorbol-12-myristate-13-acetate-induced protein 1 Homo sapiens 207-213 24387758-13 2014 CONCLUSION: We showed that parthenolide not only triggered extrinsic apoptosis by up-regulating TNFRSF10B and down-regulating CFLAR, but also induced intrinsic apoptosis through increasing the expression of PMAIP1 and decreasing the level of MCL1 in NSCLC cells. parthenolide 27-39 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 242-246 24998560-6 2014 DAPI and TUNEL staining showed that parthenolide could increase the number of apoptotic nuclei, while reducing the expression of the anti-apoptotic protein Bcl-2 and elevating the expression of related proteins, like p53, Bax, cleaved caspase9 and cleaved caspase3. parthenolide 36-48 BCL2 apoptosis regulator Homo sapiens 156-161 24998560-6 2014 DAPI and TUNEL staining showed that parthenolide could increase the number of apoptotic nuclei, while reducing the expression of the anti-apoptotic protein Bcl-2 and elevating the expression of related proteins, like p53, Bax, cleaved caspase9 and cleaved caspase3. parthenolide 36-48 tumor protein p53 Homo sapiens 217-220 24998560-6 2014 DAPI and TUNEL staining showed that parthenolide could increase the number of apoptotic nuclei, while reducing the expression of the anti-apoptotic protein Bcl-2 and elevating the expression of related proteins, like p53, Bax, cleaved caspase9 and cleaved caspase3. parthenolide 36-48 BCL2 associated X, apoptosis regulator Homo sapiens 222-225 24998560-6 2014 DAPI and TUNEL staining showed that parthenolide could increase the number of apoptotic nuclei, while reducing the expression of the anti-apoptotic protein Bcl-2 and elevating the expression of related proteins, like p53, Bax, cleaved caspase9 and cleaved caspase3. parthenolide 36-48 caspase 9 Homo sapiens 235-243 23606517-4 2014 The augmentation of pyhin1 mRNA expression was abolished by parthenolide, a NF-kappaB inhibitor. parthenolide 60-72 interferon activated gene 209 Mus musculus 20-26 23826669-7 2014 Palmitate significantly stimulated both nuclear factor kappaB (NF-kappaB) luciferase activity and NF-kappaB p65 binding activity, which were markedly diminished by pretreatment with the NF-kappaB inhibitor, parthenolide. parthenolide 207-219 RELA proto-oncogene, NF-kB subunit Homo sapiens 108-111 23826669-8 2014 Parthenolide pretreatment also abolished IL-8 mRNA and protein induction by palmitate. parthenolide 0-12 C-X-C motif chemokine ligand 8 Homo sapiens 41-45 23876538-12 2013 RESULT(S): With parthenolide pretreatment, TNF-alpha-induced IL-8 gene and protein expression in ESCs were diminished. parthenolide 16-28 tumor necrosis factor Homo sapiens 43-52 23876538-12 2013 RESULT(S): With parthenolide pretreatment, TNF-alpha-induced IL-8 gene and protein expression in ESCs were diminished. parthenolide 16-28 C-X-C motif chemokine ligand 8 Homo sapiens 61-65 23876538-14 2013 Adding parthenolide repressed TNF-alpha-induced 5-bromo-2"-deoxyuridine incorporation and IkappaB phosphorylation in ESCs. parthenolide 7-19 tumor necrosis factor Homo sapiens 30-39 23876538-15 2013 As in vivo experiments, administering parthenolide reduced the number, surface area, and weight, the level of Vegf, Il-6, Mcp-1, and Lif gene expression, and the percentage of Ki67-positive cells in murine endometriosis-like lesions. parthenolide 38-50 interleukin 6 Mus musculus 116-120 23876538-15 2013 As in vivo experiments, administering parthenolide reduced the number, surface area, and weight, the level of Vegf, Il-6, Mcp-1, and Lif gene expression, and the percentage of Ki67-positive cells in murine endometriosis-like lesions. parthenolide 38-50 mast cell protease 1 Mus musculus 122-127 23876538-15 2013 As in vivo experiments, administering parthenolide reduced the number, surface area, and weight, the level of Vegf, Il-6, Mcp-1, and Lif gene expression, and the percentage of Ki67-positive cells in murine endometriosis-like lesions. parthenolide 38-50 leukemia inhibitory factor Mus musculus 133-136 23876538-15 2013 As in vivo experiments, administering parthenolide reduced the number, surface area, and weight, the level of Vegf, Il-6, Mcp-1, and Lif gene expression, and the percentage of Ki67-positive cells in murine endometriosis-like lesions. parthenolide 38-50 antigen identified by monoclonal antibody Ki 67 Mus musculus 176-180 24432684-1 2013 OBJECTIVE: To observe the therapeutic effect of parthenolide (PTL) on rabbit knee arthritis (KOA) and its effects on serum expression of interleukin-1beta (IL-1beta) and contents of tumor necrosis factor-alpha (TNF-alpha). parthenolide 62-65 interleukin-1 beta Oryctolagus cuniculus 156-164 24432684-1 2013 OBJECTIVE: To observe the therapeutic effect of parthenolide (PTL) on rabbit knee arthritis (KOA) and its effects on serum expression of interleukin-1beta (IL-1beta) and contents of tumor necrosis factor-alpha (TNF-alpha). parthenolide 62-65 tumor necrosis factor Oryctolagus cuniculus 182-209 24432684-7 2013 The decrement was positively correlated with PTL concentrations (IL-1beta: r = 0.55, P < 0.01; TNF-alpha: r = 0.56, P < 0.01). parthenolide 45-48 interleukin-1 beta Oryctolagus cuniculus 65-73 24432684-7 2013 The decrement was positively correlated with PTL concentrations (IL-1beta: r = 0.55, P < 0.01; TNF-alpha: r = 0.56, P < 0.01). parthenolide 45-48 tumor necrosis factor Oryctolagus cuniculus 98-107 24573421-0 2014 Parthenolide exerts inhibitory effects on angiogenesis through the downregulation of VEGF/VEGFRs in colorectal cancer. parthenolide 0-12 vascular endothelial growth factor A Homo sapiens 85-89 24206617-4 2014 Taking advantage of our recently introduced tools for high-throughput P450 fingerprinting and fingerprint-driven P450 reactivity prediction, we evolved P450 variants useful for carrying out the highly regioselective hydroxylation of two aliphatic sites (C9 and C14) in parthenolide carbocyclic backbone. parthenolide 269-281 complement C9 Homo sapiens 254-264 24200081-0 2014 Dimethylaminoparthenolide, a water soluble parthenolide, suppresses lung tumorigenesis through down-regulating the STAT3 signaling pathway. parthenolide 13-25 signal transducer and activator of transcription 3 Mus musculus 115-120 24065392-0 2014 Parthenolide induces apoptosis by activating the mitochondrial and death receptor pathways and inhibits FAK-mediated cell invasion. parthenolide 0-12 protein tyrosine kinase 2 Homo sapiens 104-107 24065392-5 2014 The results suggest that parthenolide may induce apoptotic cell death in ovarian carcinoma cell lines by activating the mitochondrial pathway and the caspase-8- and Bid-dependent pathways. parthenolide 25-37 caspase 8 Homo sapiens 150-168 23999007-12 2013 TWEAK activated NFkappaB and increased MCP-1 mRNA and protein, an effect prevented by the NFkappaB inhibitor parthenolide. parthenolide 109-121 TNF superfamily member 12 Homo sapiens 0-5 23999007-12 2013 TWEAK activated NFkappaB and increased MCP-1 mRNA and protein, an effect prevented by the NFkappaB inhibitor parthenolide. parthenolide 109-121 nuclear factor kappa B subunit 1 Homo sapiens 16-24 23999007-12 2013 TWEAK activated NFkappaB and increased MCP-1 mRNA and protein, an effect prevented by the NFkappaB inhibitor parthenolide. parthenolide 109-121 C-C motif chemokine ligand 2 Homo sapiens 39-44 23999007-12 2013 TWEAK activated NFkappaB and increased MCP-1 mRNA and protein, an effect prevented by the NFkappaB inhibitor parthenolide. parthenolide 109-121 nuclear factor kappa B subunit 1 Homo sapiens 90-98 24075100-4 2013 TGFbeta1-induced NFkappaB-luciferase activity was blocked by the IkappaB inhibitor parthenolide, the IkappaB super-repressor, a dominant negative TGFbeta1-activated kinase 1 (TAK1) and genetic deletion of NFkappaB1. parthenolide 83-95 transforming growth factor, beta 1 Mus musculus 0-8 24075100-4 2013 TGFbeta1-induced NFkappaB-luciferase activity was blocked by the IkappaB inhibitor parthenolide, the IkappaB super-repressor, a dominant negative TGFbeta1-activated kinase 1 (TAK1) and genetic deletion of NFkappaB1. parthenolide 83-95 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 17-25 24075100-4 2013 TGFbeta1-induced NFkappaB-luciferase activity was blocked by the IkappaB inhibitor parthenolide, the IkappaB super-repressor, a dominant negative TGFbeta1-activated kinase 1 (TAK1) and genetic deletion of NFkappaB1. parthenolide 83-95 mitogen-activated protein kinase kinase kinase 7 Mus musculus 146-173 24075100-4 2013 TGFbeta1-induced NFkappaB-luciferase activity was blocked by the IkappaB inhibitor parthenolide, the IkappaB super-repressor, a dominant negative TGFbeta1-activated kinase 1 (TAK1) and genetic deletion of NFkappaB1. parthenolide 83-95 mitogen-activated protein kinase kinase kinase 7 Mus musculus 175-179 24075100-4 2013 TGFbeta1-induced NFkappaB-luciferase activity was blocked by the IkappaB inhibitor parthenolide, the IkappaB super-repressor, a dominant negative TGFbeta1-activated kinase 1 (TAK1) and genetic deletion of NFkappaB1. parthenolide 83-95 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 205-214 23933184-0 2013 Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel. parthenolide 0-12 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 113-118 23933184-5 2013 A major constituent of feverfew, parthenolide, may interact with TRPA1 nucleophilic sites, suggesting that feverfew"s antimigraine effect derives from its ability to target TRPA1. parthenolide 33-45 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 65-70 23933184-5 2013 A major constituent of feverfew, parthenolide, may interact with TRPA1 nucleophilic sites, suggesting that feverfew"s antimigraine effect derives from its ability to target TRPA1. parthenolide 33-45 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 173-178 23933184-6 2013 We found that parthenolide stimulates recombinant (transfected cells) or natively expressed (rat/mouse trigeminal neurons) TRPA1, where it, however, behaves as a partial agonist. parthenolide 14-26 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 123-128 23933184-7 2013 Furthermore, in rodents, after initial stimulation, parthenolide desensitizes the TRPA1 channel and renders peptidergic TRPA1-expressing nerve terminals unresponsive to any stimulus. parthenolide 52-64 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 82-87 23933184-7 2013 Furthermore, in rodents, after initial stimulation, parthenolide desensitizes the TRPA1 channel and renders peptidergic TRPA1-expressing nerve terminals unresponsive to any stimulus. parthenolide 52-64 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 120-125 23933184-9 2013 TRPA1 targeting and neuronal desensitization by parthenolide inhibits CGRP release from trigeminal neurons and CGRP-mediated meningeal vasodilatation, evoked by either TRPA1 agonists or other unspecific stimuli. parthenolide 48-60 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 0-5 23933184-10 2013 TRPA1 partial agonism, together with desensitization and nociceptor defunctionalization, ultimately resulting in inhibition of CGRP release within the trigeminovascular system, may contribute to the antimigraine effect of parthenolide. parthenolide 222-234 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 0-5 24089526-7 2013 To test this premise, we identified compounds such as parthenolide (PTL) or piperlongumine that induce almost complete glutathione depletion and severe cell death in CD34(+) AML cells. parthenolide 54-66 CD34 molecule Homo sapiens 166-170 24089526-7 2013 To test this premise, we identified compounds such as parthenolide (PTL) or piperlongumine that induce almost complete glutathione depletion and severe cell death in CD34(+) AML cells. parthenolide 68-71 CD34 molecule Homo sapiens 166-170 24176849-8 2013 During this first phase, parthenolide and DMAPT also stimulated autophagic process, as suggested by the enhanced expression of beclin-1, the conversion of microtubule-associated protein light chain 3-I (LC3-I) to LC3-II and the increase in the number of cells positive to monodansylcadaverine. parthenolide 25-37 beclin 1 Homo sapiens 127-135 23938948-0 2013 In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player. parthenolide 47-59 phosphatase and tensin homolog Homo sapiens 117-121 24432684-0 2013 [Effect of parthenolide on serum expressions of interleukin-1beta and tumor necrosis factor-alpha in rabbits with knee osteoarthritis]. parthenolide 11-23 tumor necrosis factor Oryctolagus cuniculus 70-97 24432684-1 2013 OBJECTIVE: To observe the therapeutic effect of parthenolide (PTL) on rabbit knee arthritis (KOA) and its effects on serum expression of interleukin-1beta (IL-1beta) and contents of tumor necrosis factor-alpha (TNF-alpha). parthenolide 48-60 interleukin-1 beta Oryctolagus cuniculus 137-154 24432684-1 2013 OBJECTIVE: To observe the therapeutic effect of parthenolide (PTL) on rabbit knee arthritis (KOA) and its effects on serum expression of interleukin-1beta (IL-1beta) and contents of tumor necrosis factor-alpha (TNF-alpha). parthenolide 48-60 interleukin-1 beta Oryctolagus cuniculus 156-164 24432684-1 2013 OBJECTIVE: To observe the therapeutic effect of parthenolide (PTL) on rabbit knee arthritis (KOA) and its effects on serum expression of interleukin-1beta (IL-1beta) and contents of tumor necrosis factor-alpha (TNF-alpha). parthenolide 48-60 tumor necrosis factor Oryctolagus cuniculus 182-209 24432684-1 2013 OBJECTIVE: To observe the therapeutic effect of parthenolide (PTL) on rabbit knee arthritis (KOA) and its effects on serum expression of interleukin-1beta (IL-1beta) and contents of tumor necrosis factor-alpha (TNF-alpha). parthenolide 48-60 tumor necrosis factor Oryctolagus cuniculus 211-220 24432684-1 2013 OBJECTIVE: To observe the therapeutic effect of parthenolide (PTL) on rabbit knee arthritis (KOA) and its effects on serum expression of interleukin-1beta (IL-1beta) and contents of tumor necrosis factor-alpha (TNF-alpha). parthenolide 62-65 interleukin-1 beta Oryctolagus cuniculus 137-154 23797801-13 2013 Importantly, parthenolide abrogated the baseline and dacarbazine-induced vascular endothelial growth factor secretion from melanoma cells in heterogeneous populations, whereas interleukin-8 secretion was not significantly affected by either drug. parthenolide 13-25 vascular endothelial growth factor A Homo sapiens 73-107 23660068-0 2013 Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. parthenolide 54-66 mechanistic target of rapamycin kinase Homo sapiens 6-10 23660068-4 2013 As with other mTOR inhibitors, we show that ciclopirox significantly enhances the ability of the established preclinical antileukemia compound, parthenolide, to target acute myeloid leukemia. parthenolide 144-156 mechanistic target of rapamycin kinase Homo sapiens 14-18 23898080-9 2013 Parthenolide markedly reduced the constitutive and doxorubicin-induced NF-kappaB activity measured as the nuclear NF-kappaB, and expression of matrix metalloproteinase-9 (MMP9) and it had no effect on p53. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 71-80 23898080-9 2013 Parthenolide markedly reduced the constitutive and doxorubicin-induced NF-kappaB activity measured as the nuclear NF-kappaB, and expression of matrix metalloproteinase-9 (MMP9) and it had no effect on p53. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 114-123 23898080-9 2013 Parthenolide markedly reduced the constitutive and doxorubicin-induced NF-kappaB activity measured as the nuclear NF-kappaB, and expression of matrix metalloproteinase-9 (MMP9) and it had no effect on p53. parthenolide 0-12 matrix metallopeptidase 9 Homo sapiens 143-169 23898080-9 2013 Parthenolide markedly reduced the constitutive and doxorubicin-induced NF-kappaB activity measured as the nuclear NF-kappaB, and expression of matrix metalloproteinase-9 (MMP9) and it had no effect on p53. parthenolide 0-12 matrix metallopeptidase 9 Homo sapiens 171-175 23898080-9 2013 Parthenolide markedly reduced the constitutive and doxorubicin-induced NF-kappaB activity measured as the nuclear NF-kappaB, and expression of matrix metalloproteinase-9 (MMP9) and it had no effect on p53. parthenolide 0-12 tumor protein p53 Homo sapiens 201-204 23576578-6 2013 Ro-106-9920 or parthenolide, agents that inhibit the initial steps of NF-kappaB activation, blocked ANG II-induced p65 NF-kappaB nuclear localization, COX-2 protein expression, beta-arrestin recruitment, and AT1AR internalization without inhibiting ANG II-induced p42/44 ERK activation. parthenolide 15-27 angiotensinogen Rattus norvegicus 100-106 23507557-5 2013 The results demonstrated that combination of PT and 5-FU induced apoptosis which was determined using MTT, cell cycle analysis, annexin-V assay, and Hoechst 33258 staining. parthenolide 45-47 annexin A5 Homo sapiens 128-137 23674500-0 2013 KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. parthenolide 89-101 kelch-like ECH-associated protein 1 Mus musculus 0-5 23674500-4 2013 The present study identifies KEAP1 as the downstream redox target that contributes to parthenolide"s radiosensitization effect in prostate cancer cells. parthenolide 86-98 kelch-like ECH-associated protein 1 Mus musculus 29-34 23674500-6 2013 Mechanistically, parthenolide increases the level of cellular ROS and causes oxidation of thioredoxin (TrX) in prostate cancer cells, leading to a TrX-dependent increase in a reduced state of KEAP1, which in turn leads to KEAP1-mediated PGAM5 and Bcl-xL (BCL2L1) degradation. parthenolide 17-29 thioredoxin 1 Mus musculus 90-101 23674500-6 2013 Mechanistically, parthenolide increases the level of cellular ROS and causes oxidation of thioredoxin (TrX) in prostate cancer cells, leading to a TrX-dependent increase in a reduced state of KEAP1, which in turn leads to KEAP1-mediated PGAM5 and Bcl-xL (BCL2L1) degradation. parthenolide 17-29 thioredoxin 1 Mus musculus 103-106 23674500-6 2013 Mechanistically, parthenolide increases the level of cellular ROS and causes oxidation of thioredoxin (TrX) in prostate cancer cells, leading to a TrX-dependent increase in a reduced state of KEAP1, which in turn leads to KEAP1-mediated PGAM5 and Bcl-xL (BCL2L1) degradation. parthenolide 17-29 thioredoxin 1 Mus musculus 147-150 23674500-6 2013 Mechanistically, parthenolide increases the level of cellular ROS and causes oxidation of thioredoxin (TrX) in prostate cancer cells, leading to a TrX-dependent increase in a reduced state of KEAP1, which in turn leads to KEAP1-mediated PGAM5 and Bcl-xL (BCL2L1) degradation. parthenolide 17-29 kelch-like ECH-associated protein 1 Mus musculus 192-197 23674500-6 2013 Mechanistically, parthenolide increases the level of cellular ROS and causes oxidation of thioredoxin (TrX) in prostate cancer cells, leading to a TrX-dependent increase in a reduced state of KEAP1, which in turn leads to KEAP1-mediated PGAM5 and Bcl-xL (BCL2L1) degradation. parthenolide 17-29 kelch-like ECH-associated protein 1 Mus musculus 222-227 23674500-6 2013 Mechanistically, parthenolide increases the level of cellular ROS and causes oxidation of thioredoxin (TrX) in prostate cancer cells, leading to a TrX-dependent increase in a reduced state of KEAP1, which in turn leads to KEAP1-mediated PGAM5 and Bcl-xL (BCL2L1) degradation. parthenolide 17-29 phosphoglycerate mutase family member 5 Mus musculus 237-242 23674500-6 2013 Mechanistically, parthenolide increases the level of cellular ROS and causes oxidation of thioredoxin (TrX) in prostate cancer cells, leading to a TrX-dependent increase in a reduced state of KEAP1, which in turn leads to KEAP1-mediated PGAM5 and Bcl-xL (BCL2L1) degradation. parthenolide 17-29 BCL2-like 1 Mus musculus 247-253 23674500-6 2013 Mechanistically, parthenolide increases the level of cellular ROS and causes oxidation of thioredoxin (TrX) in prostate cancer cells, leading to a TrX-dependent increase in a reduced state of KEAP1, which in turn leads to KEAP1-mediated PGAM5 and Bcl-xL (BCL2L1) degradation. parthenolide 17-29 BCL2-like 1 Mus musculus 255-261 23674500-7 2013 In contrast, parthenolide increases oxidation of KEAP1 in normal prostate epithelial cells, leading to increased Nrf2 (NFE2L2) levels and subsequent Nrf2-dependent expression of antioxidant enzymes. parthenolide 13-25 kelch-like ECH-associated protein 1 Mus musculus 49-54 23674500-7 2013 In contrast, parthenolide increases oxidation of KEAP1 in normal prostate epithelial cells, leading to increased Nrf2 (NFE2L2) levels and subsequent Nrf2-dependent expression of antioxidant enzymes. parthenolide 13-25 nuclear factor, erythroid derived 2, like 2 Mus musculus 113-117 23674500-7 2013 In contrast, parthenolide increases oxidation of KEAP1 in normal prostate epithelial cells, leading to increased Nrf2 (NFE2L2) levels and subsequent Nrf2-dependent expression of antioxidant enzymes. parthenolide 13-25 nuclear factor, erythroid derived 2, like 2 Mus musculus 119-125 23674500-7 2013 In contrast, parthenolide increases oxidation of KEAP1 in normal prostate epithelial cells, leading to increased Nrf2 (NFE2L2) levels and subsequent Nrf2-dependent expression of antioxidant enzymes. parthenolide 13-25 nuclear factor, erythroid derived 2, like 2 Mus musculus 149-153 23674500-8 2013 These results reveal a novel redox-mediated modification of KEAP1 in controlling the differential effect of parthenolide on tumor and normal cell radiosensitivity. parthenolide 108-120 kelch-like ECH-associated protein 1 Mus musculus 60-65 23403077-9 2013 Further mechanistic studies revealed that the gene expression of CXCL8 could be reduced by the MIF specific small interfering RNA (siRNA) or NF-kappaB inhibitor parthenolide, and the growth of tumor spheres was also reduced after MIF siRNA transfection. parthenolide 161-173 C-X-C motif chemokine ligand 8 Homo sapiens 65-70 23576578-6 2013 Ro-106-9920 or parthenolide, agents that inhibit the initial steps of NF-kappaB activation, blocked ANG II-induced p65 NF-kappaB nuclear localization, COX-2 protein expression, beta-arrestin recruitment, and AT1AR internalization without inhibiting ANG II-induced p42/44 ERK activation. parthenolide 15-27 synaptotagmin 1 Rattus norvegicus 115-118 23576578-6 2013 Ro-106-9920 or parthenolide, agents that inhibit the initial steps of NF-kappaB activation, blocked ANG II-induced p65 NF-kappaB nuclear localization, COX-2 protein expression, beta-arrestin recruitment, and AT1AR internalization without inhibiting ANG II-induced p42/44 ERK activation. parthenolide 15-27 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 151-156 23576578-6 2013 Ro-106-9920 or parthenolide, agents that inhibit the initial steps of NF-kappaB activation, blocked ANG II-induced p65 NF-kappaB nuclear localization, COX-2 protein expression, beta-arrestin recruitment, and AT1AR internalization without inhibiting ANG II-induced p42/44 ERK activation. parthenolide 15-27 angiotensinogen Rattus norvegicus 249-255 23575899-3 2013 The results showed that the apoptosis of porcine granulosa cells induced by CdCl2 significantly increased in a time- and dose-dependent manner along with the increasing of ROS production, and 10 muM parthenolide, an inhibitor NF-kappaB, can accelerate the process of apoptosis. parthenolide 199-211 nuclear factor kappa B subunit 1 Homo sapiens 226-235 23792430-0 2013 Parthenolide reverses doxorubicin resistance in human lung carcinoma A549 cells by attenuating NF-kappaB activation and HSP70 up-regulation. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 95-104 23792430-0 2013 Parthenolide reverses doxorubicin resistance in human lung carcinoma A549 cells by attenuating NF-kappaB activation and HSP70 up-regulation. parthenolide 0-12 heat shock protein family A (Hsp70) member 4 Homo sapiens 120-125